methylprednisolone acetate profile

Methylprednisolone Acetate: Methylprednisolone derivative that is used as an anti-inflammatory agent for the treatment of ALLERGY and ALLERGIC RHINITIS; ASTHMA; and BURSITIS; and for the treatment of ADRENAL INSUFFICIENCY. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methylprednisolone acetate : An acetate ester resulting from the formal condensation of the 21-hydroxy function of 6alpha-methylprednisolone compound with acetic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5877
CHEMBL ID	1364144
CHEBI ID	6889
SCHEMBL ID	13231
MeSH ID	M0040839

Synonym
methylprednisolone 21-acetate
medrol enpak
nsc48985
medrol acetate
mepred
pregna-1,20-dione, 21-(acetyloxy)-11,17-dihydroxy-6-methyl-, (6.alpha.,11.beta.)-
depo-medrone
component of neo-medrol
nsc-48985
depo-medrate
pregna-1,20-dione, 11.beta.,17,21-trihydroxy-6.alpha.-methyl-, 21-acetate
d-med
depomedrone
u 8210
urbason crystal suspension
(6alpha,11beta)-11,17-dihydroxy-6-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate
depo-medrol
depometicort
lemod depo
acetyl-methylprednisolone
einecs 200-171-3
nsc 48985
methylprednisolone-21-acetate
depo-medrin
pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl-, 21-acetate
solsolona [inj.]
ubrason [inj.]
pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-6-methyl-, (6alpha,11beta)-
pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-6-methyl-, (6-alpha,11-beta)-
unidrol
6alpha-methylprednisolone acetate
depo-methylprednisolone acetate
methylprednisolone acetate
m-predrol
6alpha-methylprednisolone 21-acetate
53-36-1
C08179
11beta,17,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-acetate
NCGC00159503-02
D00979
depo-medrol (tn)
methylprednisolone acetate (jan/usp)
MLS001304003
smr000718757
CHEBI:6889 ,
[2-[(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
HMS3259L07
tox21_111722
cas-53-36-1
dtxsid7023302 ,
dtxcid703302
HMS2233N14
AKOS015969745
ubrason
methyl prednisolone acetate
unii-43502p7f0p
methylprednisolone acetate [usp:jan]
solsolona
43502p7f0p ,
CHEMBL1364144
S5973
methylprednisolone acetate [orange book]
methylprednisolone acetate [usp monograph]
methylprednisolone acetate [ep monograph]
methylprednisolone acetate [green book]
methylprednisolone hydrogen succinate impurity c [ep impurity]
methylprednisolone impurity j [ep impurity]
methylprednisolone acetate [mart.]
methylprednisolone acetate component of neo-medrol acetate
neo-medrol acetate component methylprednisolone acetate
methylprednisolone acetate [vandf]
methylprednisolone acetate [usp-rs]
methylprednisolone acetate [usp impurity]
methylprednisolone acetate [jan]
methylprednisolone acetate [who-dd]
AB00375925-05
NC00628
SCHEMBL13231
bdbm233194
HY-13681
methylprednisolon-21-acetat
M2635
6alpha-methyl prednisolone 21-acetate
Q27107351
methylprednisolone ep impurity j
methylprednisolone acetate; 6?-methyl prednisolone 21-acetate; methylprednisolone hydrogen succinate ep impurity c; 11?,17-dihydroxy-6?-methyl-3,20-dioxopregna-1,4-dien21-yl acetate; 21-acetoxy-11?,17-dihydroxy-6?-methylpregna-1,4-diene-3,20-dione
PLBHSZGDDKCEHR-LFYFAGGJSA-N
methyl prednisolone 21-acetate
acetyl methylprednisolone
methylprednisolone 21 acetate
D87728
6 alpha -methylprednisolone 21-acetate
6?-methyl prednisolone 21-acetate
methylprednisolone acetate for peak identification
methylprednisolone acetate for system suitability
CS-0007549
methylprednisolone acetate (usp:jan)
hybrisil
medroloan suik
methylprednisolone acetate (mart.)
11beta,17alpha,21-trihydroxy-6alpha-methylpregna-1,4- diene-3,20-dione 21-acetate
methylprednisolone acetate inj.
methylprednisolone hydrogen succinate impurity c (ep impurity)
solsolona (inj.)
methylprednisolone acetate (usp impurity)
methylprednisolone acetate (ep monograph)
methylprednisolone impurity j (ep impurity)
methylprednisolone acetate (usp monograph)
methylprednisolone acetate (usp-rs)
medroloan ii suik
ubrason (inj.)
readysharp methylprednisolone 80

Excerpt	Reference	Relevance
"Methylprednisolone acetate (MPA) has a long history of use in the treatment of sciatic pain and other neuropathic pain syndromes. "	( The effects of glucocorticoids on neuropathic pain: a review with emphasis on intrathecal methylprednisolone acetate delivery. Kalkman, CJ; Rijsdijk, M; van Wijck, AJ; Yaksh, TL, 2014)	2.07
"Methylprednisolone acetate (MPA) has a long history of use in the treatment of sciatic pain and other neuropathic pain syndromes. "	( The effects of glucocorticoids on neuropathic pain: a review with emphasis on intrathecal methylprednisolone acetate delivery. Kalkman, CJ; Rijsdijk, M; van Wijck, AJ; Yaksh, TL, 2014)	2.07

Excerpt	Reference	Relevance
"Methylprednisolone acetate caused an increase in release of GAG into the medium at 48 and 72 hours after treatment."	( Effects of sodium hyaluronate and methylprednisolone acetate on proteoglycan synthesis in equine articular cartilage explants. Constable, PD; Doyle, AJ; Eurell, JA; Freeman, DE; Griffon, DJ; Stewart, AA, 2005)	1.33

Excerpt	Reference	Relevance
" Thus, toxic effects can be caused by preservatives or inadequate osmolarity of the vehicles alone."	( Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Arena, JE; Chandler, D; Hida, T; Machemer, R, 1986)	0.27
" The LD50 values of THS-201 both in mice and rats were estimated more than 5000 mg/kg at each route, and these are for above larger than those of TA or MPA."	( [Study on toxicity of halopredone acetate. (I) Acute toxicity study in mice and rats]. Ichinohe, M; Kaga, M; Okazaki, S; Shinpo, K; Sudo, J; Takeuchi, M; Tanabe, T; Tsuga, T, 1985)	0.27
"Systemic toxic effects may develop as a result of topical and local use of ophthalmic corticosteroid preparations in susceptible patients."	( Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. Cheng, L; Freeman, WR; Levi, L; Ozerdem, U; Scher, C; Song, MK, 2000)	0.31
" All adverse effects were self-limiting."	( Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space. Mercieca, F; Mercieca, K, 2007)	0.34
"Celiac plexus neurolysis and block are considered safe but provide limited pain relief."	( Initial evaluation of the efficacy and safety of endoscopic ultrasound-guided direct Ganglia neurolysis and block. Chari, ST; Clain, JE; de la Mora, JG; Gleeson, FC; Levy, MJ; Pearson, RK; Pelaez, MC; Petersen, BT; Rajan, E; Topazian, MD; Vege, SS; Wang, KK; Wiersema, MJ, 2008)	0.35
" The WOMAC scale was applied at 4 weeks and adverse events were recorded."	( Safety and efficacy of methylprednisolone infiltration in anserine syndrome treatment. Esquivel-Valerio, JA; Galarza-Delgado, DÁ; Garza-Elizondo, MA; Negrete-López, R; Vega-Morales, D, )	0.13
" The incidence of adverse events did not show any differences either."	( Safety and efficacy of methylprednisolone infiltration in anserine syndrome treatment. Esquivel-Valerio, JA; Galarza-Delgado, DÁ; Garza-Elizondo, MA; Negrete-López, R; Vega-Morales, D, )	0.13
" Knee pain (Numeric Rating Scale [NRS]), Oxford Knee Score, overall treatment effect (Global Perceived Effect), analgesic drug use, and adverse events were compared between CRFA and IAS cohorts at 1, 3, and 6 months after intervention."	( Prospective, Multicenter, Randomized, Crossover Clinical Trial Comparing the Safety and Effectiveness of Cooled Radiofrequency Ablation With Corticosteroid Injection in the Management of Knee Pain From Osteoarthritis. Buvanendran, A; Choi, D; Davis, T; DePalma, M; Desai, M; Gupta, A; Hunter, C; Kapural, L; Lindley, D; Loudermilk, E; Patel, N; Soloman, M, 2018)	0.48
" There were no procedure-related serious adverse events."	( Prospective, Multicenter, Randomized, Crossover Clinical Trial Comparing the Safety and Effectiveness of Cooled Radiofrequency Ablation With Corticosteroid Injection in the Management of Knee Pain From Osteoarthritis. Buvanendran, A; Choi, D; Davis, T; DePalma, M; Desai, M; Gupta, A; Hunter, C; Kapural, L; Lindley, D; Loudermilk, E; Patel, N; Soloman, M, 2018)	0.48
" A description of clinical and histological effects of polyethylene glycol and miripirium after Depo-Medrol injection, and the adverse reactions of particulate methylprednisolone acetate was conducted."	( Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use. Cisternino, S; Fontan, JE; Kabiche, S; Nguyen, D; Schlatter, J; Zamy, M, 2019)	0.98
"Intrathecal methylprednisolone acetate (Depo-Medrol) therapy seems not fully safe due to reported adverse events."	( Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use. Cisternino, S; Fontan, JE; Kabiche, S; Nguyen, D; Schlatter, J; Zamy, M, 2019)	1.16

Excerpt	Reference	Relevance
"The absolute bioavailability and pharmacokinetic parameters of two methylprednisolone formulations (methylprednisolone sodium succinate and methylprednisolone acetate) were determined in five dogs."	( Pharmacokinetics of methylprednisolone, methylprednisolone sodium succinate, and methylprednisolone acetate in dogs. Alvinerie, M; Fayolle, PM; Koritz, GD; Toutain, PL, 1986)	0.7

Excerpt	Reference	Relevance
" In the present study, the authors conducted a randomized controlled trial to compare the success of treatment between surgery and aspiration combined with methylprednisolone acetate injection plus wrist immobilization."	( Randomized controlled trial between surgery and aspiration combined with methylprednisolone acetate injection plus wrist immobilization in the treatment of dorsal carpal ganglion. Limpaphayom, N; Wilairatana, V, 2004)	0.75

Excerpt	Reference	Relevance
" This method was successfully implemented for the analysis of specimens generated from a single-dose bioavailability and safety study for a new formulation of Depo-Medrol sterile aqueous suspension."	( Validation of the simultaneous determination of methylprednisolone and methylprednisolone acetate in human plasma by high-performance liquid chromatography. Addison, TE; Brisson, J; Hopkins, NK; Wagner, CM, 1992)	0.52
"The absolute bioavailability and pharmacokinetic parameters of two methylprednisolone formulations (methylprednisolone sodium succinate and methylprednisolone acetate) were determined in five dogs."	( Pharmacokinetics of methylprednisolone, methylprednisolone sodium succinate, and methylprednisolone acetate in dogs. Alvinerie, M; Fayolle, PM; Koritz, GD; Toutain, PL, 1986)	0.7
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" The drug has low and fluctuating oral bioavailability owing to its extensive hepatic first-pass metabolism and reduced water solubility."	( Investigating the potential of utilizing glycerosomes as a novel vesicular platform for enhancing intranasal delivery of lacidipine. Abdel Halim, SA; Badr-Eldin, SM; Naguib, MJ; Salah, S, 2020)	0.56

Excerpt	Relevance	Reference
" Serum methylprednisolone levels rose rapidly, giving a dose-response curve similar to that after an intramuscular injection in humans."	( The systemic and local effects of an intramedullary injection of methylprednisolone acetate in growing rabbits. Aronson, DD; Colville, MR; Crissman, JD; Prcevski, P, )	0.37
" The optimal routes of administration, dosage, dosage interval, and other factors are unknown."	( Intermediate-dose intramuscular methylprednisolone acetate in the treatment of rheumatic disease. Kovarsky, J, 1983)	0.55
" The results reported in this paper have shown that glucocorticoid dosing produces numerous effects on motor neuron excitability and impulse generation and conduction."	( Glucocorticoid effects on the electrical properties of spinal motor neurons. Hall, ED, 1982)	0.26
" 2) Eight week treatment with the selected dosing regimen (n = 6) of the steroid and histomorphometry including strut analysis measured the development of a characteristic osteopenia which can be described briefly as "uncut but thinning" of trabecular bone structure, and which was prevented by salmon calcitonin (0."	( Glucocorticoid-induced osteopenia in rats: histomorphometrical and microarchitectural characterization and calcitonin effect. Hoshino, T; Koida, M; Nakamuta, H; Nitta, T, 1996)	0.29
" The highest dosage of MPA (10 mg/ml) reduced GAG synthesis less than lower dosages of MPA and all dosages of TA."	( Effects of dosage titration of methylprednisolone acetate and triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro. Baxter, GM; Dechant, JE; Frisbie, DD; McIlwraith, CW; Trotter, GW, 2003)	0.6
"The aim of this study was to compare the effectiveness of triamcinolone hexacetonide (THA) and methylprednisolone acetate (MPA), given via the intra-articular route at equipotent dosage to patients with symptomatic knee OA with effusion, in a double-blind randomized comparative trial."	( Intra-articular steroids in knee osteoarthritis: a comparative study of triamcinolone hexacetonide and methylprednisolone acetate. Bhanji, A; Ioannou, Y; Mootoo, R; Pyne, D, 2004)	0.76
" The use of systemic corticosteroids in the treatment of TEN is controversial because of a lack of randomized, controlled, prospective studies, and because the effects of steroid therapy vary depending on the dosage and time of its administration during the course of TEN."	( Skin biopsies to assess response to systemic corticosteroid therapy in early-stage TEN: case report and review of the literature. Céspedes, YP; Nigra, TP; O'Donoghue, JM; Rockley, PF, 2009)	0.35
" The dosage of immunosuppressive systemic therapy was reduced or able to be stopped in three patients (50%)."	( Periocular corticosteroid injection in the management of uveitis in children. Grigg, JR; Habot-Wilner, Z; Kabasele, PM; Lightman, S; McCluskey, P; Roufas, A; Sallam, A, 2010)	0.36
"Pharmacokinetics of MP may differ among IA MPA dosing protocols, and MP may be detected in plasma and urine for a longer time than previously reported."	( Pharmacokinetics of methylprednisolone acetate after intra-articular administration and subsequent suppression of endogenous hydrocortisone secretion in exercising horses. Bertone, AL; Hothem, EA; Menéndez, MI; Phelps, MA, 2012)	0.7
" Transdermal drug delivery system is the main route with discrete, self-contained dosage forms when placed on the skin, transporting the medicament through the skin into the systemic circulation in a wellcontrolled manner."	( Design and Evaluation of Transdermal Patches of Timolol Maleate. Jamakandi, VG; Panchayya Hiremath, SS; Reddy, JJ, 2018)	0.48

Role	Description
anti-inflammatory drug	A substance that reduces or suppresses inflammation.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
20-oxo steroid	An oxo steroid carrying an oxo group at position 20.
17alpha-hydroxy steroid	The alpha-stereoisomer of 17-hydroxy steroid.
11beta-hydroxy steroid	Any 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
glucocorticoid	Glucocorticoids are a class of steroid hormones that regulate a variety of physiological processes, in particular control of the concentration of glucose in blood.
acetate ester	Any carboxylic ester where the carboxylic acid component is acetic acid.
steroid ester
3-oxo-Delta(1),Delta(4)-steroid	A 3-oxo-Delta(1) steroid containing an additional double bond between positions 4 and 5.
tertiary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	22.3872	0.0032	45.4673	12,589.2998	AID2517
USP1 protein, partial	Homo sapiens (human)	Potency	0.2818	0.0316	37.5844	354.8130	AID743255
TDP1 protein	Homo sapiens (human)	Potency	0.2593	0.0008	11.3822	44.6684	AID686979
AR protein	Homo sapiens (human)	Potency	0.6167	0.0002	21.2231	8,912.5098	AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.0671	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	4.4606	0.0002	29.3054	16,493.5996	AID743069; AID743075; AID743078; AID743079; AID743091
IDH1	Homo sapiens (human)	Potency	11.5821	0.0052	10.8652	35.4813	AID686970
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	0.0473	0.0017	23.8393	78.1014	AID743083
nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus (Norway rat)	Potency	7.9433	0.1000	9.1916	31.6228	AID1346983
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	0.0517	0.0041	9.9848	25.9290	AID504444; AID720524
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	32.6427	5.8048	36.1306	65.1308	AID540253
snurportin-1	Homo sapiens (human)	Potency	32.6427	5.8048	36.1306	65.1308	AID540253
GTP-binding nuclear protein Ran isoform 1	Homo sapiens (human)	Potency	32.6427	5.8048	16.9962	25.9290	AID540253
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	10.0000	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	10.0000	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	10.0000	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	0.4486	0.0046	11.3741	33.4983	AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)	Ki	540.5000	1.1910	5.1291	9.9410	AID1802951
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
pentose-phosphate shunt	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
lipid metabolic process	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
cholesterol biosynthetic process	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
NADP metabolic process	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
NADPH regeneration	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
glutathione metabolic process	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
pentose-phosphate shunt, oxidative branch	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
response to iron(III) ion	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
negative regulation of protein glutathionylation	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
response to organic cyclic compound	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
pentose biosynthetic process	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
substantia nigra development	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
response to food	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
cellular response to oxidative stress	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
erythrocyte maturation	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
regulation of neuron apoptotic process	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
response to ethanol	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
ribose phosphate biosynthetic process	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
glucose 6-phosphate metabolic process	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell development	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
glucose metabolic process	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
glucose-6-phosphate dehydrogenase activity	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
protein binding	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
glucose binding	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
identical protein binding	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
protein homodimerization activity	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
NADP binding	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytoplasm	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
cytosol	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
cytoplasmic side of plasma membrane	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
membrane	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
centriolar satellite	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
intracellular membrane-bounded organelle	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
extracellular exosome	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
cytosol	Glucose-6-phosphate 1-dehydrogenase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1802951	In Vitro Inhibition Assay from Article 10.3109/14756360903489581: \\Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.\\	2010	Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 25, Issue:6	Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	193 (27.41)	18.7374
1990's	126 (17.90)	18.2507
2000's	162 (23.01)	29.6817
2010's	198 (28.13)	24.3611
2020's	25 (3.55)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	157 (20.13%)	5.53%
Reviews	26 (3.33%)	6.00%
Case Studies	132 (16.92%)	4.05%
Observational	1 (0.13%)	0.25%
Other	464 (59.49%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (714)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Comparative Study of Strategies for Management of Duchenne Myopathy in Assiut University Children Hospital [NCT03633565]	Phase 4	45 participants (Anticipated)	Interventional	2018-09-30	Not yet recruiting
Hypertonic Dextrose Versus Corticosteroid Intra-Articular Injections for the Treatment of Trapeziometacarpal Arthritis: A Prospective Double-blind Randomized Controlled Clinical Trial [NCT04791202]	Phase 3	130 participants (Anticipated)	Interventional	2021-04-01	Not yet recruiting
Electroretinographic Changes in Healthy Young Men Before and After Induction of Glucose Intolerance by Glucocorticoids Treatment, Hyperphagia and Lack of Exercise [NCT01140932]		10 participants (Actual)	Interventional	2010-02-28	Completed
EuroPainClinics® Study II (Prospective Randomized Double Blinded Trial) [NCT02459392]		300 participants (Actual)	Interventional	2021-12-31	Completed
Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification [NCT01193504]	Phase 4	100 participants (Anticipated)	Interventional	2010-09-30	Recruiting
Efficacy and Tolerability of Systemic Methylprednisolone in Children and Adolescents With Chronic Rhinosinusitis [NCT01205984]	Phase 4	48 participants (Actual)	Interventional	2007-07-31	Completed
Vestibular Prognosis Assessment of the Idiopathic Sudden Sensorineural Hearing Loss With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids [NCT03974867]		72 participants (Anticipated)	Interventional	2019-07-31	Not yet recruiting
Effect of Preoperative Administration of Dexamethasone Versus Methylprednisolone in Surgical Extraction of Retained Lower Third Molars [NCT05752305]	Phase 2/Phase 3	84 participants (Actual)	Interventional	2022-01-15	Completed
A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) [NCT04127578]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2020-01-03	Recruiting
Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial. [NCT01134432]	Phase 3	65 participants (Actual)	Interventional	2005-03-31	Completed
[NCT01137084]		300 participants (Anticipated)	Interventional	2005-01-31	Completed
Steroid Treatment as Anti-inflammatory and Neuroprotective Agent Following Out-of-Hospital Cardiac Arrest. A Randomized Trial [NCT04624776]	Phase 2	158 participants (Actual)	Interventional	2020-10-10	Completed
An Investigator Initiated Open Study to Evaluate the Efficacy and Safety of Intra Arterial Infusion for Treatment of Steroid Resistant Acute Hepatic Graft Versus Host Disease (AGVHD) [NCT01140984]		2 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to technical issues)
Role of Add-on Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis [NCT05842681]		30 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
Intravenous Methylprednisolone Versus High Dose Oral Prednisolone for the Treatment of Infantile Spasms: a Randomized Open-labelled Trial [NCT03876444]	Phase 2/Phase 3	128 participants (Anticipated)	Interventional	2019-04-01	Recruiting
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP: a Randomized, Open, Multicenter Clinical Study [NCT05280626]	Phase 2	100 participants (Anticipated)	Interventional	2022-03-25	Not yet recruiting
Effect of Corticosteroids On MyocardiaL Injury Among Patients Hospitalized for Community-AcquirEd PneUMonia - COLOSSEUM TRIAL [NCT03745664]	Phase 3	122 participants (Anticipated)	Interventional	2021-01-10	Recruiting
A Single-Center, Randomized, Double-Masked, Vehicle and Active-Controlled, Dose-Ranging Phase 2 Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis Using the Conjunctival Allergen Challenge M [NCT03320434]	Phase 2	120 participants (Actual)	Interventional	2017-10-13	Completed
Ruxolitinib and Methylprednisolone as First Line Therapy for Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation [NCT03701698]	Phase 2	30 participants (Anticipated)	Interventional	2018-11-01	Not yet recruiting
Efficacy and Safety of Subacromial Corticosteroid Injection in Type-2 Diabetic [NCT03652480]		20 participants (Actual)	Observational	2013-03-31	Completed
The Effect of a Preoperative Single-dose Methylprednisolone on the Postoperative Rehabilitation After Abdominal Hysterectomy: A Prospective, Double Blinded, Placebo Controlled Study [NCT01106547]	Phase 4	55 participants (Anticipated)	Interventional	2009-08-31	Completed
Sonographic Assessment in Severe Ulcerative Colitis Patients Admitted for Intravenous Corticosteroids and Eligible for Infliximab Rescue Therapy; a Prospective Clinician-blinded Observational Study Protocol. [NCT03942861]		50 participants (Anticipated)	Observational	2019-02-21	Recruiting
A Randomized Clinical Trial Comparing Hyaluronic Acid (Hylan G-F 20) and Corticosteroid (Methylprednisolone Acetate) for Knee Osteoarthritis [NCT01132677]		78 participants (Anticipated)	Interventional	2010-05-31	Enrolling by invitation
Preemptive Therapy Study of Cetuximab(Erbitux®)Induced Skin Rash Using Doxycycline, Sunscreen, Hydrocortisone and Moisturizer in Colorectal and Head and Neck Cancer Patients [NCT01874860]	Phase 2	24 participants (Actual)	Interventional	2013-08-31	Completed
Comparison Between Intra-articular Pulsed Radiofrequency With Steroids Injection Versus Intra-articular Steroids Injection in Chronic Sacroiliac Joint Arthritis [NCT03564106]	Phase 2/Phase 3	40 participants (Actual)	Interventional	2019-03-01	Completed
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease [NCT03584516]	Phase 2/Phase 3	155 participants (Actual)	Interventional	2019-01-17	Active, not recruiting
High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma [NCT01177371]	Phase 2	13 participants (Actual)	Interventional	1988-03-31	Completed
Effect of Preoperative Intravenous High Dose Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Patients Scheduled for Total Hip-arthroplasty [NCT02445898]	Phase 2/Phase 3	64 participants (Actual)	Interventional	2015-09-30	Completed
Randomized Clinical Trial Comparing Conventional Conservative Treatment for Plantar Fasciopathia With Endoscopic Surgery With Fascial Release. [NCT02448316]	Phase 4	30 participants (Actual)	Interventional	2015-04-01	Completed
Prospective Evaluation of Perioperative Steroid Dosing on Postsurgical Edema in Orthognathic Surgery [NCT03190642]	Phase 4	180 participants (Actual)	Interventional	2018-01-01	Completed
Single Dose Oral Dexamethasone Versus Multi-dose Prednisolone in the Treatment of Acute Exacerbations of Asthma in Children Who Attend the Emergency Department [NCT03698630]	Phase 4	250 participants (Actual)	Interventional	2011-07-06	Completed
Efficacy and Tolerance of Ultrasound-guided Needling and Lavage of Calcific Tendinitis of the Rotator Cuff Performed With or Without Subacromial Corticosteroid Injection: A Double Blind Controlled Study [NCT02403856]	Phase 4	136 participants (Actual)	Interventional	2015-04-04	Completed
Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease [NCT02392780]	Phase 2	10 participants (Anticipated)	Interventional	2015-04-30	Not yet recruiting
DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses [NCT04479748]	Phase 4	13 participants (Actual)	Interventional	2020-10-01	Completed
A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma With Acalabrutinib [NCT04546620]	Phase 2	453 participants (Anticipated)	Interventional	2021-10-19	Recruiting
Can Injection of Methylprednisoloneacetate 80 mg, in the Cavity After Mastectomy for Primary Breast Cancer, at the Time of Removal of the Drain, Prevent Seroma Formation? [NCT01380912]		160 participants (Anticipated)	Observational	2010-08-31	Recruiting
Evaluating Clinical and Immunological Effects of Rituximab With Cyclophosphamide Compared to Rituximab Alone in AAV Patients [NCT03942887]	Phase 3	100 participants (Anticipated)	Interventional	2019-05-03	Recruiting
To Study the Effect of Adjunctive Oral Methylprednisolone Therapy in Pediatric Urinary Tract Infection [NCT02331862]	Phase 3	160 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
A Single-center, Prospective, Non-comparative Clinical Trial of Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome [NCT05137496]	Phase 3	40 participants (Anticipated)	Interventional	2022-06-01	Not yet recruiting
MP3-pulses-COVID-19. Methylprednisolone Pulses Versus Dexamethasone According RECOVERY Protocol in Patients With Pneumonia Due to SARS-COV-2 Coronavirus Infection [NCT04780581]	Phase 4	127 participants (Actual)	Interventional	2021-02-01	Terminated(stopped due to Impossibility of reaching the sample size established by protocol)
An Open-Label, Single-Arm, Multiple Center Extension Study to Evaluate One Year of Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer With YONSA™ 500 mg (4 x 125 mg qd) With Methylprednisolone (4 mg Bid) [NCT02962284]	Phase 2	20 participants (Actual)	Interventional	2016-11-30	Completed
Corticosteroids for Acute Migraine. An ED-based, Randomized, Comparative Effectiveness Trial [NCT02847494]	Phase 4	220 participants (Actual)	Interventional	2016-09-01	Completed
Health Related Quality of Life and Pain Managment Using Infiltration or Suprascapular Nerve Block Ultrasound Guided in Patients With Glenohumeral Arthirtis [NCT03794505]	Phase 3	40 participants (Actual)	Interventional	2018-04-01	Completed
Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis [NCT01305837]	Phase 2	30 participants (Actual)	Interventional	2011-04-30	Completed
Clinical Study of Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of Checkpoint Inhibitor-related Pneumonitis [NCT05280873]	Phase 1	48 participants (Anticipated)	Interventional	2021-10-10	Recruiting
Efficacy and Cost-effectiveness of Intra-Articular Ketorolac Injection for Knee Osteoarthritis: A Randomized, Controlled, Double-Blinded Study [NCT03694821]	Phase 4	18 participants (Actual)	Interventional	2018-07-05	Terminated(stopped due to Low enrollment)
The Efficacy of Steroid Therapy in Vestibular Neuritis Confirmed by Head Impulse Test: Prospective Randomized Controlled Study [NCT02098330]	Phase 3	40 participants (Actual)	Interventional	2014-03-31	Completed
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis: Two-arm, Open, Single-center Study [NCT06119490]	Early Phase 1	30 participants (Anticipated)	Interventional	2023-07-05	Recruiting
Corticosteroid(CS) Injections for the Treatment of Common Upper Extremity Pathologies, With or Without Lidocaine [NCT03704584]	Phase 4	62 participants (Actual)	Interventional	2019-05-14	Terminated(stopped due to Enrollment and study activities were initially suspended due to COVID-19. The investigator has also left Emory and the study will not resume.)
Phase II Study of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine and Methylprednisolone for Relapsed/Refractory Myeloma [NCT01332617]	Phase 2	0 participants (Actual)	Interventional	2011-04-30	Withdrawn(stopped due to Investigators no longer interested in activating study)
Feasibility and Safety of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord: an Open-Labeled, Dose-Escalating Clinical Trial [NCT01354483]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2011-09-30	Completed
Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis. [NCT01941589]	Phase 4	149 participants (Actual)	Interventional	2013-09-30	Completed
Subcutaneous Injection of TNFα Monoclonal Antibody for Treating Traumatic Acute Spinal Cord Injury [NCT04988425]	Phase 1/Phase 2	90 participants (Anticipated)	Interventional	2022-09-01	Not yet recruiting
Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma [NCT00109928]	Phase 2	34 participants (Actual)	Interventional	2005-09-30	Completed
A Phase II, Open-labeled, Ophthalmological External Investigator-blinded, Single-center, Randomized, Superiority, Non Profit, Pilot Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO) in Hypercholesterolemic Patients With Mo [NCT03110848]	Phase 2	88 participants (Actual)	Interventional	2020-06-01	Completed
Manipulation Versus Steroid Injection in the Treatment of Morton's Neuroma [NCT05707572]		62 participants (Actual)	Interventional	2014-09-30	Completed
Randomized, Double-blind, Placebo- and Active Comparator- Controlled Crossover Study in Healthy Male Subjects and an Open Label Study in Healthy Subjects and MS Patients to Assess the Safety, Pharmacokinetics and Pharmacodynamics of 2B3-201 [NCT02048358]	Phase 1	47 participants (Actual)	Interventional	2013-11-30	Terminated
Does Injection Site Matter? A Randomized Controlled Trial to Evaluate Efficacy of Knee Intraarticular Injections on Improval of Patient Reported Outcomes. [NCT02176304]	Phase 4	60 participants (Actual)	Interventional	2014-06-30	Completed
[NCT01281748]	Phase 4	83 participants (Actual)	Interventional	2005-07-31	Terminated(stopped due to Low rate of enrollment)
Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata [NCT01167946]	Phase 4	42 participants (Actual)	Interventional	2003-01-31	Completed
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas [NCT01189864]		3,493 participants (Actual)	Observational	2010-02-01	Terminated(stopped due to Terminated to initiate FDA IND-cleared study protocol)
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study [NCT01560052]		503 participants (Actual)	Interventional	2012-05-05	Completed
Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA) [NCT00418145]	Phase 3	16 participants (Actual)	Interventional	2003-09-30	Terminated(stopped due to low enrollment - data was not analyzed for this study)
A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®) vs Intravenous Methylprednisolone (Solu-Medrol®) Treatment in Patients With Acute Exacerbation of Rela [NCT01039103]	Phase 2	15 participants (Actual)	Interventional	2009-12-31	Terminated
Corticosteroid Treatment in the Acute Phase of Caustic Ingestion Management for the Prevention of Refractory Stenosis of the Esophagus and Pharynx- The CORTICAU Study [NCT03760354]	Phase 2	30 participants (Anticipated)	Interventional	2019-02-15	Not yet recruiting
Ultrasound-guided Medial Lumbar Bundle Branch Block by Caudal-cranial Approach: Radiographic Comparison of a New Ultrasound-guided Method [NCT05930236]		40 participants (Anticipated)	Interventional	2023-04-21	Recruiting
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) [NCT02953678]	Phase 2	71 participants (Actual)	Interventional	2016-12-30	Completed
Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE) [NCT03387046]	Phase 2	7 participants (Actual)	Interventional	2018-03-26	Terminated(stopped due to Study was terminated early due to slow recruitment rate.)
A Prospective, Randomized, Controlled, Open Label, Assessor-blinded, Parallel-group Phase III Clinical Trial to Evaluate the Impact of Tapering Systemic Immunosuppressive Therapy in a Treat-to-target Approach on Maintaining Minimal Disease Activity in Adu [NCT04610476]	Phase 3	270 participants (Anticipated)	Interventional	2020-10-19	Recruiting
A Multicentre Double-blind Randomised Controlled Trial to Assess the Clinical- and Cost-effectiveness of Facet-joint Injections in Selected Patients With Non-specific Low Back Pain: a Feasibility Study [NCT03339362]	Phase 4	9 participants (Actual)	Interventional	2015-07-31	Completed
Impact of Local Steroid Application in Extreme Lateral Lumbar Interbody Fusion [NCT03327272]	Phase 3	0 participants (Actual)	Interventional	2018-05-22	Withdrawn(stopped due to Did not enroll, PI decided not to proceed.)
Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA [NCT02205489]	Phase 4	58 participants (Actual)	Interventional	2014-10-31	Completed
A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR) [NCT05436652]	Phase 2	48 participants (Anticipated)	Interventional	2022-07-22	Recruiting
Evaluation of Intraoperative Use of Dexycu on the Signs and Symptoms of Dry Eye [NCT04184999]	Phase 4	40 participants (Actual)	Interventional	2019-08-10	Completed
A Prospective, Randomized, Double-Blind Study to Compare the Effects of Dexamethasone Versus Depo-Medrol When Used in Lumbar Epidural Injections [NCT01397552]		8 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to Low enrollment, too many subjects getting second injection)
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) [NCT00792948]	Phase 2	97 participants (Actual)	Interventional	2009-09-01	Active, not recruiting
MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE [NCT03355482]	Phase 2	40 participants (Anticipated)	Interventional	2017-04-10	Suspended(stopped due to recruitment, funding)
Effects of Intraoperative Local Steroid Utilization in a Single-Level Minimally Invasive Transforaminal Lumbar Interbody Fusion [NCT03308084]	Phase 3	105 participants (Actual)	Interventional	2015-11-13	Completed
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract [NCT05191706]	Phase 4	60 participants (Anticipated)	Interventional	2022-01-04	Recruiting
A Phase IIA, Open-label Study Designed to Evaluate Efficacy and Safety of BL-8040 Followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects With Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS) [NCT02462252]	Phase 2	11 participants (Actual)	Interventional	2015-10-31	Completed
Glucocorticoid Inflammation Paradox in Human Skeletal Muscle [NCT03529929]	Phase 3	0 participants (Actual)	Interventional	2019-06-01	Withdrawn(stopped due to withdrawn)
The Effect of High Dose Steroid and Normobaric Oxygen Therapy on Recent Onset Non-arteritic Anterior Ischemic Optic Neuropathy(NAION); a Randomized Clinical Trial [NCT02439866]	Phase 3	90 participants (Anticipated)	Interventional	2014-02-28	Recruiting
A Randomized, Parallel Group, Double-masked, Active-controlled Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of Dexamethasone Sodium Phosphate Visulex System for the Treatment of Non-infectious Anterior Uveitis [NCT02309385]	Phase 1/Phase 2	44 participants (Actual)	Interventional	2014-10-31	Completed
Targeting Steroid Resistance During Acute Exacerbations of Chronic Obstructive Pulmonary Disease With Respiratory Failure - The AECOPD Resistance Study [NCT03680495]		46 participants (Anticipated)	Observational [Patient Registry]	2017-07-21	Recruiting
Evaluation of Ultrasound Guided Platelet Rich Plasma Injection Versus Steroids Injection for Pain Relief in Cases of Partial Rotator Cuff Tears [NCT05317624]	Early Phase 1	60 participants (Actual)	Interventional	2021-08-10	Completed
Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study [NCT03674099]	Phase 2	200 participants (Anticipated)	Interventional	2018-10-01	Recruiting
Calcific Tendinitis: Comparing Minimally Invasive Modalities [NCT02367560]		60 participants (Anticipated)	Interventional	2015-07-31	Recruiting
Effect of Preoperative Intravenous High Dose Methylprednisolone on Complement Activation in Patients Scheduled for Total Knee-arthroplasty [NCT02332616]	Phase 3	70 participants (Actual)	Interventional	2015-01-31	Completed
Sodium Hyaluronate Injection and Corticosteroids in Trochanteric Bursitis: a Randomized Controlled Study. [NCT02039804]	Phase 3	30 participants (Anticipated)	Interventional	2014-03-31	Not yet recruiting
An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose LY3884961 in Infants With Type 2 Gaucher Disease [NCT04411654]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2021-06-29	Recruiting
Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis: a Multinational, Randomised, Open Label, Phase III Trial - The iCaD Study [NCT05947669]	Phase 3	195 participants (Anticipated)	Interventional	2023-08-22	Recruiting
[NCT02591953]		22 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to Unable to meet enrollment and follow up criteria)
Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction [NCT05462730]	Phase 2	530 participants (Actual)	Interventional	2022-11-14	Active, not recruiting
Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Less Than 2 Years of Age: a Point-of-care Testing Guided Randomized, Double-blind, Placebo-controlled Trial [NCT05444699]	Phase 4	210 participants (Anticipated)	Interventional	2022-10-11	Recruiting
Transforaminal Epidural Injection in Acute Sciatica [NCT03924791]		142 participants (Anticipated)	Interventional	2019-06-01	Recruiting
Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial [NCT01496976]	Phase 2	45 participants (Actual)	Interventional	2012-03-30	Active, not recruiting
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis [NCT00676832]	Phase 2	190 participants (Actual)	Interventional	2008-05-31	Completed
Ultrasound Guided Continuous Suprascapular Nerve Block With Oral Gabapentin For Pain Management In Patients With Frozen Shoulder [NCT05037994]		40 participants (Actual)	Interventional	2021-04-01	Completed
A Phase 3, Multicenter, Randomized, Evaluator-blinded Clinical Trial to Assess the Safety and Efficacy of Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% Compared to Prednisolone Acetate, 1% in the Treatment of Inflammation After Cataract Surgery in [NCT05724446]	Phase 3	60 participants (Anticipated)	Interventional	2022-12-12	Recruiting
Chidamide Combines With Etoposide and Methylprednisolone in the Treatment of Hemophagocytic Lymphohistiocytosis [NCT05137522]		20 participants (Anticipated)	Interventional	2021-07-01	Recruiting
Local Steroid Injection vs Wrist Splinting for Carpal Tunnel Syndrome: A Randomized Clinical Trial [NCT02140632]	Phase 4	50 participants (Actual)	Interventional	2013-12-31	Completed
[NCT02253966]	Phase 2	48 participants (Actual)	Interventional	2014-10-31	Completed
Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. [NCT02160132]	Phase 2	180 participants (Anticipated)	Interventional	2014-06-30	Recruiting
Efficacy of Steroids on Functional Outcomes After Musculoskeletal Injuries of the Hand [NCT05003596]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2021-09-01	Not yet recruiting
Effect of High-dose Glucocorticoids on Markers of Inflammation and Bone Metabolism in Patients With Primary Glomerular Disease [NCT04987450]		40 participants (Anticipated)	Observational	2018-10-01	Recruiting
A Parallel-arm, Single Blind Randomised Controlled Trial Comparing 'AIRWAY PRESSURE RELEASE VENTILATION' and 'LOW-TIDAL VOLUME VENTILATION' in Children With Acute Respiratory Distress Syndrome [NCT02167698]		52 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to Increased mortality in the intervention arm at 50% enrolment)
Stop LCNP: High Dose Steroid Therapy for Late Radiation-Associated Lower Cranial Neuropathy: A Phase I/II Dose Finding Trial and Data Registry [NCT04151082]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2019-10-31	Active, not recruiting
Efficacy and Safety of Methylprednisolone Versus Dexamethasone in Caudal Block for Children Undergoing Hypospadias Surgical Repair: A Bi-center Randomized Controlled Study [NCT05717374]		80 participants (Anticipated)	Interventional	2023-02-13	Recruiting
The Efficacy and Safety of 36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-Induced Liver Injury [NCT03266146]	Phase 1/Phase 2	90 participants (Actual)	Interventional	2017-09-02	Completed
The Prospective Evaluation of Peri-Operative Glucocorticoid Use in the Management of Cervicofacial Infections of Odontogenic Origin [NCT05951504]	Phase 2/Phase 3	29 participants (Actual)	Interventional	2022-06-22	Completed
Corticosteroid Pulse Therapy Effects on MRI Asymptomatic Gadolinium-enhancing Lesions Conversion to a Non-enhancing Black Hole With or Without Treatment in MS Clinic of Booalisina Hospital Sari 2021-2023 [NCT04979650]	Phase 2	104 participants (Anticipated)	Interventional	2021-05-22	Enrolling by invitation
The Impact of Dexamethasone Versus Methylprednisolone Upon Neutrophil/Lymphocyte Ratio (NLR) in COVID-19 Diseased Patients Admitted in ICU [NCT04909918]	Phase 3	60 participants (Actual)	Interventional	2021-05-28	Completed
Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life: an Observational Study [NCT04900948]	Phase 4	108 participants (Actual)	Interventional	2017-12-10	Completed
Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing Femtosecond Laser-Assisted Cataract Surgery With Premium Intraocular Lens - The ENHANCE Study [NCT04863742]	Phase 4	30 participants (Anticipated)	Interventional	2021-04-26	Recruiting
Single-blind, Investigator-initiated, Randomized, Controlled Trial to Assess the Safety and Efficacy of Intravenous Corticosteroid Therapy to Treat Patients With Acute Myocarditis With Mildly Reduced Left Ventricular Ejection Fraction [NCT05974462]	Phase 3	174 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Evaluation of the Feasibility of Depomedrol Added to Bupivacaine in Ultrasound-guided Genicular Nerve Block in the Combination With Adductor Canal Block for Postoperative Analgesia and Rehabilitation After Reconstructive Knee Surgery. [NCT05893771]		48 participants (Actual)	Interventional	2023-06-07	Completed
Mechanisms of Neurodynamic Treatments (MONET) [NCT05859412]		108 participants (Anticipated)	Interventional	2023-04-13	Recruiting
Methylprednisolone Taper After Total Knee Replacement: A Prospective Randomized Trial [NCT05859269]	Phase 4	200 participants (Anticipated)	Interventional	2023-10-16	Recruiting
Lateral Elbow Tendinopathy: A Randomized Controlled Trial Examining The Treatment Effect Of Strength Training Combined With Cortico-Steroid Injection, Dry-Needling Or Placebo [NCT02521298]		60 participants (Actual)	Interventional	2015-10-31	Completed
Ultrasound Guided Botulinum Toxin Type A Injection of Subacromial-Subdeltoid Bursa in Hemiplegic Shoulder Pain: Comparative Study Versus Corticosteroid Injection [NCT04467450]	Early Phase 1	36 participants (Anticipated)	Interventional	2020-06-01	Recruiting
Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome [NCT03371498]	Phase 3	356 participants (Anticipated)	Interventional	2018-12-27	Recruiting
High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII [NCT03535090]		26 participants (Actual)	Observational	2011-01-01	Completed
Methylprednisolone Taper to Treat Delayed Post-Operative Recovery After Total Knee Arthroplasty: a Double-Blind Randomized Controlled Trial [NCT05113901]	Phase 4	4 participants (Actual)	Interventional	2022-03-03	Terminated(stopped due to Extremely low participation, decided to focus on similar study instead)
Benefit of a Flash Dose of Corticosteroids in Digestive Surgical Oncology: a Randomized, Double Blind, Placebo-controlled Trial [NCT03875690]	Phase 3	1,200 participants (Anticipated)	Interventional	2019-07-02	Recruiting
Comparative Study Between the Uses of High Dose Corticosteroid Therapy for Short Duration Versus Low Dose Corticosteroid for Long Duration in Severe Lung Contusion With ARDS [NCT04467892]	Phase 2	240 participants (Actual)	Interventional	2018-01-02	Completed
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones [NCT03007147]	Phase 3	475 participants (Anticipated)	Interventional	2017-08-08	Recruiting
Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura [NCT03647852]		150 participants (Anticipated)	Interventional	2019-09-01	Recruiting
A Randomised Controlled Trial to Compare the Clinical Effectiveness of Lower Extremity Manipulation to That of Steroid Injection in the Treatment of Morton's Neuroma [NCT02304094]		64 participants (Anticipated)	Interventional	2015-10-31	Recruiting
GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease [NCT03139604]	Phase 3	439 participants (Actual)	Interventional	2017-07-19	Completed
The Efficacy of Nasal Steroids in Treatment of Otitis Media With Effusion: Acomparative Study [NCT03491098]	Early Phase 1	60 participants (Anticipated)	Interventional	2018-05-15	Not yet recruiting
Mycophenolate Mofetil and Prednisolone Versus Prednisolone Alone in Fibrotic Hypersensitivity Pneumonitis: a Randomized Controlled Trial [NCT05626387]	Phase 4	144 participants (Anticipated)	Interventional	2022-11-23	Recruiting
A Prospective, Randomized, Controlled Phase Ⅱ Study of Preventively Use of Methylprednisolone After Split-course Chemoradiotherapy to Reduce the Risk of Radiation-induced Pulmonary Injury For Bulky Local Advanced None-small Cell Lung Cancer [NCT03661567]	Phase 2	52 participants (Actual)	Interventional	2018-08-09	Terminated(stopped due to slow enrollment)
A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy. [NCT03948191]	Phase 4	50 participants (Actual)	Interventional	2017-10-16	Completed
A Prospective, Open-label Trial of Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children [NCT01217099]		47 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to terminated)
Double-Masked, Randomized, Parallel Group Study for Evaluation of Non-Inferiority of 0.3%Gatifloxacin/1.0% Prednisolone Association Compared With Their Isolated Administration in the Prevention of Ocular Infection/Inflammation After LASIK Surgery [NCT01218737]	Phase 3	101 participants (Actual)	Interventional	2009-01-31	Completed
Phase 2 Double-blinded, Placebo-controlled, Clinical Trial for Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment [NCT01205477]	Phase 2	58 participants (Actual)	Interventional	2009-09-30	Completed
The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation [NCT02495662]	Phase 2	30 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to Slow inclusion)
Clinical Trial of Belimumab Combined With Multi-target Induction Therapy in Adult Patients With Severe Lupus Nephritis [NCT05863936]	Phase 3	15 participants (Anticipated)	Interventional	2023-04-01	Recruiting
Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus [NCT04874610]		15 participants (Actual)	Observational	2021-08-16	Completed
A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL [NCT01465334]	Phase 2	30 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Terminated early due to change in practice.)
The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial [NCT02422368]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2022-09-01	Withdrawn(stopped due to Do not access to the drug)
A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Double and Triple Hit Lymphoma, Double Expressor Lymphoma and High-Gr [NCT04479267]	Phase 2	49 participants (Anticipated)	Interventional	2020-08-21	Recruiting
An Open Label Study to Evaluate the Safety and Efficacy of Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With Methotrexate [NCT01000610]	Phase 4	18 participants (Actual)	Interventional	2008-03-17	Completed
A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab [NCT00379431]	Phase 2	9 participants (Actual)	Interventional	2006-11-27	Completed
Phase 4, Randomized Study of Oral Glucocorticosteroid Administration in the Treatment of Acute Severe Asthma Exacerbation in Hospitalized Patients [NCT00627731]	Phase 4	50 participants (Actual)	Interventional	2007-06-30	Completed
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma [NCT00577993]	Phase 3	210 participants (Actual)	Interventional	1998-03-16	Completed
Impact of the Administration of Systemic Glucocorticoids on Inflammatory Response and Clinical Evolution of Patients Diagnosed With Moderate- Severe Bronchiolitis [NCT02571517]	Phase 4	94 participants (Actual)	Interventional	2011-11-30	Completed
Viral Inception of Asthma: Prospective Study From Infancy to School-age. [NCT00731575]		200 participants (Anticipated)	Interventional	2007-06-30	Active, not recruiting
Immunomodulatory Effect of Extracorporeal Cytokine Adsorption in Cardiac Surgery [NCT02666703]	Phase 3	60 participants (Actual)	Interventional	2016-02-01	Completed
Comparison of Intravenous Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Proliferative Lupus Nephritis [NCT02645565]	Phase 4	75 participants (Actual)	Interventional	2015-12-31	Completed
Effectiveness of Hydrolyzed Collagen Peptide Injection for the Treatment of Collateral Ligament Pain: A Randomized Controlled Trial [NCT05971004]		62 participants (Actual)	Interventional	2022-04-13	Completed
Treatment With Methylprednisolone in Acute Exacerbations of Multiple Sclerosis: Enhanced Effect With Nighttime Treatment? [NCT00764413]		57 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Low inclusion frequency and not enough human resources for completing study)
Subacromial Injection of Methylprednisolone Versus Ketorolac to Treat Shoulder Impingement: a Double-blind Randomized Controlled Trial [NCT03913702]	Phase 2	1 participants (Actual)	Interventional	2019-09-09	Terminated(stopped due to Inadequate patient enrollment)
Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy [NCT00595335]	Phase 2/Phase 3	25 participants (Actual)	Interventional	2008-04-30	Completed
Intra-articular Doxycycline: A Novel Treatment of Adhesive Capsulitis [NCT03479502]	Phase 4	1 participants (Actual)	Interventional	2018-01-05	Terminated(stopped due to Lack of personnel to help with recruiting)
A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis [NCT01838174]	Phase 4	37 participants (Actual)	Interventional	2013-05-31	Terminated(stopped due to Sponsor requested)
Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee Treated With Fixed Dose Combination of Glucosamine and Chondroitin Sulfate. [NCT00805519]	Phase 4	230 participants (Actual)	Interventional	2009-02-28	Completed
A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study To Evaluate The Safety And Efficacy Of TRU-015 In Subjects With Active Seropositive Rheumatoid Arthritis On A Stable Background Of Methotrexate [NCT00634933]	Phase 2	222 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No safety reasons contributed to the termination of the study.)
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of a BI 653048 BS H3PO4 Capsule Formulation Administered as Multiple Doses of 25 mg to 200 mg Once Daily (qd) for 3 Days Assessing Pharmacodynamics as Endotoxin-induced Inflammatory Response of a [NCT02224105]	Phase 1	56 participants (Actual)	Interventional	2010-03-31	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled TRial Evaluating Immunosuppressive Treatment in Patients With Chronic Virus-Negative Inflammatory cardiomyopaThY (TRINITY Trial) [NCT05570409]	Phase 2/Phase 3	130 participants (Anticipated)	Interventional	2023-03-28	Recruiting
Assessment of the Efficacy of Medrol Dose Pack for Post-Concussive Headaches [NCT04685772]		25 participants (Anticipated)	Observational [Patient Registry]	2021-04-01	Recruiting
Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease [NCT04509219]	Phase 1	10 participants (Anticipated)	Interventional	2020-04-15	Recruiting
The Effect on Wrist Range of Motion With Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures: A Randomized Controlled Trial [NCT03898154]	Phase 4	200 participants (Anticipated)	Interventional	2019-07-10	Recruiting
The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19 [NCT04499313]	Phase 3	60 participants (Anticipated)	Interventional	2020-08-02	Recruiting
A Feasibility Study to Undertake a Definitive Randomised Multi-centre, Double-blind, Double-dummy Controlled Study of a Novel Agent Anakinra vs. Depo-Medrone for Acute Gout Attacks in Patients With Moderate Chronic Kidney Disease [NCT02578394]	Phase 2/Phase 3	21 participants (Actual)	Interventional	2016-04-30	Completed
Effects of Methylprednisolone Plus Ropivacaine Infiltration Before Wound Closure on Laminoplasty or Laminectomy [NCT04493463]	Phase 4	132 participants (Actual)	Interventional	2020-07-31	Completed
Syndrome du Tunnel Carpien - Essai Clinique randomisé évaluant l'efficacité de l'Utilisation de l'échographie Lors de l'Infiltration de corticostéroïdes [NCT02036125]		50 participants (Anticipated)	Interventional	2013-10-31	Recruiting
Zonisamide and Methylprednisolone to Prevent Noise-induced Temporary Hearing Loss [NCT02049073]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2017-10-31	Withdrawn(stopped due to new data makes this trial unethical)
Randomised Trial of Intra-articular Injection of Lidocaine Versus Placebo in Inflammatory Arthritis [NCT05302232]		80 participants (Anticipated)	Interventional	2022-04-18	Not yet recruiting
Comparison of High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19 - Retrospective Cross-sectional Study [NCT05047874]		200 participants (Anticipated)	Observational	2021-09-20	Recruiting
An Open-Label, Parallel Group, Controlled Study in Healthy Subjects to Characterize Biological Responses to Immunological Challenges and to Measure the Effect of Marketed Anti-Inflammatory Agents on Those Responses [NCT02252809]	Early Phase 1	51 participants (Actual)	Interventional	2008-11-30	Completed
Comparative Evaluation of Preoperative Methylprednisolone or Ibuprofen on Anesthetic Efficacy of Inferior Alveolar Nerve Blocks in Patients With Symptomatic Irreversible Pulpitis [NCT04157036]	Phase 3	3 participants (Actual)	Interventional	2020-02-01	Terminated(stopped due to COVID halted recruitment for 2 years. A majority of patients eligible for the study had already taken preoperative analgesics, which disqualified them for the study.)
A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome [NCT04933292]	Phase 4	78 participants (Anticipated)	Interventional	2021-06-16	Recruiting
Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia: A Randomized, Controlled, 2x2 Factorial Study [NCT04485429]	Phase 3	0 participants (Actual)	Interventional	2020-07-20	Withdrawn(stopped due to It was not possible to perform the study due to the availability and logistics of porcine heparin)
Phase 2a, Double-blind, Randomized, Placebo-controlled Trial of Methylprednisolone Versus Placebo in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS) [NCT05986422]	Phase 2	418 participants (Anticipated)	Interventional	2023-10-01	Recruiting
Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Crescents : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. [NCT04833374]	Phase 3	200 participants (Anticipated)	Interventional	2021-05-24	Recruiting
Open-label Pilot Study of Methylprednisolone for the Treatment of Patients With Friedreich Ataxia (FRDA) [NCT02424435]	Early Phase 1	11 participants (Actual)	Interventional	2015-06-30	Completed
Comparison Of Efficacy Of Hydrocortisone And Methyl Prednisolone In Acute Severe Asthma [NCT06171932]		60 participants (Anticipated)	Observational [Patient Registry]	2023-11-26	Enrolling by invitation
A Pilot Study Examining Selinexor's Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. [NCT04519476]	Phase 1	22 participants (Anticipated)	Interventional	2020-11-01	Recruiting
Evaluation of the Efficacy of 2% Cyclosporine in Preventing Graft Rejection [NCT02206789]		200 participants (Anticipated)	Interventional	2012-02-29	Recruiting
Using SMART Design to Develop Dynamic Treatment Regimens for Glucocorticoid Tapering [NCT06072768]	Phase 2	200 participants (Anticipated)	Interventional	2023-03-09	Recruiting
Impact of Cyclosporine or Steroid Withdrawal at 3 Months Post Transplantation on Graft Function, Patient Survival and Cardiovascular Surrogate Markers the First 5 Years After Renal Transplantation. [NCT00903188]	Phase 4	152 participants (Anticipated)	Interventional	2008-10-31	Recruiting
Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis [NCT01011621]	Phase 3	170 participants (Anticipated)	Interventional	2010-02-28	Not yet recruiting
Randomised Double-blinded Trial Comparing Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis Relapses [NCT00984984]	Phase 3	200 participants (Anticipated)	Interventional	2008-03-31	Recruiting
To Assess the Role of Sphingosine-1-phosphate in the Pathobiology of Pneumonia: Generate a New Strategy for Treatment of Severe Community-acquired Pneumonia [NCT04007328]	Phase 2/Phase 3	400 participants (Anticipated)	Interventional	2019-06-15	Recruiting
(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy. [NCT00751205]	Phase 2	150 participants (Actual)	Interventional	2008-08-31	Completed
Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment [NCT00977444]	Phase 2/Phase 3	114 participants (Actual)	Interventional	2007-11-30	Active, not recruiting
A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB T [NCT00057811]	Phase 2	97 participants (Actual)	Interventional	2004-06-30	Completed
Phase II Study of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults With B-lymphocyte Antigen CD20 (CD20) Positive Post-Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT) [NCT00066469]	Phase 2	55 participants (Actual)	Interventional	2004-04-30	Completed
A Phase II Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease [NCT01028313]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to A decision was made to not move forward with the study. No participants were enrolled or treated.)
Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. [NCT00888901]	Phase 4	30 participants (Actual)	Interventional	2009-05-31	Completed
Prospective Donor-specific Cellular Alloresponse Assessment for Immunosuppression Minimization in de Novo Renal Transplantation [NCT02540395]		184 participants (Actual)	Interventional	2015-03-31	Completed
Impact of Obesity on the Pharmacokinetics of Anticancer Therapy in Children With High Risk Acute Lymphoblastic Leukemia (ALL) [NCT00900445]		0 participants (Actual)	Observational	2008-03-24	Withdrawn
Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis [NCT00908089]	Phase 4	100 participants (Actual)	Interventional	2003-03-31	Active, not recruiting
Corticoids in Severe Community-acquired Pneumonia [NCT00908713]	Phase 4	120 participants (Actual)	Interventional	2004-01-31	Completed
The Impact of Early Protocol Biopsy in Kidney Transplant Recipients Receiving TAC and MMF; a Prospective Observational Study [NCT02733510]		200 participants (Anticipated)	Observational	2016-04-30	Recruiting
ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial [NCT05765266]		45 participants (Anticipated)	Interventional	2023-08-12	Not yet recruiting
Clinical Treatment of Traumatic Optic Neuropathy: Optic Nerve Decompression Randomized Controlled Study [NCT02711982]		2 participants (Anticipated)	Interventional	2010-01-31	Recruiting
Greater Occipital Nerve Block for Migraine Prophylaxis [NCT00915473]	Phase 4	70 participants (Actual)	Interventional	2009-06-30	Completed
A Pilot Randomized Controlled Trial of Efficacy of Perineural Local Anesthetics and Steroids for Chronic Post-traumatic Neuropathic Pain in the Ankle and the Foot: The PREPLAN Study [NCT02680548]	Early Phase 1	8 participants (Actual)	Interventional	2015-11-30	Completed
Ultrasound Guided Platelet Rich Plasma Injections for Post Traumatic Greater Occipital Neuralgia: A Randomized Controlled Pilot Study [NCT04051203]	Phase 1	35 participants (Anticipated)	Interventional	2019-02-01	Active, not recruiting
Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial [NCT04244591]	Phase 2/Phase 3	80 participants (Actual)	Interventional	2020-01-26	Completed
Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain Following Total Knee Arthroplasty: a Pilot Prospective, Randomized, Crossover Trial [NCT03973177]	Phase 4	0 participants (Actual)	Interventional	2019-05-24	Withdrawn(stopped due to Covid restrictions on recruitment)
A Prospective Study to Assess the Safety and Effectiveness of Medrol® in Acute Asthma in Indian Patients [NCT00971893]		0 participants (Actual)	Observational	2009-10-31	Withdrawn
A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined With Induction in Acute Leukemias Who Exhibit In Vitro Kinase Inhibitor Sensitivity [NCT02779283]	Phase 1	7 participants (Actual)	Interventional	2016-01-13	Completed
A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipi [NCT02763761]	Phase 2	0 participants (Actual)	Interventional	2016-08-16	Withdrawn(stopped due to Insufficient enrollment)
Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism and Beta-Cell Dysfunction in Males With the Metabolic Syndrome X: A Randomized, Placebo-controlled, Double-blind Intervention Study With a 2x2 Factorial Design [NCT00721552]		82 participants (Actual)	Interventional	2008-10-31	Completed
Effects of Volume and Dose of Local Anaesthetic Solution in Epidural Steroidal Injections for Patients With Chronic Lower Back Pain [NCT00887003]		252 participants (Actual)	Interventional	2005-05-31	Completed
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma [NCT05675410]	Phase 3	1,875 participants (Anticipated)	Interventional	2023-05-11	Recruiting
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphom [NCT03914625]	Phase 3	6,720 participants (Anticipated)	Interventional	2019-07-03	Recruiting
A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis [NCT01201798]	Phase 3	111 participants (Actual)	Interventional	2010-10-31	Completed
Transplantation of Umbilical Cord Blood for Myeloid Leukemia Patients Not in CR With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen and UCB NK Cells [NCT00354172]	Phase 2	16 participants (Actual)	Interventional	2006-02-28	Terminated(stopped due to Competing study was started.)
A Comparison of Three Different Formulations of Topical Prednisolone Acetate 1% for Control of Post Glaucoma and/or Cataract Surgery Inflammation. [NCT00345046]	Phase 4	60 participants (Actual)	Interventional	2002-09-30	Completed
Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome in In-vitro Fertilization Cycles: A Randomized Controlled Trial [NCT01014104]	Phase 1/Phase 2	218 participants (Actual)	Interventional	2009-10-31	Completed
Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA) [NCT00443430]	Phase 4	85 participants (Actual)	Interventional	2007-05-31	Completed
Effects of Pre-operative Methylprednisolone (125mg iv) After Total Hip Arthroplasty: A Prospective, Randomized, Double-blind, Placebo-controlled Trail [NCT00968903]	Phase 4	48 participants (Actual)	Interventional	2010-04-30	Completed
Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif) [NCT01049451]	Phase 1	23 participants (Actual)	Interventional	2009-11-30	Completed
Methylprednisolone Combined Electric-acupuncture Treatment Effects on Cognitive Function After Surgery for Elderly Patients With General Anesthesia [NCT02535039]	Phase 1/Phase 2	80 participants (Anticipated)	Interventional	2015-10-31	Recruiting
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma [NCT00481832]	Phase 2	50 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Accrual Factor)
Comparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II Trial [NCT04377503]	Phase 2	30 participants (Actual)	Interventional	2020-05-01	Terminated(stopped due to The number of critically ill patients wirh COVID-19 decrease abruptly)
Preoperative Methylprednisolone in Endovascular Aortic Repair - a Randomized Double Blind Placebo Controlled Clinical Trial [NCT00989729]		150 participants (Actual)	Interventional	2009-10-31	Completed
Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Tagraxofusp (SL-401) in Combination With HCVAD/Mini-CVD and VENETOCLAX [NCT04216524]	Phase 2	40 participants (Anticipated)	Interventional	2020-05-29	Recruiting
A Prospective, Randomized Single-Masked Clinical Trial Comparing OCT and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone [NCT00698724]	Phase 4	200 participants (Anticipated)	Interventional	2008-06-30	Completed
The MAGIC Algorithm Probability Guided Preemption of Steroid-refractory Graft-versus-host Disease With Methylprednisolone [NCT05368181]	Phase 2	56 participants (Anticipated)	Interventional	2022-05-01	Recruiting
Comparing Subacromial Injection of Platelet-rich Plasma Versus Methylprednisolone in the Treatment of Shoulder Subacromial Impingement Syndrome [NCT02669303]		19 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to low recruitment rate and high rate of loss-to-followup)
Incidence of Flare Reaction Following Shoulder Steroid Injections: Comparison of Depo-medrol (Methylprednisolone) and Kenalog (Triamcinolone) [NCT05438277]	Phase 4	421 participants (Actual)	Interventional	2020-01-01	Completed
PreOperative Steroid in Abdominal Wall Reconstruction: A Double-blinded Randomized Clinical Trial [NCT02594241]		42 participants (Actual)	Interventional	2016-03-31	Completed
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen [NCT05626478]	Phase 4	100 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Prednisolone Acetate 1% Treating Pain, and inflamMation Following Corneal Transplant Surgery Compared to Topical Prednisolone Acetate 1%. [NCT04521140]	Phase 4	36 participants (Actual)	Interventional	2020-10-16	Completed
Phase II Trial Of Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin's Lymphoma [NCT00732498]	Phase 2	28 participants (Actual)	Interventional	2006-05-15	Completed
Low Dose Versus High Dose Steroids in Treatment of Viral Encephalitis [NCT04103684]	Phase 4	100 participants (Anticipated)	Interventional	2020-03-30	Not yet recruiting
Effectiveness of Transtympanic Steroids in Unilateral Ménière's Disease: a Randomised Controlled Double-Blind Trial [NCT00802529]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2009-04-30	Completed
"Are Steroids Efficacious in Hospitalized Patients With Bronchiolitis Who Show an Objective Clinical Improvement After Albuterol (Albuterol Responders)?" [NCT00798616]		0 participants (Actual)	Interventional		Withdrawn(stopped due to We were unable to enroll a sufficient number of patients due to manpower.)
Assessment of Clinical Efficacy of 1% Prednisolone Acetate (Ster ®), Produced by união química, Compared to 1% Prednisolone Acetate (Pred ® Fort), Produced by Allergan, in the Control of Postoperative Inflammation in Cataract Surgery. [NCT01227876]	Phase 3	106 participants (Actual)	Interventional	2011-01-31	Completed
Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease [NCT04936854]	Phase 2	60 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. [NCT00755859]	Phase 4	206 participants (Actual)	Interventional	1998-05-31	Completed
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery [NCT00758199]	Phase 4	49 participants (Actual)	Interventional	2008-07-31	Completed
An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) [NCT05345119]		30 participants (Actual)	Observational	2020-01-15	Completed
Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) [NCT00968253]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2009-11-30	Completed
An Open-label Extension (OLE), Expanded Access Study, to Assess Long-term Safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) With Methylprednisolone (4mg Bid) in Patients Who Completed Study Number CHL-AA-201 [NCT02887976]	Phase 3	2 participants (Actual)	Interventional	2016-09-30	Completed
The Effect of Steroid Pulse Therapy for the Reduction of Acute Rejection Episode in Subclinical Borderline Changes: An Open-Label, Randomized Clinical Trial [NCT02664493]		154 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Treatment of Chronic Subdural Hematoma by Corticosteroids [NCT02650609]	Phase 3	202 participants (Actual)	Interventional	2016-06-24	Completed
Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study) [NCT02647255]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2016-03-31	Terminated(stopped due to Due to the rarity and rapid progressive course of the disease, patients were less likely to participate in randomization.)
Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men [NCT00957801]	Phase 4	29 participants (Actual)	Interventional	2009-03-31	Completed
A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients [NCT00782717]	Phase 2	263 participants (Actual)	Interventional	2008-11-30	Completed
Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia [NCT00632554]	Phase 4	50 participants (Anticipated)	Interventional	2008-06-30	Completed
Phase II Trial of the Addition of PEG-Asparaginase to the Hyper-CVAD Regimen in Adult Newly-Diagnosed Acute Lymphoblastic Leukemia [NCT01005914]	Phase 2	11 participants (Actual)	Interventional	2009-06-30	Terminated(stopped due to Increased rate of bacterial infections)
Effect of Anti-inflammatory Topical Prednisolone Acetate 1%, Nepafenac of 0.1% and Ketorolac Tromethamine 0.4% in Intra-operative Mydriasis in Facetectomies [NCT00865540]	Phase 4	30 participants (Actual)	Interventional	2009-03-31	Active, not recruiting
Intra-discal Steroid Injection for MODIC I Discopathy: A Randomized Control Trial [NCT00804531]	Phase 4	137 participants (Actual)	Interventional	2009-04-30	Completed
Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps [NCT05157412]	Phase 3	60 participants (Anticipated)	Interventional	2022-03-01	Not yet recruiting
The Role of Anterior Segment Optical Coherence Tomography in Management of Acquired Punctal Stenosis [NCT04318652]	Phase 4	80 participants (Actual)	Interventional	2018-09-02	Completed
Randomized, Prospective Single-center Study Comparing a Rapid Discontinuation of Corticosteroids (Steroid Withdrawal) With Corticosteroid Therapy in Kidney Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy [NCT00596947]	Phase 4	18 participants (Actual)	Interventional	2005-10-31	Terminated(stopped due to due to low study enrollment)
Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1) [NCT02798068]	Phase 4	60 participants (Anticipated)	Interventional	2016-05-31	Recruiting
Evaluation of Efficacy in the Resolution of Post-Operative Inflammation and Pain in Patients Receiving Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery [NCT04316936]	Phase 4	15 participants (Actual)	Interventional	2019-12-10	Completed
GON-injection for a Sooner and Better Treatment of Cluster Headache: a Double-blind Randomized Controlled Trial [NCT04014634]	Phase 4	80 participants (Anticipated)	Interventional	2019-08-01	Recruiting
A Phase I, Randomised, Single-blind Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567 in Healthy Volunteers Using Prednisolone as Positive Control [NCT02760316]	Phase 1	64 participants (Anticipated)	Interventional	2016-05-02	Completed
Rituximab Plus Short-term Methylprednisolone Versus Standard Dose Methylprednisolone in Newly Diagnosed Participants With Immune Thrombocytopenia (ITP): A Multicenter, Randomized Phase II Study in China [NCT02757196]	Phase 2	112 participants (Anticipated)	Interventional	2016-05-31	Not yet recruiting
Budesonide Inhalation Suspension for Acute Asthma in Children [NCT00393367]	Phase 4	179 participants (Actual)	Interventional	2006-12-31	Completed
An Open Label, Multicenter, Phase I/II Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease [NCT04220632]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2020-06-18	Terminated(stopped due to Adverse events of the first patient)
A Phase IIIB, Multicenter, Randomized, Double-Masked, Parallel-Group, Active-Controlled Study of the Safety and Efficacy of Difluprednate Ophthalmic Emulsion, 0.05% (Durezol™) 4 Times Daily (QID) and Prednisolone Acetate Ophthalmic Suspension, 1.0% (Pred [NCT01124045]	Phase 3	80 participants (Actual)	Interventional	2010-08-31	Completed
Intrathecal Rituximab in Progressive Multiple Sclerosis [NCT02545959]	Phase 2	10 participants (Actual)	Interventional	2015-11-30	Completed
Randomized, Placebo-Controlled Trial of Bilateral 3rd/4th Common Digital Foot Nerve Injections to Treat Restless Legs Syndrome [NCT00656110]		60 participants (Anticipated)	Interventional	2008-04-30	Recruiting
Topical Epidural Steroid Usage in Patients Undergoing Posterior Lumbar Decompression: A Randomized Control Trial [NCT05058287]	Phase 3	150 participants (Anticipated)	Interventional	2021-11-05	Recruiting
Multicenter, Randomized, Double Blind, Clinical Trial to Compare the Clinical and Radiological Efficacy of Equivalent Doses of Methylprednisolone Administered Orally or Intravenously in Patients With Multiple Sclerosis During Relapse [NCT00753792]	Phase 4	49 participants (Actual)	Interventional	2008-11-30	Completed
Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II：A Randomized Controlled Open-label Clinical Trial [NCT04617561]	Phase 4	90 participants (Anticipated)	Interventional	2020-11-01	Recruiting
Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome: A Randomized Controlled Trial [NCT00863889]	Phase 4	0 participants (Actual)	Interventional	2009-03-31	Withdrawn
An Unusual Association Between Pancreatic Cancer and Purtscher-like Retinopathy: Presentation of a Unique Case [NCT05350384]		1 participants (Actual)	Observational	2021-06-18	Completed
Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter Trial [NCT01392833]	Phase 3	46 participants (Actual)	Interventional	1999-12-31	Completed
Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma [NCT02293109]	Phase 1	10 participants (Actual)	Interventional	2015-12-17	Completed
Phase 1, Open-label, Randomized, Single-dose, 2-treatment, Crossover Be Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/ml To Methylprednisolone 16 Mg Tablet Under Fasting Conditions [NCT01405157]	Phase 1	0 participants (Actual)	Interventional	2012-01-01	Withdrawn
Phase 1, Open-label, Randomized, Single-dose, 2-treatment, Crossover Be Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/ml To Methylprednisolone 32 Mg Tablet Under Fed Conditions [NCT01405170]	Phase 1	0 participants (Actual)	Interventional	2011-10-14	Withdrawn
A Phase IV Single Blind Placebo-controlled Cross Over Study to Investigate the Efficacy of Greater Occipital Nerve Block With Local Anesthetic and Steroid in Patients With Chronic Migraine [NCT04017741]	Phase 4	8 participants (Actual)	Interventional	2018-02-14	Completed
Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis [NCT01408836]	Phase 2/Phase 3	150 participants (Actual)	Interventional	1995-03-31	Terminated(stopped due to Completed)
Comparison Between Standard Dose Methyl Prednisolone and Megadose Methyl Prednisolone as Regards Outcome in SARS.COV.2 Patients in Intensive Care Unit : Retrospective Study [NCT05279482]		104 participants (Actual)	Observational	2022-01-19	Completed
A Randomized Phase II Study for the Evaluation of Extracorporeal Photopheresis (ECP) in Combination With Corticosteroids for the Initial Treatment of Acute Graft-Versus-Host Disease (GVHD) [NCT00609609]	Phase 2	81 participants (Actual)	Interventional	2008-01-31	Completed
Effects of Pre-operative Methylprednisolone (125mg iv) After Total Knee Arthroplasty: A Prospective, Randomized, Double-blind, Placebo-controlled Trail [NCT00968578]	Phase 4	48 participants (Actual)	Interventional	2009-08-31	Completed
Phase II Study of The Modified Hyper-CVAD Program for Acute Lymphoblastic Leukemia [NCT00671658]	Phase 2	220 participants (Actual)	Interventional	2002-11-30	Completed
Effect of Preoperative Intravenous High Dose Methylprednisolone on Immune Signaling in Patients Scheduled for Total Hip-arthroplasty [NCT02542592]	Phase 2/Phase 3	64 participants (Actual)	Interventional	2015-09-30	Completed
Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies [NCT01093586]	Phase 2	14 participants (Actual)	Interventional	2007-09-30	Completed
An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia [NCT04263402]	Phase 4	100 participants (Anticipated)	Interventional	2020-02-01	Recruiting
A Randomized, Parallel-Cohort Phase 1 Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute Graft Versus Host Disease [NCT02614612]	Phase 1	31 participants (Actual)	Interventional	2015-12-31	Completed
Prednisolone-induced Impairment of Glucose Metabolism and Beta-cell Dysfunction and the Protective Effects of Exenatide: a Single-center, Randomized, Double-blind, Placebo-controlled Crossover Study in Healthy Volunteers [NCT00744224]		8 participants (Anticipated)	Interventional	2009-02-28	Completed
Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol [NCT00991744]	Phase 3	100 participants (Anticipated)	Interventional	2009-01-31	Suspended(stopped due to Sterility problems in DepoCyte production)
A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014) [NCT02611492]	Phase 3	265 participants (Anticipated)	Interventional	2016-04-30	Recruiting
Efficacy of Vigabatrin With High Dose Prednisolone Combination Therapy Versus Vigabatrin Alone for Infantile Spasm: a Randomized Trial [NCT04302116]		250 participants (Anticipated)	Interventional	2020-05-18	Recruiting
Pilot Randomized, Placebo-Controlled Trial to Evaluate The Effect of Oral Pulsed Methylprednisolone on Seizure Frequency in Pediatric Patients With Idiopathic Intractable Convulsive Epilepsy [NCT04219995]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2020-02-03	Recruiting
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation [NCT00309907]	Phase 2	39 participants (Actual)	Interventional	2006-04-30	Completed
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults [NCT02166463]	Phase 3	600 participants (Actual)	Interventional	2015-03-19	Active, not recruiting
Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis [NCT02717871]	Phase 3	35 participants (Actual)	Interventional	2016-03-31	Completed
Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) [NCT00720109]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2008-07-14	Completed
Evaluation of Inhaled Corticosteroid Treatment in Sinusitis [NCT01907204]	Phase 2/Phase 3	50 participants (Actual)	Interventional	2013-07-31	Completed
Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Stu [NCT00947895]	Phase 2/Phase 3	30 participants (Actual)	Interventional	2009-10-31	Terminated(stopped due to Study reached halfway point in approximately one year time period and was halted to analyze data.)
Lessdrops™ Prophylactic Treatment After Routine Phacoemulsification Compared to Standard Drops Regimen [NCT03578276]	Phase 4	35 participants (Actual)	Interventional	2018-06-22	Completed
[NCT00000147]		0 participants	Interventional	1988-07-31	Active, not recruiting
Acute Respiratory Distress Syndrome Clinical Network (ARDSNet) [NCT00000579]	Phase 3	0 participants	Interventional	1994-09-30	Completed
A Controlled Randomized Trial to Study the Efficacy of Adjunctive Methylprednisolone for the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Pediatric AIDS Patients [NCT00000741]	Phase 3	0 participants (Actual)	Interventional		Withdrawn
"Efficacy of Infliximab as Bridging Therapy in the Treatment of Patients Affected by Corticodependent Crohn's Disease Under Standard Treatment With Azathioprine" [NCT00796250]	Phase 3	9 participants (Actual)	Interventional	2003-11-01	Terminated(stopped due to Due to poor patient recruitment, a decision was made to terminate this trial.)
Intérêt de la corticothérapie Dans la Pneumocystose Grave du Patient immunodéprimé Non VIH. Essai Prospectif Multicentrique Randomisé Contrôlé : PIC [NCT02944045]	Phase 3	222 participants (Anticipated)	Interventional	2017-02-15	Recruiting
Efficacy of Methylprednisolone in Severe Community-acquired Pneumonia，A Multi-center Randomized Controlled Trial [NCT02552342]	Phase 4	610 participants (Anticipated)	Interventional	2015-05-31	Recruiting
A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis [NCT02406209]	Phase 2	45 participants (Actual)	Interventional	2015-03-31	Completed
Acute Unilateral Vestibulopathy and Corticosteroid Treatment [NCT02912182]	Phase 4	78 participants (Actual)	Interventional	2015-12-31	Terminated(stopped due to Placebo medication expired)
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas [NCT01024322]		1,189 participants (Actual)	Observational	2009-10-01	Terminated(stopped due to Terminated to initiate FDA IND-cleared study protocol)
Utility of Intramuscular Corticosteroids for Radicular Low Back Pain [NCT00290589]	Phase 3	82 participants (Actual)	Interventional	2003-06-30	Completed
Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients. A Single-blind Randomized Clinical Trial [NCT03742466]		50 participants (Actual)	Interventional	2018-11-10	Completed
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib [NCT01324596]	Phase 3	1,132 participants (Actual)	Interventional	2011-04-30	Completed
A Randomized, Multicenter, Open-label, 6-month Study to Explore the Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare [NCT00423098]	Phase 2	81 participants (Actual)	Interventional	2007-02-28	Completed
An Open-label, Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation [NCT00186628]	Phase 2	36 participants (Actual)	Interventional	2005-06-30	Completed
Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord: an Open-Labeled, Dose-Escalating Clinical Tiral [NCT01046786]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2010-01-31	Completed
An Oral Methylprednisolone Taper Within a Multimodal Analgesic Regimen After Total Knee Arthroplasty: a Double-Blind Randomized Placebo-Controlled Trial [NCT05097976]	Phase 4	420 participants (Anticipated)	Interventional	2022-03-01	Recruiting
Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis [NCT00332696]	Phase 2	64 participants (Actual)	Interventional	2005-09-30	Completed
A Randomized Trial of Rituximab in Induction Therapy for Living Donor Renal Transplantation [NCT01095172]	Phase 4	100 participants (Actual)	Interventional	2010-11-30	Active, not recruiting
High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Transplantation in Patients With Refractory Idiopathic Inflammatory Myopathy Diseases: A Phase I Trial [NCT00278564]	Phase 1	7 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to high relapse rate)
An Open-Label, Phase 1 Study to Examine the Pharmacokinetic Interactions Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects [NCT01886209]	Phase 1	28 participants (Anticipated)	Interventional	2013-06-30	Completed
Assessing the Efficacy of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert, When Placed Within the Lower Eye Lid Canaliculus in Comparison to Topical Prednisolone Acetate Following Bilateral Small Incision Lenticule Extraction (SMILE) [NCT04380857]	Phase 4	20 participants (Actual)	Interventional	2020-06-18	Completed
A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease [NCT00410657]	Phase 2	53 participants (Anticipated)	Interventional	2006-07-31	Completed
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial [NCT01939691]	Phase 4	9 participants (Actual)	Interventional	2018-09-12	Terminated(stopped due to Difficulty enrolling)
A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study [NCT00241254]	Phase 3	138 participants (Actual)	Interventional	2005-12-31	Completed
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Itolizumab in Subjects With Newly Diagnosed Acute Graft Versus Host Disease [NCT05823675]	Phase 1	44 participants (Anticipated)	Interventional	2023-05-19	Recruiting
Phase II Study of High-dose Methylprednisolone and Rituximab in Previously Treated Patients With High Risk Chronic B Lymphocytic Leukemia [NCT00558181]	Phase 2	29 participants (Actual)	Interventional	2007-09-30	Completed
European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study) [NCT01955187]	Phase 3	86 participants (Actual)	Interventional	2014-01-31	Completed
Steroid Injections vs. Platelet Rich Plasma Injections in Patients With Plantar Fasciitis: A Comparison of Clinical and Ultrasound Findings [NCT01957631]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2013-06-30	Withdrawn(stopped due to Lack of funding)
A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy [NCT01969019]	Phase 4	70 participants (Anticipated)	Interventional	2010-01-31	Recruiting
Antiemetic Corticosteroid Rotation From Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated With Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial [NCT01974024]	Phase 3	65 participants (Actual)	Interventional	2013-10-01	Completed
A Prospective Randomized 3-arm Trial Comparing Intra-articular Corticosteroid Injection vs Arthrographic Distention vs Arthrographic Distention Plus Intra-articular Corticosteroid Injection in the Treatment of Adhesive Capsulitis [NCT01983527]		132 participants (Anticipated)	Interventional	2013-12-31	Not yet recruiting
Comparing the Effectiveness of Steroid Injection Versus Placebo and Immobilization Versus no Immobilization in Treating Patients With Lateral Epicondylitis [NCT01986465]	Phase 2/Phase 3	78 participants (Actual)	Interventional	2013-05-31	Completed
Multicenter, Randomized, Double-blind Clinical Trial to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse. [NCT01986998]	Phase 4	49 participants (Actual)	Interventional	2013-10-31	Completed
Optimal Treatment of Plantar Fasciitis: A Randomized Clinical Trial Using Physical Training, Glucocorticoid Injections or a Combination Thereof. [NCT01994759]	Phase 4	90 participants (Actual)	Interventional	2013-09-01	Completed
Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease [NCT04603729]	Phase 3	100 participants (Actual)	Interventional	2020-05-30	Completed
PhaseIV Study of Intra-articular Methylprednisolone in TMJ Arthralgia [NCT01995019]	Phase 4	56 participants (Actual)	Interventional	2013-12-10	Completed
Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) [NCT04593706]		40 participants (Anticipated)	Interventional	2020-11-01	Not yet recruiting
Preoperative Glucocorticoid Use in Major Hepatectomy - A Randomized Controlled Trial [NCT01997658]	Phase 2/Phase 3	200 participants (Actual)	Interventional	2014-10-31	Completed
High Doses of Methylprednisolone in the Management of Caustic Esophageal Burns in Children [NCT02002078]	Phase 4	83 participants (Actual)	Interventional	2007-02-28	Completed
Efficacy of the Intralesional Infusion of Local Anesthetic and Steroids After Major Abdominal Surgery: a Randomized Double Blind Phase III Trial [NCT02002663]	Phase 3	120 participants (Actual)	Interventional	2013-08-31	Completed
Randomised, Multicentre, Open Label, Parallel Group Pragmatic Clinical Trial of Local Steroid Injection Versus Night Splinting in Mild to Moderate Carpal Tunnel Syndrome (CTS) [NCT02038452]	Phase 4	234 participants (Actual)	Interventional	2014-04-30	Completed
Influence of Corticoids on Renal Function in Cardiac Surgery [NCT00879931]	Phase 2	80 participants (Actual)	Interventional	2013-01-31	Completed
Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass [NCT00934843]		77 participants (Actual)	Interventional	2007-03-31	Completed
Do Intraoperative Topical Corticosteroids Aid in the Prevention of Postoperative Dysphagia Following Elective Anterior Cervical Discectomy and Fusion? A Randomized, Controlled, Double Blinded Clinical Trial [NCT02539394]		128 participants (Actual)	Interventional	2015-08-31	Completed
Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled Trial [NCT03265405]	Phase 4	86 participants (Actual)	Interventional	2017-04-01	Completed
Efficacy and Safety of Difluprednate Ophthalmic Emulsion vs. a Fixed-Combination of Prednisolone Acetate - Phenylephrine Ophthalmic Suspension on Post-operative Inflammation Following Cataract Surgery. [NCT04631315]	Phase 4	255 participants (Actual)	Interventional	2019-03-24	Completed
Study on the Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica and Gene Polymorphism: a Cohort Study [NCT04601142]		350 participants (Anticipated)	Observational	2020-10-31	Recruiting
Peking University Third Hospital Medical Science Research Ethics Committee [NCT04590183]		30 participants (Anticipated)	Interventional	2020-10-01	Recruiting
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination With Standard of Care (Mycophenolate Mofetil and Steroid [NCT01085097]	Phase 2	46 participants (Actual)	Interventional	2010-09-01	Completed
The Efficacy Of Magnesium In Radicular Lower Limb Pain When It Is Added To Local Anesthetics And Steroids In The Transforaminal Epidural Injections. A Comparative Study [NCT04532775]	Phase 1	100 participants (Anticipated)	Interventional	2020-08-30	Not yet recruiting
Cadaveric Organ Donor Management: Thyroid and Adrenocortical Hormone Replacement [NCT04528797]		199 participants (Actual)	Interventional	2010-09-02	Completed
Comparison of the Efficacy Between Ultrasound-guided Dextrose Injection Versus Dextrose With Methylprednisolone Injection in Patients With Carpal Tunnel Syndrome: a Prospective, Randomized Double-blind Clinical Trial. [NCT06045013]	Phase 3	70 participants (Anticipated)	Interventional	2023-09-13	Recruiting
Ultrasound Guided Sacroiliac Joint Injections With Ketorolac Versus Corticosteroid: A Prospective Non-inferiority Study [NCT06081101]	Early Phase 1	80 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Risk Stratification-directed Low-dose Glucocorticoid Prophylaxis for Acute GVHD After Unmanipulated Haploidentical Blood and Marrow Transplantation--a Randomized, Controlled, Clinical Trial [NCT01607580]		145 participants (Actual)	Interventional	2012-06-30	Completed
Evaluation of the Bioavailability of Methylprednisolone Succinate Administered Intranasally [NCT05649878]		8 participants (Actual)	Interventional	2021-11-05	Completed
Non-Invasive Mechanical Ventilation in Elderly Patients Affected by Acute Hypercapnic Respiratory Failure:A Randomized Control Study vs Standard Medical Therapy A Multicentric Randomized Controlled Trial [NCT00600639]	Phase 4	82 participants (Actual)	Interventional	2004-01-31	Terminated
Local Steroid Injection in the Treatment of Idiopathic Carpal Tunnel Syndrome: A Randomized Double-blind Placebo-controlled Trial Among Patients Planned for Surgical Treatment [NCT00806871]	Phase 2/Phase 3	112 participants (Actual)	Interventional	2008-11-30	Completed
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis [NCT00424489]	Phase 1	9 participants (Actual)	Interventional	2002-02-28	Terminated(stopped due to No participants enrolled for more than two years. No plan to continue study.)
Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study [NCT04168112]	Phase 4	20 participants (Actual)	Interventional	2020-02-12	Completed
Incretin Physiology and Beta-Cell Function Before and After Treatment With Steroid Hormone in Healthy Individuals [NCT00713440]		10 participants (Actual)	Interventional	2008-07-31	Completed
A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia [NCT05761171]	Phase 2	78 participants (Anticipated)	Interventional	2023-11-20	Recruiting
Preoperative Methylprednisolone to Patients Suspected of Appendicitis Undergoing Laparoscopy [NCT02711449]	Phase 2	78 participants (Actual)	Interventional	2016-04-30	Completed
An Open-label Multicenter Trial to Study the Efficacy and Safety of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura [NCT04074187]	Phase 2/Phase 3	21 participants (Actual)	Interventional	2019-10-21	Completed
A Randomized Controlled Clinical Trial on the Efficacy and Safety of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-induced Liver Injury [NCT02651350]	Phase 1/Phase 2	80 participants (Actual)	Interventional	2015-12-31	Completed
Efficacy of Intra-operative Subacromial Corticosteroid Injections on Surgical Outcomes After Arthroscopic Shoulder Surgery [NCT02867904]	Phase 4	12 participants (Actual)	Interventional	2016-03-31	Terminated(stopped due to It was difficult to recruit patients to get the appropriate sample size.)
Comparison of Corticosteroids Versus Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the Intensive Care Unit: a Multicentre Randomized Controlled Trial [NCT04163536]	Phase 3	440 participants (Anticipated)	Interventional	2021-10-25	Recruiting
Desensitization for Preformed Anti-HLA Antibodies in Kidney Transplantation [NCT00908583]	Phase 4	44 participants (Actual)	Interventional	2009-05-31	Completed
Corticosteroids for Cancer Pain [NCT00676936]	Phase 3	50 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized Trial of Cortisone Injection Versus Bone Marrow Aspirate Injection Therapy for Glenohumeral Osteoarthritis [NCT03580148]	Phase 2/Phase 3	34 participants (Actual)	Interventional	2015-10-08	Completed
Phase 1, Open-label, Randomized, Single-dose, 2-treatment, 2 Period Crossover Bioequivalence Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/ml To Methylprednisolone 32 Mg Tablet Under Fasted Conditions [NCT01405131]	Phase 1	0 participants (Actual)	Interventional	2012-01-01	Withdrawn
Assessment of Corticosteroid Effect in the Prevention of Facial Palsy After Cerebella-pontine Angle Surgery [NCT00438087]	Phase 3	313 participants (Actual)	Interventional	2007-03-31	Completed
Retrospective Study of Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome [NCT01423864]	Phase 2	29 participants (Actual)	Interventional	2005-06-30	Completed
Comparison Between Prednisolone and Dexamethasone on D28 Mortality in Patients on Oxygen Therapy, With CoViD-19: Multicenter, Randomized, Open-label Non-inferiority Study [NCT04765371]	Phase 3	89 participants (Actual)	Interventional	2021-03-03	Completed
A Randomized, Multicentre, Double-blind Study to Evaluate the Efficacy of High-dose Administration of Methylprednisolone in Addition to Standard Treatment, in SARS-CoV2 (COVID-19) Pneumonia Patients [NCT04673162]	Phase 3	260 participants (Actual)	Interventional	2020-12-17	Completed
Efficacy of High-dose Corticosteroid Pulses Added to Conventional Oral Corticosteroid Course for Moderate Flares of Ulcerative Colitis. [NCT02921555]	Phase 4	75 participants (Actual)	Interventional	2018-10-11	Completed
Assessing the Efficacy and Safety of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert, When Placed Within the Lower Eye Lid Canaliculus in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment [NCT04464629]	Phase 4	7 participants (Actual)	Interventional	2020-07-14	Terminated(stopped due to Poor enrollment)
A Randomized Pilot Trial of a Steroid-free Immunosuppressant Regimen in Pediatric Liver Transplantation [NCT00694408]	Phase 3	15 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to Study terminated due to withdrawal from market of Daclizumab)
Evaluation of the Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study VS Methylprednisolone (MP) [NCT00561067]	Phase 3	10 participants (Actual)	Interventional	2008-04-30	Terminated(stopped due to Italian Medicines Agency decision)
Double-Blind, Placebo Controlled, Randomized, Multicenter, Parallel-Group Study to Compare the Efficacy and Safety of Advantan Cream Twice Weekly With Advabase Cream During a Maintenance Phase of 16 Weeks After Successful Treatment of Atopic Dermatitis Wi [NCT00185510]	Phase 4	250 participants (Actual)	Interventional	2005-03-31	Completed
Can Montelukast Shorten Corticosteroid Therapy In Children With Mild To Moderate Acute Asthma? [NCT00213252]	Phase 2	130 participants (Actual)	Interventional	2005-09-30	Completed
Multisystem Inflammatory Syndrome Therapies in Children (MISTIC) Comparative Effectiveness Study [NCT04898231]	Phase 2/Phase 3	180 participants (Anticipated)	Interventional	2020-12-22	Active, not recruiting
A Phase 2b, Double-Blind, Three Arm, Randomized, Placebo Controlled Trial With Restricted Response Adaptive Randomization Testing the Efficacy and Safety of High Dose Methylprednisolone or Equine Anti-Thymocyte Globulin as Treatment for Acute Liver Failur [NCT04862221]	Phase 2	163 participants (Anticipated)	Interventional	2022-02-09	Recruiting
Comparison of the Efficacy and Safety of Two Corticosteroid Regimens in the Treatment of Diffuse Lung Disease After Coronavirus Disease 2019 (COVID-19) Pneumonia [NCT04657484]		130 participants (Actual)	Interventional	2020-12-01	Completed
Comparison of the Effectiveness of the Ultrasound Guided Subacromial, Acromioclavicular With Subacromial Injection and Suprascapular Nerve Block in Patients With Shoulder Impingement Syndrome ; A Randomized Controlled, Single Blind, Clinical Trial [NCT05015322]	Phase 4	88 participants (Actual)	Interventional	2017-01-01	Completed
Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology [NCT02416128]		0 participants (Actual)	Interventional	2015-04-30	Withdrawn(stopped due to No participants enrolled)
A Two-Part, Multi-Center, Prospective, Phase 2/3 Clinical Study to Evaluate the Safety and Efficacy of GLASSIA as an Add-On Biopharmacotherapy to Conventional Steroid Treatment in Subjects With Acute Graft-Versus-Host Disease With Lower Gastrointestinal I [NCT02956122]	Phase 2/Phase 3	1 participants (Actual)	Interventional	2017-04-26	Terminated(stopped due to The decision to discontinue the study was based on business reasons.)
[NCT00000138]	Phase 3	0 participants	Interventional	1989-05-31	Active, not recruiting
High-Dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation With Temozolomide for Immunocompetent Patients With Primary Central Nervous System Lymphoma - a Phase II Study [NCT00455286]	Phase 2	25 participants	Interventional	2006-11-30	Recruiting
Phase IV Study of Perioperative Steroid's Effects on Death or MI in High-Risk Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass [NCT00427388]	Phase 4	7,507 participants (Actual)	Interventional	2007-06-30	Active, not recruiting
[NCT00480675]		65 participants (Actual)	Interventional	2007-03-31	Completed
[NCT00469781]	Phase 4	95 participants (Actual)	Interventional	2007-05-31	Completed
[NCT00501579]	Phase 3	0 participants	Interventional		Completed
A Randomized, Masked Multi-center Safety & Efficacy Study of the Effects of Preoperative & Postoperative Cataract Surgery Use of Difluprednate Ophthalmic Emulsion, 0.05% Compared to Prednisolone Acetate Ophthalmic Suspension 1% on Visual Acuity & Corneal [NCT01244334]	Phase 4	52 participants (Actual)	Interventional	2009-03-31	Completed
A Multicenter, Double-blinded, Randomized, Placebo-controlled Trial to Compare the Effectiveness of Intratympanic Injections methylPREDnisolon Versus Placebo in the Treatment of Vertigo Attacks in MENière's Disease (PREDMEN Trial). [NCT05851508]	Phase 3	148 participants (Anticipated)	Interventional	2023-10-01	Recruiting
Prednisolone and Vitamin B1, B6, and B12 in Patients With Post-COVID-19-Syndrome (PC19S) - a Randomized Controlled Trial in Primary Care [NCT05638633]	Phase 3	340 participants (Anticipated)	Interventional	2022-11-11	Recruiting
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement [NCT02828358]	Phase 2	78 participants (Actual)	Interventional	2017-04-01	Active, not recruiting
Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance [NCT00752479]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Necessity of major revision of the protocol)
Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy [NCT00523692]	Phase 4	20 participants (Anticipated)	Interventional	2007-09-30	Not yet recruiting
A Multicentre Placebo-Controlled Evaluation of Prednisolone and/or Valaciclovir for the Treatment of Bell's Palsy [NCT00510263]	Phase 4	839 participants (Actual)	Interventional	2001-05-31	Completed
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) [NCT00557193]	Phase 3	218 participants (Actual)	Interventional	2008-01-15	Active, not recruiting
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants [NCT02935101]	Phase 2	4 participants (Actual)	Interventional	2016-10-31	Terminated(stopped due to difficulties in recruiting study participants)
Pilot Study Investigating the Utility of Epidural AlloGen-LI Injection for Treatment of Spinal Stenosis Symptoms [NCT02932020]		0 participants (Actual)	Interventional	2016-10-31	Withdrawn
A Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, Crossover Bioavailability Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/Ml to Methylprednisolone 32 Mg Tablet Under Fasted Conditions [NCT01267201]	Phase 1	24 participants (Actual)	Interventional	2010-11-30	Completed
Clinical and Radiological Comparison of the Efficacy of Hyaluronic Acid, PRP and Steroid Injections in Partial Rotator Cuff Tears: A Prospective Randomized Study [NCT04681937]		80 participants (Anticipated)	Interventional	2021-06-01	Not yet recruiting
High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab [NCT01211665]	Phase 4	3 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to This study was stopped prematurely due to lack of enrollment within a 1-5-year period.)
DEXTENZA for the Treatment of Post-Surgical Pain and Inflammation ComparEd to StandaRd of Care Topical Cortico-Steroid Treatment In PatientS Who Undergo BilaTeral Pterygium Surgery PERSIST Study [NCT04351737]	Phase 4	20 participants (Anticipated)	Interventional	2020-07-15	Active, not recruiting
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia [NCT05320380]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2023-08-01	Withdrawn(stopped due to Withdrawn per CS0150757)
Effects of Peri-Operative Glucosteroid Administration on Outcomes Following Distal Radius Fracture [NCT05655130]	Phase 1	60 participants (Anticipated)	Interventional	2018-11-06	Active, not recruiting
An Open-label, Single-arm Study to Describe Glucocorticoid Use in Rheumatoid Arthritis Patients Treated With Tocilizumab in Daily Clinical Practice and to Evaluate Systematic Glucocorticoid Dose Reduction Once Low Disease Activity is Reached (ACT-ALONE) [NCT01219933]	Phase 4	68 participants (Actual)	Interventional	2011-01-31	Completed
[NCT00854061]	Phase 3	172 participants (Actual)	Interventional	2009-02-28	Completed
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma [NCT00882895]	Phase 2	18 participants (Actual)	Interventional	2009-05-05	Active, not recruiting
Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm [NCT04355247]	Phase 2	20 participants (Anticipated)	Interventional	2020-04-14	Recruiting
Matched Unrelated and Haploidentical Bone Marrow Transplantation for Hematologic Malignancies [NCT00003960]	Phase 2	36 participants (Anticipated)	Interventional	1998-04-30	Completed
A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation [NCT00357084]	Phase 2	53 participants (Anticipated)	Interventional	2006-05-31	Completed
Research on the Treatment of Severe Community-acquired Pneumonia in Children [NCT05768204]	Phase 4	160 participants (Anticipated)	Interventional	2023-03-10	Recruiting
Open Randomized Study on the Efficacy of corticoïd Infiltration Versus Physiological Solution Infiltration Versus Feigning of Infiltration Via Sacro-coccygien Hiatus Versus Natural Evolution in Discal Sciatica [NCT01482897]	Phase 3	13 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Enrolment stopped on December 01, 2014 since after 3 years, only 13 patients were included (instead of 274) (Date of last visit last patient : October 3, 2013).)
Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans [NCT00281710]	Phase 4	20 participants	Interventional	2005-10-31	Completed
Prospective Phase II Study of Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome (ARDS) After Thoracic Surgery (E-START) [NCT00290602]	Phase 2	40 participants	Interventional	2004-02-29	Completed
Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma [NCT00307606]	Phase 4	40 participants (Anticipated)	Interventional	2005-12-31	Recruiting
The Efficacy and Safety of Intravenous Pulse Steroids Compared to Standard Oral Steroids in the Treatment of Problematic Hemangiomas in Infants: A Randomized Controlled Trial [NCT00312520]	Phase 3	20 participants	Interventional	2002-07-31	Completed
Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus [NCT04233164]	Early Phase 1	47 participants (Actual)	Interventional	2020-03-04	Active, not recruiting
A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Treatment [NCT05665270]	Phase 4	40 participants (Anticipated)	Interventional	2023-01-30	Enrolling by invitation
[NCT00433225]	Phase 4	0 participants	Interventional		Completed
A Masked Comparison of Acular LS Plus Steroid Versus Steroid Alone for the Prevention of Macular Leakage in Cataract Patients [NCT00348244]	Phase 4	0 participants	Interventional		Completed
A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monothe [NCT00112034]	Phase 4	350 participants	Interventional	2003-06-30	Completed
Double-Blind Randomized Placebo-Controlled Trial on Clinical and Biological Effects of Oral Corticosteroids or Doxycyclin in Patients With Nasal Polyposis [NCT00480298]	Phase 2	48 participants	Interventional	2002-11-30	Completed
A Multicenter, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Combination With MMF and Steroids in Patients Undergoing Kidney Transplantation and a Pharmacokinetics Study. [NCT00481819]	Phase 3	240 participants (Actual)	Interventional	2007-07-31	Completed
The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome [NCT00127985]	Phase 4	240 participants (Anticipated)	Interventional	2005-08-31	Recruiting
A Randomised, Placebo-controlled, Parallel Group Single Dose Study of SB681323 in Patients With Active RA to Investigate the CRP Dose Response Relationship [NCT00134693]	Phase 2	77 participants (Actual)	Interventional	2005-06-21	Completed
Medication Overuse Headache: A Randomised Double Blind Study of Prednisolone or Placebo in Withdrawal Therapy (Phase 3), and a Randomised 1 Year Follow up by Neurologist or General Physician After Successful Withdrawal Therapy [NCT00135122]	Phase 3	100 participants (Actual)	Interventional	2003-09-30	Completed
Assessment of the Efficacy of Glucocorticoids in Improving Post-operative Organ Dysfunction in Patients With Acute Type A Aortic Dissection(GLAD): a Randomized Controlled Trial [NCT05329740]	Phase 4	212 participants (Actual)	Interventional	2022-02-07	Completed
Repeated Corticosteroid Injections Around the Greater Occipital Nerve (GON) as Prophylactic Treatment in Chronic Cluster Headache [NCT05324748]	Phase 3	50 participants (Anticipated)	Interventional	2022-11-07	Recruiting
A Phase I Randomized, Double-blind, Placebo-controlled, Dose-increasing Single Dose Study Evaluating the Safety, Tolerability，Pharmacokinetics and Pharmacodynamics Analysis of Pegloticase in Subjects With Asymptomatic Hyperuricemia [NCT05302388]	Phase 1	45 participants (Actual)	Interventional	2022-04-11	Completed
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma [NCT04759586]	Phase 3	244 participants (Anticipated)	Interventional	2021-10-05	Recruiting
The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study [NCT02784210]	Phase 2	30 participants (Anticipated)	Interventional	2016-10-05	Recruiting
A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma [NCT00004192]	Phase 2	60 participants (Anticipated)	Interventional	2000-05-01	Completed
Phase 3 Open Label Randomised Multicentre Controlled Trial of Rituxmab and Mycophenolate Mofetil Without Oral Steroids for the Treatment of Lupus Nephritis [NCT01773616]	Phase 3	24 participants (Actual)	Interventional	2015-04-30	Terminated(stopped due to Study assessments for patients recruited continuing per protocol so patients receive a minimum of 6 months follow up. No safety concerns have been raised.)
Trial of High Dose Immunosuppressive Therapy With Hematopoietic Stem Cell Support in Devic's Disease [NCT00787722]	Phase 1/Phase 2	13 participants (Actual)	Interventional	2009-10-10	Completed
Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and Granulocyte Colony-stimulating Factor (GCSF) in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome [NCT00806598]	Phase 2	53 participants (Actual)	Interventional	2005-05-31	Completed
A Prospective Randomized Controlled Trial of Early Non-Invasive Positive Pressure Ventilation in Patients With Hypoxemic Respiratory Failure and Malignancies [NCT02464696]		256 participants (Anticipated)	Interventional	2015-10-06	Recruiting
Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30) [NCT01105650]	Phase 2	13 participants (Actual)	Interventional	2010-07-31	Completed
Injection of Dorsal Scapular n at Different Levels, Dose it Make Difference? [NCT04693312]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2020-01-01	Completed
Multi-center, Randomized, Double Masked, Vehicle Controlled Phase IV Study to Compare the Efficacy, Ocular Safety and Tolerability of a Two Day Treatment With Eye Drops (0.5% Prednisolone Acetate, One Drop Four Times Per Day) in Patients With Intraocular [NCT00170729]	Phase 4	62 participants (Actual)	Interventional	2004-08-17	Completed
The Impact of Pre-emptive Large Doses of Methylprednisolone Combined With Gabapentin on Pain Treatment and Convalescence After Total Knee Arthroplasty in Elderly: A Double-blind Randomized Study [NCT04653415]	Phase 4	160 participants (Actual)	Interventional	2019-06-01	Completed
Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA) [NCT01331018]	Phase 1	3 participants (Actual)	Interventional	2012-02-22	Active, not recruiting
A Phase III Study to Determine Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease [NCT00929695]	Phase 3	164 participants (Actual)	Interventional	2009-06-30	Completed
CSP #574 - Evaluate the Safety and Efficacy of Methylprednisolone in Hospitalized Veterans With Severe Community-Acquired Pneumonia [NCT01283009]	Phase 3	584 participants (Actual)	Interventional	2012-01-09	Completed
Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, [NCT00348413]		80 participants (Anticipated)	Interventional	2003-06-30	Completed
A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Docetaxel Combined With Platinum-based Drugs Compared With Docetaxel Alone for Metastatic Hormone-sensitive Prostate Cancer Patients Carrying DNA Repair Mutation [NCT05461261]	Phase 2	50 participants (Anticipated)	Interventional	2022-07-01	Recruiting
Intradiscal Gelified Ethanol Versus Intradiscal Steroid in Refractory Lumbar Discogenic Pain: a Randomized Single-blind Study [NCT03415828]		83 participants (Actual)	Interventional	2018-05-29	Active, not recruiting
Pilot, Phase I, Single Blind Trial to Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers. (PRURITUS- Nimpa Study). [NCT01529320]	Phase 1	18 participants (Actual)	Interventional	2012-02-29	Completed
Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease [NCT00109993]	Phase 2	34 participants (Actual)	Interventional	2005-01-31	Completed
[NCT00000146]	Phase 3	0 participants	Interventional	1988-07-31	Active, not recruiting
[NCT02115997]	Phase 4	30 participants (Actual)	Interventional	2015-07-06	Completed
[NCT00017628]	Phase 1	20 participants	Interventional	2001-04-30	Completed
A Phase III, Randomized, Placebo-Controlled, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Oral Beclomethasone 17, 21-Dipropionate (BDP) in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gr [NCT00043147]	Phase 3	0 participants	Interventional	2002-04-30	Completed
Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study [NCT00135967]	Phase 2/Phase 3	30 participants	Interventional	2002-05-31	Completed
Randomised, Double-Arm, Controlled, Open-Label Study Comparing Calcineurin Inhibitor-Free Immunosuppression (Zenapax®, CellCept® and Prednisolone) and Cyclosporine A Based Immunosuppression (Sandimmun Neoral®, CellCept® and Prednisolone) on the Outcome of [NCT00138970]	Phase 4	70 participants	Interventional	2002-01-31	Completed
A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Tacrolimus and Corticosteroid as Immunosuppressive Treatment for Lupus Membra [NCT00404794]	Phase 3	20 participants (Anticipated)	Interventional	2005-11-30	Completed
A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS) [NCT00404833]	Phase 3	16 participants (Anticipated)	Interventional	2003-01-31	Completed
Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone [NCT00396747]	Phase 4	45 participants (Actual)	Interventional	2003-06-30	Completed
A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy [NCT03098225]	Phase 4	120 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Induction Therapy for Lupus Nephritis With no Added Oral Steroids: An Open Label Randomised Multicentre Controlled Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF [NCT04702256]	Phase 3	196 participants (Anticipated)	Interventional	2021-12-09	Recruiting
Treatment of Acute Graft vs. Host Disease With Steroids Plus Daclizumab (Zenapax) or Placebo [NCT00053976]	Phase 3	105 participants (Actual)	Interventional	2001-01-31	Completed
Single-Center, Randomized, Double Masked, Two-Period Cross-Over, Three Days Per Period, Phase IV Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers [NCT00134992]	Phase 4	30 participants	Interventional	2004-08-31	Completed
The Role of Topical Prednisolone Acetate Following Selective Laser Trabeculoplasty [NCT00406042]		25 participants	Interventional	2005-09-30	Completed
Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease [NCT00152620]		40 participants	Interventional	2004-06-30	Terminated(stopped due to study completed)
A Phase I Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin in the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma [NCT00053105]	Phase 1	0 participants	Interventional	2002-02-28	Active, not recruiting
A Multi-Center, Randomized, Double Masked, Bioequivalence Study of Tobramycin and Prednisolone Acetate (0.3/1.0%, ISTA) Ophthalmic Suspension Compared to PredForte (1.0% Prednisolone Acetate, Allergan) Ophthalmic Suspension [NCT00198523]	Phase 3	132 participants	Interventional	2005-07-31	Completed
Prevention of Post-Extubation Laryngeal Edema With Intravenous Corticosteroids: a Prospective, Double-Blind, Placebo-Controlled Trial. [NCT00199576]	Phase 3	670 participants	Interventional	2000-12-31	Completed
the Effect of Single Dose of Etomidate Used During Emergency Intubation on Hemodynamics and Adrenal Cortex: a Randomized Clinical Trial [NCT01792037]	Phase 4	90 participants (Actual)	Interventional	2012-12-31	Completed
Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery [NCT04200651]	Phase 4	25 participants (Actual)	Interventional	2020-01-13	Completed
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy [NCT01381874]	Phase 2	297 participants (Actual)	Interventional	2011-08-24	Completed
Peri-articular Injections Containing a Corticosteroid During Total Knee Arthroplasty [NCT00492973]		101 participants (Actual)	Interventional	2006-03-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of CRx-102 in Subjects With Symptomatic Knee Osteoarthritis and Optional One-Year Extension [NCT00521989]	Phase 2	279 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to CRx-102-006 study results, negative)
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRx-102 Over Each of Its Components When Given to Subjects With Active Rheumatoid Arthritis (RA) [NCT00551707]	Phase 2	51 participants (Actual)	Interventional	2007-10-31	Completed
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AM [NCT00568633]	Phase 3	58 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to Poor accrual)
Adrenal Cortical Function and Vitamin A Deficiency in Sepsis, Severe Sepsis and Septic Shock: Prospective Randomized, Double Blind Placebo Controlled Clinical Trials [NCT03152474]	Phase 4	300 participants (Actual)	Interventional	1993-02-28	Completed
Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis [NCT00682357]		25 participants (Actual)	Interventional	2008-05-31	Completed
Pilot Study of Methylprednisolone Replacement for Dexamethasone-induced Hiuup Patients [NCT01277731]		0 participants (Actual)	Interventional	2010-07-31	Withdrawn
Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2 [NCT05736549]	Phase 2	66 participants (Anticipated)	Interventional	2023-02-07	Recruiting
[NCT00699803]	Phase 2	64 participants (Actual)	Interventional	2008-05-31	Completed
Azithromycin for Preventing the Development of Upper Respiratory Tract Illness Into Lower Respiratory Tract Symptoms in Children and Oral Corticosteroids for Treating Episodes of Significant Lower Respiratory Tract Symptoms in Children [NCT01272635]	Phase 3	607 participants (Actual)	Interventional	2011-03-31	Completed
An Open-label, Randomized, Cross-over Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression [NCT04345445]	Phase 3	310 participants (Anticipated)	Interventional	2020-04-15	Not yet recruiting
Phase II Randomized Double Blind Trial of Methylprednisolone and N-acetylcysteine in Hepatic Resections. [NCT01726465]	Phase 2	50 participants (Actual)	Interventional	2012-11-30	Terminated(stopped due to The first phase was completed)
Efficacy and Safety Evaluation of Rapamycin Combined With Methylprednisolone in the Treatment of Hyperthyroidism Exophthalmos: A Randomized, Controlled, Multicenter Clinical Trial. [NCT05532072]	Early Phase 1	140 participants (Anticipated)	Interventional	2022-09-30	Not yet recruiting
Intraorbital Injection Versus Oral Steroid in Patients With Anterior Idiopathic Orbital Inflammation: A Randomized Clinical Trial [NCT03958344]	Phase 3	120 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Extended Follow-up of a Randomized Placebo-controlled Trial of Local Steroid Injection in Carpal Tunnel Syndrome [NCT02652390]	Phase 4	111 participants (Actual)	Interventional	2016-02-29	Completed
Perks of Methylprednisolone for Hospitalized COVID-19 Patients: A Clinical Trial [NCT04559113]		200 participants (Anticipated)	Interventional	2020-05-01	Recruiting
Maternal Epidural Steroids to Prevent Neonatal Exposure to Hyperthermia and Inflammation [NCT02212210]	Early Phase 1	135 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study is closed)
The Use of Intra-articular Corticosteroid Injection to Treat Osteoarthritis of the Carpometacarpal Joint: A Randomized Control Trial [NCT04177433]	Phase 4	90 participants (Anticipated)	Interventional	2020-12-02	Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Biomarkers) of BI 653048 BS H3PO4 Capsule Formulation Administered as Multiple Doses of 25 mg to 200 mg qd for 10 Days. A Randomised, Double-blind Within Dose Groups, Placebo-controlled, Multipl [NCT02217631]	Phase 1	140 participants (Actual)	Interventional	2009-10-31	Completed
A Proof of Concept Study to Determine the Local Delivery and Efficacy of Intravenously Injected PEG-liposomal Prednisolone Sodium Phosphate (Nanocort) in Atherosclerotic Tissue in Subjects With Peripheral Artery Disease. [NCT01647685]	Phase 1/Phase 2	21 participants (Anticipated)	Interventional	2012-05-31	Recruiting
Efficacy of Moxifloxacin 0.5%/Prednisolone 1% Fixed Combination Compared With Individual Administration of Moxifloxacin 0.5% and Prednisolone 1% in the Prevention of Post Operative Inflammation in Patients Having Lasik Surgery [NCT01603030]	Phase 3	66 participants (Anticipated)	Interventional	2012-06-30	Not yet recruiting
Preemptive Effect of Dexamethasone and Methylprednisolone on Pain, Swelling and Trismus After Third Molar Surgery: a Split-mouth Randomized Triple-blind Clinical Trial [NCT01603498]		18 participants (Actual)	Interventional	2011-04-30	Completed
A Multicentre, Randomised, Double Blind, Double Dummy, Active Comparator Controlled, Parallel Group Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis [NCT00299013]	Phase 3	796 participants (Actual)	Interventional	2006-03-31	Completed
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants [NCT00307671]	Phase 4	108 participants (Actual)	Interventional	2005-07-31	Completed
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease [NCT00282503]	Phase 3	19 participants (Actual)	Interventional	2006-01-31	Terminated(stopped due to Lack of recruitment)
A Comparison of Intravenous Versus Oral Administration of Prednisolone in the Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease [NCT00311961]	Phase 4	256 participants	Interventional	2001-06-30	Completed
Long Term Tapering or Standard Steroids for Nephrotic Syndrome [NCT00308321]	Phase 4	50 participants (Anticipated)	Interventional	2003-09-30	Recruiting
Multicenter, Open-label, Randomized Study on Steroid-free Immunosuppression, in Comparison With Daily Steroid Therapy, in Children With Stable Renal Transplant Function Under Cyclosporine (CyA) and Mycophenolate Mofetil (MMF) [NCT00309218]	Phase 3	42 participants (Actual)	Interventional	1999-03-31	Completed
Comparison of Efficacy of Intra-articular Morphine vs Methylprednisolone in Patients With Knee Osteoarthritis. A Single - Blind, Randomized-controlled Study [NCT06163755]	Phase 2	0 participants (Actual)	Interventional	2018-01-01	Withdrawn(stopped due to Lack of funding)
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours [NCT05489211]	Phase 2	670 participants (Anticipated)	Interventional	2022-09-06	Recruiting
Epidural Steroid Following Discectomy for Herniated Lumbar Disc Reduces Neurological Impairment and Enhances Recovery. A Randomized Study With Two-year Follow-up [NCT01499641]		200 participants (Actual)	Interventional	2001-05-31	Completed
A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspen [NCT01505088]	Phase 3	193 participants (Actual)	Interventional	2011-12-31	Completed
The Efficacy of Exercise Therapy Followed by Ultrasound Guided Injection in Patients With a Painful Shoulder - a Randomised Controlled Study With Blinded Observer [NCT01506804]		99 participants (Actual)	Interventional	2010-11-30	Completed
[NCT01627236]		120 participants (Anticipated)	Interventional	2012-12-31	Recruiting
Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) [NCT03111810]	Phase 2	32 participants (Actual)	Interventional	2017-05-25	Completed
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation: a Randomized Study [NCT01640743]		58 participants (Actual)	Interventional	2010-03-31	Completed
Randomized, Multicentric Study Evaluating the Efficacy and the Safety of Methylprednisolone Bolus in the Treatment of Renal Sarcoidosis [NCT01652417]		40 participants (Actual)	Interventional	2012-10-31	Terminated(stopped due to insufficient recruitment)
The Effect of Different Intra-articular Injections on Pain and Function in Primary Gonarthrosis [NCT05291793]		80 participants (Actual)	Interventional	2020-04-01	Completed
Single Center, Randomized, Double-Masked Evaluation of the Efficacy of PredAcetate 1% Ophthalmic Suspension Compared to Pred Acetate 0.12% Ophthalmic Suspension, Lot Etab 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model [NCT00689078]	Phase 4	36 participants (Actual)	Interventional	2008-05-31	Completed
The Effect of Moderate-Dose Steroid Therapy in Sepsis: A Placebo-Controlled, Randomized Study [NCT01275638]	Phase 4	55 participants (Actual)	Interventional	2005-04-30	Completed
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen [NCT02199041]	Phase 2	24 participants (Actual)	Interventional	2014-07-11	Terminated(stopped due to The study was halted early due to slow accrual.)
Assessment of the Efficacy of an Intradiscal Injection of Corticoids in Modic I Discopathies. [NCT01694134]	Phase 3	50 participants (Actual)	Interventional	2012-07-12	Completed
Evaluation of a Strategy Based on the 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation: the I4BiS Study [NCT02444429]	Phase 3	346 participants (Anticipated)	Interventional	2015-09-30	Recruiting
Alternative Treatment Paradigm for Natalizumab Trial [NCT01710228]	Phase 2	0 participants (Actual)	Interventional	2013-07-31	Withdrawn(stopped due to sponsor stopped)
Determining Optimal Dose of Corticosteroids in COPD Exacerbations: A Pilot Study [NCT01742338]	Phase 4	125 participants (Anticipated)	Interventional	2012-05-03	Suspended(stopped due to The study has been suspended to address research staffing and the feasibility of continued recruitment)
Effect of Steroids on Cerebrospinal Fluid Markers of Inflammation and Neuronal Damage After Surgical Aortic Valve Replacement [NCT01755338]		30 participants (Actual)	Interventional	2012-12-31	Completed
Phase II, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children [NCT01757899]	Phase 2	0 participants (Actual)	Interventional	2014-01-31	Withdrawn(stopped due to Technical problems)
A Randomised, Single Blind, Placebo-Controlled, Cross-over, Phase 1 Methodology Study to Validate the Cantharidin Blister Model in Healthy Male Volunteers [NCT01762787]	Phase 1	40 participants (Actual)	Interventional	2010-08-17	Completed
FDG PET/CT: Reducing False Positive Mediastinal Uptake by Premedicating With Methylprednisolone [NCT01789892]		0 participants (Actual)	Interventional	2011-06-30	Withdrawn(stopped due to no patient accrual)
Safety and Efficacy of Nonsteroidal Antiinflammatory Drug and Glucocorticoids in Acute Sciatica [NCT01816334]	Phase 4	50 participants (Actual)	Interventional	2013-01-31	Completed
Addition of Pyridoxine to Prednisolone in the Treatment of Infantile Spasms: A Randomized Controlled Trial [NCT01828437]	Phase 3	62 participants (Actual)	Interventional	2012-11-30	Completed
A Multi-center Randomized Controlled Trial of Efficacy and Safety of Perineural Local Anesthetics and Steroids for Chronic Peripheral Post-traumatic Neuropathic Pain: The Resperist Study [NCT03009500]	Phase 3	3 participants (Actual)	Interventional	2017-01-31	Completed
Study of Visual Recovery After Erythropoietin (EPO) Injection, in Patients With Traumatic Optic Neuropathy (TON) [NCT01783847]	Phase 1/Phase 2	117 participants (Actual)	Interventional	2015-02-28	Completed
A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib [NCT02294357]	Phase 2	45 participants (Anticipated)	Interventional	2014-12-31	Terminated(stopped due to Early termination due to the difficulties to enroll subjects.)
Predicting Response to Intra-Articular Corticosteroid Injection in Patients With Osteoarthritis of the Glenohumeral Joint [NCT03232749]	Phase 4	25 participants (Actual)	Interventional	2018-04-18	Terminated(stopped due to The physician in charge is leaving the University of Florida)
Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis [NCT01809132]	Phase 2/Phase 3	104 participants (Actual)	Interventional	2013-09-30	Completed
SMART Trial: Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia [NCT03852537]	Phase 2	44 participants (Actual)	Interventional	2019-12-02	Completed
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncolo [NCT00553202]	Phase 2	158 participants (Actual)	Interventional	2008-01-31	Completed
Towards a Self-Administered Hearing Protection Regimen [NCT04826237]	Phase 4	100 participants (Anticipated)	Interventional	2023-02-09	Recruiting
Efficacy of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial. [NCT04343729]	Phase 2	416 participants (Actual)	Interventional	2020-04-18	Completed
Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY) [NCT04826588]	Phase 3	76 participants (Actual)	Interventional	2021-05-23	Completed
A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) Versus Corticosteroids in the Treatment of Patients With Secondary Progressive Multiple Sclerosis (SPMS) [NCT02296346]		13 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Low enrollment/PI relocated. New site couldn't reach agreement with manufacturer)
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% [NCT01437982]	Phase 4	140 participants (Anticipated)	Interventional	2010-08-05	Completed
Efficacy of Peripheral Nerve Blocks for Episodic Migraine Treatment and Prophylaxis [NCT05734625]	Phase 2	60 participants (Anticipated)	Interventional	2023-07-10	Recruiting
The Evaluation of the Safety and Efficacy of Sustained Release Dexamethasone Intracanalicular Insert (DEXTENZA) in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (TENDER) [NCT05620901]	Early Phase 1	30 participants (Anticipated)	Interventional	2023-02-01	Recruiting
Focal Cerebral Arteriopathy Steroid Trial [NCT06040255]	Phase 4	80 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
Single Blind Randomized Controlled Trial to Assess the Safety and Efficacy of High Dose Pulse Intravenous Corticosteroid Therapy to Treat Patients With Complicated/Fulminant Acute Myocarditis [NCT05150704]	Phase 3	288 participants (Anticipated)	Interventional	2021-10-07	Recruiting
Randomized Multicenter Phase 3 Single-blind Trial Comparing the Efficacy of Corticosteroid Control to Mesenchymal Stem Cell Preparations From Autologous Bone Marrow Concentrate (BMAC), Adipose-derived Stem Cells in the Form of Stromal Vascular Fraction (S [NCT03818737]	Phase 3	475 participants (Actual)	Interventional	2019-03-28	Completed
Glucocorticoid Treatment in Patients Undergoing TAVR to Reduce the Incidence of Atrioventricular Block and Pacemaker Implantation [NCT06076824]	Phase 4	100 participants (Anticipated)	Interventional	2023-08-12	Recruiting
Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease [NCT04988282]	Phase 4	262 participants (Actual)	Interventional	2021-05-24	Completed
Early Short Course Corticosteroids in Hospitalized Patients With COVID-19 [NCT04374071]		250 participants (Actual)	Observational	2020-03-12	Completed
Medrol® In Contact Dermatitis: A Prospective Study To Assess The Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Subjects [NCT00929981]		80 participants (Actual)	Observational	2009-09-30	Completed
A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy [NCT03018535]	Phase 3	76 participants (Actual)	Interventional	2012-01-31	Active, not recruiting
The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy [NCT03122847]		30 participants (Anticipated)	Observational	2017-06-07	Active, not recruiting
Phase 2/Phase 3 of the Randomized Control Trial to Evaluate the Efficacy of Autologous Blood Injection Versus Local Corticosteroid Injection for Treatment of Lateral Epicondylitis. [NCT00947765]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2007-01-31	Completed
Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfunction [NCT03593902]	Phase 2/Phase 3	9 participants (Actual)	Interventional	2018-05-17	Terminated(stopped due to PI Sabbatical)
Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone [NCT04744623]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2020-09-30	Active, not recruiting
Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome [NCT04323592]		173 participants (Actual)	Observational [Patient Registry]	2020-03-23	Completed
Low Dose Versus High Dose Methylprednisolone for Children With Severe Mycoplasma Pneumoniae Pneumonia : a Multicenter Randomized Blinded Trial [NCT02303587]		424 participants (Actual)	Interventional	2014-12-31	Completed
Clinical Effectiveness of Symptomatic Therapy Compared to Standard Step up Care for the Treatment of Low Impact Psoriatic Oligoarthritis: a 2 Arm Parallel Group Feasibility Study [NCT03797872]	Phase 4	1 participants (Actual)	Interventional	2019-04-17	Completed
Effect of Preoperative Intravenous High Dose Methylprednisolone on Endothelial Function in Patients Scheduled for Total Knee-arthroplasty [NCT02332629]	Phase 3	70 participants (Actual)	Interventional	2015-01-31	Completed
Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy [NCT02167217]	Phase 2	25 participants (Actual)	Interventional	2014-04-17	Completed
Pilot Study in AIDS-Related Lymphomas [NCT00002524]	Phase 2	46 participants (Actual)	Interventional	1993-06-30	Completed
A Prospective Randomized Double-blinded Controlled Single Center Clinical Study of the Efficacy and Safety for Tofacitinib Compared With Glucocorticoid in the Remission-reduction Treatment of Active Takayasu's Arteritis [NCT05749666]	Phase 3	50 participants (Anticipated)	Interventional	2023-01-20	Recruiting
Treatment of Metastatic Prostate Cancer That is Hormone-Independent: Evaluation of the Role of Chemotherapy on the Quality of Life of Patients. Phase II Study [NCT00003682]	Phase 3	160 participants (Anticipated)	Interventional	1998-10-31	Terminated(stopped due to lack of inclusions)
Sudden Hearing Loss Multicenter Treatment Trial [NCT00097448]	Phase 3	255 participants (Actual)	Interventional	2004-12-31	Completed
Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract [NCT02176031]	Phase 2	21 participants (Actual)	Interventional	2015-01-31	Completed
STeroids to REduce Systemic Inflammation After Infant Heart Surgery (STRESS) [NCT03229538]	Phase 3	1,263 participants (Actual)	Interventional	2017-10-18	Completed
A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy [NCT01114503]	Phase 2	2 participants (Actual)	Interventional	2010-07-07	Terminated(stopped due to Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of an efficacious dose with Otelixizumab from other clinical studies.)
Single Center, Randomized, Double-Blind, Placebo-Controlled Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab [NCT01144143]	Phase 4	16 participants (Actual)	Interventional	2007-07-31	Completed
Intratympanic Dexamethasone or Methylprednisolone for Sudden Hearing Loss as a Salvage Treatment: a Randomized, Double-blind, Multi-center Study [NCT04129697]		30 participants (Anticipated)	Interventional	2020-01-01	Not yet recruiting
Comparison of the Efficacy of Two Different Glucocorticoid Regimens for Treatment of Active Moderate-to-severe Graves' Orbitopathy [NCT05793359]		62 participants (Actual)	Observational [Patient Registry]	2017-07-25	Completed
Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails [NCT04273321]		86 participants (Actual)	Interventional	2020-02-14	Completed
Retrobulbar Methylprednisolone as Adjunctive Treatment in Optic Neuritis. Randomized Controlled Trial. [NCT04942002]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2021-06-15	Recruiting
Safety and Efficacy of Topical Loteprednol Etabonate 0.5%, Versus Prednisolone Acetate 1%, for the Treatment of Intraocular Inflammation Following Surgery for Childhood Cataract [NCT01475643]	Phase 3	107 participants (Actual)	Interventional	2013-06-30	Completed
Hyper-CVAD With Liposomal Vincristine (Hyper-CMAD) in Acute Lymphoblastic Leukemia [NCT01319981]	Phase 2	31 participants (Actual)	Interventional	2013-03-05	Completed
Evaluation of DEXTENZA on the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids [NCT04426734]	Phase 4	30 participants (Anticipated)	Interventional	2020-07-01	Not yet recruiting
Corticosteriods vs. Saline vs. Air Placebo Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial [NCT02995083]	Early Phase 1	0 participants (Actual)	Interventional	2017-06-30	Withdrawn(stopped due to Study deemed not feasible)
Yale Steroid Enhanced Versus Exparel Nerveblock TKA Randomized Controlled Trial (RCT) Study [NCT05279092]	Phase 2	250 participants (Anticipated)	Interventional	2022-09-08	Recruiting
Oral Prednisolone Dosing in Children Hospitalized With Asthma [NCT00257933]	Phase 4	152 participants (Actual)	Interventional	2006-02-28	Completed
Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial. [NCT05748561]	Phase 2/Phase 3	18 participants (Anticipated)	Interventional	2022-04-05	Recruiting
Musculoskeletal Ultrasound Changes in the Plantar Fascia After a Single Injection of Platelet Rich Plasma Compared to Steroid [NCT05339542]		98 participants (Actual)	Interventional	2022-03-10	Completed
Randomized Controlled Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery [NCT01559675]		121 participants (Actual)	Interventional	2010-09-30	Completed
Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes [NCT04977427]	Phase 4	200 participants (Anticipated)	Interventional	2021-07-31	Not yet recruiting
A Pilot Study Investigating the Feasibility and Efficacy of Locoregional Intra-arterial Administration of Methylprednisolone as a Bridge Therapy to Treat Symptomatic Flares in Inflammatory Bowel Disease. [NCT05587673]	Phase 1	30 participants (Anticipated)	Interventional	2022-10-06	Recruiting
Comparison of Efficacy and Safety of Two Different Ultrasound-Guided Suprascapular Nerve Block Techniques in Chronic Shoulder Pain: A Prospective Double-Blinded Randomized Controlled Study [NCT04938037]		80 participants (Anticipated)	Interventional	2021-06-01	Recruiting
A Feasibility Randomised Placebo-controlled Trial With Objective Outcome Measures to Evaluate the Efficacy of Biosimilar Rituximab in Musculoskeletal and Mucocutaneous Systemic Lupus Erythematosus [NCT03054259]	Phase 2	30 participants (Anticipated)	Interventional	2017-09-21	Recruiting
Transverse Abdominis Plane Block Using Liposomal Bupivacaine for Post-operative Cesarean Delivery Analgesia- Walking Towards Recovery [NCT04393207]	Phase 4	300 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Intracanalicular Dexamethasone Insert for Management of Post-operative Pain and Inflammation in Patients Undergoing Vitreoretinal Surgery [NCT04371445]	Phase 4	30 participants (Anticipated)	Interventional	2020-12-01	Enrolling by invitation
Evaluation of Sleep EEG Changes in Paediatric Patients With Language Dysfunction: A Follow up Study. Evaluation of Sleep EEG Changes in Paediatric Patients With Language Dysfunction: A Follow up Study. Evaluation of Sleep EEG Changes in Pediatric Patients [NCT05487521]	Phase 3	93 participants (Actual)	Interventional	2020-02-20	Completed
Clinical Study of the Effect of Methylprednisolone Combined With Two Hydroxypropyl Theophylline on Respiratory Dynamics During Thoracoscopic Lobectomy [NCT04810819]		110 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
Efficacy and Safety of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 Chronic Kidney Disease [NCT05510323]	Phase 3	208 participants (Anticipated)	Interventional	2022-08-31	Not yet recruiting
The Effectiveness of Pulsed Radiofrequency of the Suprascapular Nerve and Shoulder Joint Compared to Intra-articular Corticosteroid Injection for Hemiplegic Shoulder Pain Management and Functional Improvement. [NCT05563571]		20 participants (Anticipated)	Interventional	2022-04-01	Recruiting
DEXTENZA VS. PREDNISOLONE ACETATE 1% in the Incidence of Pseudophakic Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery [NCT04362241]	Phase 4	30 participants (Anticipated)	Interventional	2020-08-07	Recruiting
The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy [NCT01579539]	Phase 3	18 participants (Actual)	Interventional	2013-06-27	Completed
Pre-operative Intravenous Steroid in Unilateral Primary Total Knee Replacement for Pain Relief and Recovery: A Double-Blind Randomized Controlled Trial [NCT03082092]	Phase 4	60 participants (Actual)	Interventional	2017-06-01	Completed
Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD) [NCT03829566]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2019-11-30	Withdrawn(stopped due to Discontinued by Investigator)
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment [NCT02283996]	Phase 4	260 participants (Anticipated)	Interventional	2014-11-30	Recruiting
Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL) - a 12-week, Prospective, Open-label, Pilot Study [NCT01790022]	Phase 2	20 participants (Actual)	Interventional	2012-07-31	Active, not recruiting
Multicenter Randomized Controlled Trial of Epidural Steroid Injections for Spinal Stenosis in Persons 50 and Older [NCT01238536]	Phase 4	400 participants (Actual)	Interventional	2011-04-30	Completed
Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery [NCT01872611]	Phase 3	819 participants (Actual)	Interventional	2013-06-30	Completed
Comparison of Intraarticular Platelet-rich Plasma Injections With Intraarticular Corticosteroid Injections in the Treatment of Primary Knee Osteoarthritis : A Randomized Control Trial [NCT01923909]	Phase 4	0 participants (Actual)	Interventional	2013-04-30	Withdrawn(stopped due to No participants enrolled)
Biomarkers of Lupus Disease: Study of Biomarker Changes Before and After Treatment With Depomedrol and Background Medication Withdrawal in Patients With Mild to Moderate SLE Disease Activity [NCT00987831]	Phase 1/Phase 2	158 participants (Actual)	Interventional	2009-05-31	Completed
Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Relapsed or Refractory CLL/SLL The HiLOG Trial [NCT01497496]	Phase 2	29 participants (Actual)	Interventional	2012-01-26	Completed
Dextenza in Pterygium Surgery [NCT04403516]	Phase 4	30 participants (Actual)	Interventional	2020-10-01	Completed
Comparison of Dropless Prophylaxis After Routine Phacoemulsification to Standard Drops Regimen [NCT02515045]	Phase 4	59 participants (Actual)	Interventional	2015-01-31	Completed
Prospective, Randomized Clinical Trial of Meibomian Gland Probing Versus Sham Procedure for Refractory Meibomian Gland Dysfunction [NCT02256969]	Phase 4	45 participants (Actual)	Interventional	2014-10-31	Completed
Use of G-CSF Stimulated HLA-Identical Allogeneic Peripheral Blood Stem Cells for Patients With High Risk Acute Myelogenous Leukemia or CML in Blast Crisis [NCT00002833]	Phase 2	53 participants (Actual)	Interventional	1994-10-31	Completed
Safety and Effectiveness of Single-dose Subconjunctival Triamcinolone Compared to Topical Prednisolone Eye Drops in Manual Small Incision Cataract Surgery [NCT05248139]		100 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis [NCT00004357]	Phase 2	6 participants (Actual)	Interventional	1997-09-30	Completed
Phase III Randomized, Double-Blind Study of Methylprednisolone by 24- Versus 48-Hour Infusion Versus Tirilazad for Acute Spinal Cord Injury [NCT00004759]	Phase 3	497 participants	Interventional	1991-12-31	Completed
An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Disease Activity in Patients With Active Rheumatoid Arthritis After DMARD Treatment Failure [NCT02006706]	Phase 3	15 participants (Actual)	Interventional	2006-08-10	Completed
Intra-articular and Intravenous Infliximab in the Treatment of Resistant Seronegative Oligoarthritis of the Knee [NCT01216631]	Phase 2	1 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to Unable to recruit)
De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study [NCT02909335]	Phase 3	0 participants (Actual)	Interventional	2016-11-30	Withdrawn
Does Anesthetic Contribute to Symptomatic Relief in Corticosteroid Injections for Knee Osteoarthritis? A Double-Blind Randomized Trial Comparing Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections [NCT02576249]	Phase 4	29 participants (Actual)	Interventional	2015-10-31	Completed
A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Caudal Epidural Injections in Lumbar Disc Herniations, Spinal Stenosis, Discogenic Pain, and Post-Lumbar Laminectomy Syndrome [NCT00370799]	Early Phase 1	240 participants (Actual)	Interventional	2007-01-31	Completed
A Multicenter, Randomized, Open-label, Blinded-assessor, Follow-up, Phase 4 Study in Patients With Rheumatoid Arthritis Who Have Completed the Initial Treatment Part in the NORD-STAR Study and Have Reached Stable Low Disease Activity [NCT02466581]	Phase 4	25 participants (Actual)	Interventional	2015-02-03	Active, not recruiting
Preoperative Methylprednisolone on Thoracic Endovascular Repair for Reducing Post-implantation Syndrome [NCT05349071]		158 participants (Anticipated)	Interventional	2022-05-01	Not yet recruiting
Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease [NCT01977781]	Phase 1	40 participants (Actual)	Interventional	2013-12-31	Completed
Efficacy and Safety of Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis. [NCT05990894]		248 participants (Actual)	Observational	2018-01-01	Completed
A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgki [NCT01724021]	Phase 3	743 participants (Actual)	Interventional	2012-12-31	Completed
High Dose Steroids for Liver Resection - Effect on Complications and Endothelial Function in the Immediate Postoperative Phase - a Randomized, Doubleblind, Controlled Trial [NCT03403517]	Phase 4	174 participants (Actual)	Interventional	2017-12-11	Completed
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age [NCT03596723]	Phase 3	2 participants (Actual)	Interventional	2018-07-03	Terminated(stopped due to NDA #210565 did not trigger the need for a Pediatric Research Equity Act study.)
Post-operative Methylprednisolone Taper Course for Orthopedic Surgery [NCT03661645]	Phase 4	1,000 participants (Anticipated)	Interventional	2018-09-07	Enrolling by invitation
A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma [NCT00002835]	Phase 3	116 participants (Actual)	Interventional	1995-10-30	Completed
[NCT00004785]	Phase 3	54 participants	Interventional	1995-11-30	Completed
Phase I/II Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) [NCT02464657]	Phase 1/Phase 2	44 participants (Actual)	Interventional	2015-07-31	Completed
Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19 [NCT04341038]	Phase 3	84 participants (Anticipated)	Interventional	2020-04-01	Recruiting
Physiologic Effects of Stress Dose Corticosteroids in the Management of Inhospital Cardiac Arrest - CORTICA [NCT02790788]	Phase 1/Phase 2	100 participants (Actual)	Interventional	2016-11-04	Completed
Efficacy and Safety of Loteprednol 0.5% Gel for Routine Prophylaxis After Photorefractive Keratectomy Compared to Prednisolone Acetate 1% Suspension and Fluorometholone 0.1% Suspension [NCT03123614]	Phase 4	131 participants (Actual)	Interventional	2014-09-19	Completed
A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge ( [NCT01534195]	Phase 4	11 participants (Actual)	Interventional	2012-01-31	Completed
Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial [NCT04438980]	Phase 3	72 participants (Actual)	Interventional	2020-05-15	Completed
Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease [NCT02339142]	Phase 4	100 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis [NCT03324503]		8 participants (Actual)	Interventional	2017-12-08	Completed
Intra-articular Injections of Platelet-rich Plasma, Hyaluronic Acid, or Corticosteroids for Knee Osteoarthritis, Which is Better? A Prospective Study of a Single-blind Randomized Control Trial RCT From the Iraqi Population [NCT04980105]	Phase 3	150 participants (Actual)	Interventional	2020-03-02	Active, not recruiting
Hit Hard and Early. The Effect of High Dose Methylprednisolone on Nailfold Capillary Changes and Biomarkers in Early SSc: a 12-week Randomised Explorative Double-blind Placebo-controlled Trial. [NCT03059979]	Early Phase 1	30 participants (Anticipated)	Interventional	2017-01-31	Recruiting
Second Affiliated Hospital, College of Medicine, Zhejiang University [NCT04918953]	Phase 2	90 participants (Anticipated)	Interventional	2021-06-02	Not yet recruiting
The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma [NCT03045471]		50 participants (Anticipated)	Observational	2017-03-01	Not yet recruiting
Study of the Excretion of Orally Administered Corticosteroids for the Improval of the Detection of Said Substances in Anti-doping Controls [NCT04791345]	Phase 1	50 participants (Anticipated)	Interventional	2021-02-26	Recruiting
Autologous Platelet Rich Fibrin Versus Steroid in Ultrasound-Guided Sacroiliac Joint Injection for Joint Dysfunction (Randomized Comparative Study) [NCT04757740]	Phase 4	94 participants (Anticipated)	Interventional	2021-03-01	Recruiting
The Role of Doxycycline in Management of Moderate to Severe Chronic Rhinosinusitis With Nasal Polyps [NCT02569437]	Phase 2	49 participants (Actual)	Interventional	2014-09-30	Terminated(stopped due to A high percentage of patients were dropping out of the study and were not able to complete the protocol.)
Topical Use of Corticosteroid to Prevent Epiretinal Membrane Formation in Eyes With Retinal Tear Undergoing Laser Retinopexy: a Pilot Prospective Clinical Study [NCT02412059]		200 participants (Actual)	Interventional	2015-08-31	Completed
Triamcinolone Versus Methylprednisolone in Ultrasound Guided Transversus Abdominis Plane Block in Major Open Abdominal Surgery [NCT04480775]	Phase 2/Phase 3	84 participants (Actual)	Interventional	2020-07-15	Completed
Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group [NCT02375867]	Phase 4	33 participants (Actual)	Interventional	2015-01-31	Completed
Once a Month High-dose Methylprednisolone During Wash-out Period Between Natalizumab and Fingolimod Treatments in Patients With Multiple Sclerosis: a Randomised, Controlled, Double-blind Trial (NTZ2FTY) [NCT02769689]	Phase 4	56 participants (Anticipated)	Interventional	2019-06-12	Recruiting
Intra-Arterial Steroid Administration of De Novo Acute Graft-vs-Host Disease of the Gastrointestinal Tract: A Phase II Study [NCT02425813]	Phase 2	0 participants (Actual)	Interventional	2015-10-31	Withdrawn(stopped due to Slow Accrual)
Comparison of the Treatment Efficacy of High-Dose Corticosteroid and Tocilizumab During Clinical Worsening in Patients With COVID-19 Pneumonia [NCT05133635]	Phase 4	0 participants (Actual)	Interventional	2021-02-01	Withdrawn(stopped due to A recent study suggested a new corticosteroid regime for intensive care unit patients.)
Corticosteroids in Severe Alcoholic Hepatitis Patients With Early Spontaneous Improvement [NCT03160651]		140 participants (Anticipated)	Interventional	2018-02-09	Recruiting
Comparison Between Ultrasound Guided Ozone, Platelet-Rich Plasma or Steroid Injection in the Treatment of Sacroiliitis; a Randomized Double Blinded Controlled Study [NCT05914350]		105 participants (Anticipated)	Interventional	2023-06-23	Recruiting
Investigating Differences in Flare Reaction Incidence and Intensity Following Trigger Finger Injections Using Betamethasone and Methylprednisolone [NCT04900220]	Phase 4	66 participants (Actual)	Interventional	2021-09-15	Completed
Genomic Response of Human Immune and Non-Immune Cells to Glucocorticoids [NCT02798523]	Phase 1	33 participants (Actual)	Interventional	2017-01-24	Completed
Steroid Versus Platelet Rich Plasma in Ultrasound Guided Sacroiliac Joint Injection for Chronic Low Back Pain [NCT02334475]		40 participants (Actual)	Interventional	2013-07-31	Completed
Effect of Preoperative Intravenous High Dose Methylprednisolone on Glucose Homeostasis in Patients Scheduled for Total Hip- and Knee-arthroplasty [NCT02332603]	Phase 3	134 participants (Actual)	Interventional	2015-01-31	Completed
Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Against Systemic Corticotherapy in Patients Admitted by Covid-19 With Bilateral Pneumonia and Poor Evolution [NCT05002517]	Phase 3	60 participants (Anticipated)	Interventional	2020-09-03	Active, not recruiting
Antiviral Treatment in Facial Palsy. Randomized Control Trial [NCT02328079]		50 participants (Actual)	Interventional	2013-04-30	Completed
Comparison Of Two Corticosteroid Dosing Regimens For Prevention Of Corneal Transplant Rejection Episodes After Descemet's Membrane Endothelial Keratoplasty [NCT01448213]	Phase 2	264 participants (Actual)	Interventional	2011-10-31	Completed
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Methylprednisolone as a Treatment for Presumed Hantavirus Cardiopulmonary Syndrome [NCT00128180]	Phase 2	66 participants (Actual)	Interventional	2003-01-31	Completed
A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma [NCT00248534]	Phase 2	16 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to slow accrual/lack of resources/low priority due to combining 2 consortia)
Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to a Single Intrabursal Injection of Corticosteroids in Patients With Shoulder Calcific Tendinopathy [NCT01652495]	Phase 4	44 participants (Actual)	Interventional	2012-03-31	Completed
A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies [NCT01875237]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2013-12-27	Terminated
Prospective, Randomized Comparison of Corticosteroid Dosing Regimens Following Endothelial Keratoplasty [NCT01853696]	Phase 4	167 participants (Actual)	Interventional	2013-03-31	Completed
Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery [NCT01853072]	Phase 3	881 participants (Actual)	Interventional	2013-06-30	Completed
Blood Pressure Profile and NT-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy [NCT03590080]		32 participants (Actual)	Observational	2011-01-01	Completed
Impact of Preoperative Single Corticosteroid Flash on Morbidity After Colorectal Resection: Monocentric Prospective Pilot Study [NCT03437746]	Phase 2	78 participants (Actual)	Interventional	2018-03-01	Terminated(stopped due to insufficient rate of inclusion)
Effect of Depo-Medrol Application on the Psoas Muscle After Transpsoas LLIF on Post-operative Hip Flexor Weakness, Thigh Pain and Numbness [NCT05929755]	Phase 4	80 participants (Anticipated)	Interventional	2023-05-12	Recruiting
Effect of Methylprednisolone on Systemic Inflammatory Response and Clinical Parameters During Pediatric Congenital Open-Heart Surgery: A Randomized Controlled Trial [NCT05927233]	Phase 4	60 participants (Anticipated)	Interventional	2023-04-01	Recruiting
The D3 Study: Drug Delivery vs Drops - A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1% in Controlling Post-operative Pain and Inflammation in Patients Undergoing Sequential Cataract Surgery [NCT04273282]	Phase 4	31 participants (Actual)	Interventional	2019-12-16	Completed
The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy [NCT01451710]		30 participants (Actual)	Interventional	2011-03-31	Completed
Double-Blind, Randomized, Parallel Group, Multicenter Study of Durolane Compared to Methylprednisolone in Subjects With Osteoarthritis of the Knee [NCT01209364]	Phase 3	442 participants (Actual)	Interventional	2007-03-31	Completed
High Dose Steroids in Children With Stroke and Unilateral Focal Arteriopathy: Paediatric Arteriopathy Steroid Aspirin (PASTA) Project. A Multicentre Randomized Trial. [NCT03249844]	Phase 3	0 participants (Actual)	Interventional	2022-09-01	Withdrawn(stopped due to discontinuation of the trial)
Allogeneic Hematopoietic Cell Transplantation of Positively Selected CD34+ Cells and Defined Inoculum of T Cells From Related Haploidentical Donors for Older Patients With Indolent Hematologic Malignancies [NCT00185692]	Phase 2	16 participants (Actual)	Interventional	2000-08-31	Completed
Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics in Kidney Transplant Recipients [NCT06044558]		507 participants (Actual)	Observational	2022-09-01	Completed
[NCT00733096]	Phase 2/Phase 3	84 participants (Actual)	Interventional	2008-08-31	Completed
Steroids in Pediatric Acute Lung Injury/ARDS Trial: A Blinded, Placebo-controlled, Randomized Clinical Trial [NCT01274260]	Phase 2	100 participants (Anticipated)	Interventional	2010-10-31	Active, not recruiting
SAAB: Randomized, Double Blind STudy of Corticosteroid Pulse After Ablation [NCT00807586]	Phase 4	119 participants (Actual)	Interventional	2008-12-31	Completed
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia [NCT06124157]	Phase 3	680 participants (Anticipated)	Interventional	2024-01-22	Not yet recruiting
A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN) [NCT04408625]	Phase 1/Phase 2	23 participants (Anticipated)	Interventional	2020-11-09	Recruiting
The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis: A Pilot Study [NCT03511625]	Phase 3	6 participants (Anticipated)	Interventional	2018-10-02	Active, not recruiting
Phase II Study of Infliximab for the Treatment of Ipilimumab Colitis [NCT04305145]	Phase 2	42 participants (Anticipated)	Interventional	2020-08-31	Recruiting
High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease [NCT05103397]	Phase 4	75 participants (Anticipated)	Interventional	2021-10-16	Recruiting
Patient PReference, Efficacy, and SaFety of an Intracanalicular DExamenthasone InseRt comparEd to Topical PrednisoloNe in PatienTs UndergoIng SequentiAl PhacoemuLsification With Intraocular Lens Surgery OR Combined Phacoemulsification With IOL and a Minim [NCT04563559]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2020-11-30	Withdrawn(stopped due to PI decided not to open study)
Health Sciences University Bursa Yüksek Ihtisas Training and Research Hospital [NCT04847687]		300 participants (Actual)	Observational	2021-03-01	Completed
Is the Effect of Systemic Steroids Treating Pollen Induced Allergic Rhinitis Mainly Due to a Placebo Effect [NCT04622917]	Phase 4	44 participants (Actual)	Interventional	2019-04-10	Active, not recruiting
Randomized Controlled Trial on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow [NCT05062681]	Phase 4	60 participants (Anticipated)	Interventional	2021-09-15	Recruiting
Methylprednisolone and Hyaluronic Acid Versus Each Agent Alone to Control Post-extraction Complications of Impacted Mandibular Third Molar [NCT04816253]		72 participants (Actual)	Interventional	2021-02-10	Completed
[NCT03067753]	Phase 2	28 participants (Anticipated)	Interventional	2016-12-31	Recruiting
A Phase I/II Study of High-Dose Deoxyazacytidine, Busulfan, and Cyclophosphamide With Allogeneic Stem Cell Transplantation for Hematologic Malignancies [NCT00002831]	Phase 1/Phase 2	24 participants (Actual)	Interventional	1995-08-01	Completed
Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections [NCT04563299]	Phase 4	10 participants (Actual)	Interventional	2020-12-09	Terminated(stopped due to Subject Enrollment)
Niacin (as a Vasodilator), and a Topical Steroid (for Macular Edema), Non-Ischemic CRVO,HRVO,BRVO [NCT00493064]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2006-10-31	Completed
A Phase II, Randomized, Clinical Trial Assessing Efficacy And Safety Of Oral Prednisolone vs Intravenous Vincristine In The Treatment Of Infantile [NCT00555464]	Phase 2	8 participants (Actual)	Interventional	2007-11-30	Terminated(stopped due to The introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas)
Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass [NCT01579513]		190 participants (Actual)	Interventional	2012-06-30	Completed
A Pilot Study: Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas [NCT00624416]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2007-10-31	Completed
A Phase II, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Withdrawal Design Trial Using Adaptive Randomization Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis [NCT01369745]	Phase 2	294 participants (Actual)	Interventional	2011-06-30	Completed
Effect of Drop-less Surgery Compared to Topical NSAID Alone and Combination of Steroid and NSAID on Central Macular Thickness After Cataract Surgery, a Randomized Controlled Trial [NCT03383328]	Phase 4	470 participants (Actual)	Interventional	2018-02-01	Completed
Randomized Controlled Trial of Ultrasound-guided Steroid Injection Versus Wrist Splint in Patients With Carpal Tunnel Syndrome [NCT04515966]	Phase 4	70 participants (Anticipated)	Interventional	2020-12-01	Recruiting
Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO [NCT02378298]	Phase 4	26 participants (Actual)	Interventional	2011-12-31	Active, not recruiting
High Dose Steroids in Children With Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial PASTA (Paediatric Arteriopathy Steroid Aspirin) Trial [NCT04873583]	Phase 3	70 participants (Anticipated)	Interventional	2021-11-16	Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy [NCT03959085]	Phase 3	4,772 participants (Anticipated)	Interventional	2019-10-31	Recruiting
Improvement in Function and Pain Due to Subacromial Bursitis in Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone [NCT02242630]		61 participants (Actual)	Interventional	2014-09-30	Completed
A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model [NCT01730872]	Phase 4	16 participants (Actual)	Interventional	2012-11-30	Completed
The Utility of feNO in the Differential Diagnosis of Chronic Cough: The Response to Anti-inflammatory Therapy With Prednisolone and Montelukast [NCT02479074]	Phase 4	49 participants (Actual)	Interventional	2016-01-31	Completed
First Line Treatment of Familiar Lymphohistiocytosis by Alemtuzumab (CAMPATH®) [NCT02472054]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2015-06-29	Completed
Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy [NCT04391439]		40 participants (Actual)	Observational	2011-01-01	Completed
Zoledronic Acid or Methylprednisolone in the Management of Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus: A Randomized, Double-blind, Placebo Controlled Trial [NCT03289338]	Phase 2/Phase 3	36 participants (Actual)	Interventional	2016-06-01	Completed
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients [NCT03110822]	Phase 1	134 participants (Anticipated)	Interventional	2017-02-01	Recruiting
Effectiveness and Safety of Efgartigimod in the Acute Phase of Neuromyelitis Optica Spectrum Disorders-a Multicentric, Controlled, Retrospective, Real-Word Study [NCT06118398]		24 participants (Anticipated)	Observational	2023-11-05	Not yet recruiting
The Effect of Positive Airway Pressure on Idiopathic Sudden Sensorineural Hearing Loss Comorbided With Obstructive Sleep Apnea: A Clinical Randomized Controlled Study [NCT04192656]	Phase 4	102 participants (Anticipated)	Interventional	2019-11-01	Recruiting
Effect of Preoperative Intravenous High Dose Methylprednisolone on Quadriceps Muscle Function in Patients Scheduled for Total Knee-arthroplasty [NCT02319343]	Phase 3	70 participants (Actual)	Interventional	2015-01-31	Completed
Phase III Study to Evaluate the Efficacy and Safety of NPB-01 in Patients With Autoimmune Encephalitis Refractory to Steroid Pulse Therapy [NCT05177939]	Phase 3	40 participants (Anticipated)	Interventional	2022-03-03	Recruiting
Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. [NCT04662723]	Phase 4	878 participants (Anticipated)	Interventional	2023-05-01	Recruiting
Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy [NCT04876534]	Phase 2	64 participants (Anticipated)	Interventional	2019-12-18	Recruiting
A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Co-Administration of FOV1101-00 (Cyclosporine 0.01% or 0.02%) and Prednisolone Acetate 0.12% (PredMild®) Compared to Prednisolone Acetate 1% Alone or Vehicle Alone in Patients With Mi [NCT00833495]	Phase 2	155 participants (Actual)	Interventional	2009-01-31	Completed
Parasitic Ulcer Treatment Trial Pilot [NCT03484507]	Phase 2	49 participants (Actual)	Interventional	2018-01-01	Active, not recruiting
A National Prospective Study of Patients With Hepatitis Induced by Immune Checkpoint Inhibitors; Characterization of Liver Injury, Outcome of Therapy and Randomization to Either Prednisolone or Mycophenolate Mofetil Treatment in Case of Relapse [NCT04810156]	Phase 2	60 participants (Anticipated)	Interventional	2021-04-07	Recruiting
Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms [NCT02299115]	Phase 3	0 participants (Actual)	Interventional	2017-09-05	Withdrawn(stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.)
Pre-emptive Scalp Infiltration With Ropivacaine Plus Methylprednisolone vs Ropivacaine Alone for Relief of Postoperative Pain After Craniotomy in Children (RP/MP vs RP) [NCT03636165]	Phase 4	90 participants (Anticipated)	Interventional	2022-09-01	Not yet recruiting
Preoperative Single-high Dose Glucocorticoid for Patients Undergoing Hip Fracture Surgery and the Effect on Postoperative Delirium. [NCT02317601]	Phase 4	122 participants (Actual)	Interventional	2014-12-31	Completed
Randomized Controlled Trial of Methylprednisolone Versus Dexamethasone in COVID-19 Pneumonia (MEDEAS Trial) [NCT04636671]	Phase 3	690 participants (Actual)	Interventional	2021-04-14	Completed
Effect of Preoperative Low-dose of Methylprednisolone on Postoperative Pain and Immune Functions After Video-assisted Thoracoscopic Surgery: A Prospective Randomized Controlled Trial [NCT03393949]	Phase 4	112 participants (Actual)	Interventional	2015-07-01	Completed
A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspe [NCT02517619]	Phase 3	251 participants (Actual)	Interventional	2016-01-16	Completed
Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS) [NCT01624805]	Phase 2	100 participants (Anticipated)	Interventional	2012-06-25	Recruiting
CORTERAS STUDY: The Effect of Corticosteroids on Early Recovery After Major Surgery in Elderly Patients [NCT05220319]	Phase 4	672 participants (Anticipated)	Interventional	2022-02-03	Recruiting
Comparison of Follow-up and Steroid Treatment Results in Intussusception in Children [NCT05640375]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2019-12-24	Recruiting
The Effects of Intraoperative Local and Systemic Corticosteroid Administration on Postoperative Dysphagia After Anterior Cervical Fusion [NCT03311425]	Phase 3	140 participants (Actual)	Interventional	2014-08-01	Completed
Effects of a Multiple Sclerosis Relapse Therapy With Methylprednisolone (MP) During Pregnancy on Offspring Cognitive Function, Stress Sensitivity, Behaviour and Functional and Structural Brain Development [NCT04832269]		80 participants (Anticipated)	Observational	2020-10-19	Recruiting
Randomized, Double-blinded, Comparison Between Ultrasound-Guided Genicular Nerve Phenol Neurolysis and Intra-articular Steroid Injections [NCT06000709]	Phase 4	40 participants (Anticipated)	Interventional	2023-10-20	Not yet recruiting
A Phase 2a Single-arm, Prospective, Open-label Pilot Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant [NCT04046549]	Phase 2	25 participants (Actual)	Interventional	2019-10-30	Completed
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI) [NCT02260934]	Phase 2	43 participants (Actual)	Interventional	2015-07-09	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00057811 (4) [back to overview]	Response Rate
NCT00057811 (4) [back to overview]	Grade ≥ 3 Stomatitis
NCT00057811 (4) [back to overview]	Minimal Residual Disease
NCT00057811 (4) [back to overview]	Toxic Death
NCT00066469 (1) [back to overview]	Event-free Survival
NCT00097448 (1) [back to overview]	Hearing Improvement
NCT00109928 (4) [back to overview]	2-year Overall Survival Rate
NCT00109928 (4) [back to overview]	2-year Progression-free Survival Rate
NCT00109928 (4) [back to overview]	Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT00109928 (4) [back to overview]	Response Rate
NCT00128180 (10) [back to overview]	Duration of ICU Stays
NCT00128180 (10) [back to overview]	Duration of Hospital Stay in Days
NCT00128180 (10) [back to overview]	Development of Serum Creatinine Greater Than or Equal to 3.0 mg/dL After Study Entry
NCT00128180 (10) [back to overview]	Number of Participants With SAEs
NCT00128180 (10) [back to overview]	The Proportion of Subjects Who Develop Death, PaO2/FiO2 Ratio Less Than or Equal to 55, Cardiac Index Less Than or Equal to 2.2, Pulseless Electrical Activity, Ventricular Tachycardia or Fibrillation
NCT00128180 (10) [back to overview]	Number of Participants Who Developed Refractory Shock Despite Fluid Resuscitation After Study Entry
NCT00128180 (10) [back to overview]	Duration of Shock and/or Pressor/Inotropic Support
NCT00128180 (10) [back to overview]	Length of Time on a Ventilator
NCT00128180 (10) [back to overview]	Number of Participants Intubated and Placed on a Ventilator After Study Entry.
NCT00128180 (10) [back to overview]	Number of Participants on Extracorporeal Membrane Oxygenation (ECMO)
NCT00185692 (2) [back to overview]	Engraftment of Haploidentical CD34+ Selected Blood Stem Cells in Older Patients or Those With Medical Co-morbidities Following Total Lymphoid Irradiation and Antithymocyte Globulin Transplant Conditioning
NCT00185692 (2) [back to overview]	Acute Graft-versus-Host Disease (GVHD) Grade 2-4 Risk From Time of Transplant Until Day 90 Post-transplant
NCT00186628 (4) [back to overview]	Incidence of Relapse
NCT00186628 (4) [back to overview]	Chronic Graft-vs-Host Disease (cGvHD)
NCT00186628 (4) [back to overview]	Overall Survival
NCT00186628 (4) [back to overview]	Mortality
NCT00248534 (4) [back to overview]	6-month Progression-free Survival
NCT00248534 (4) [back to overview]	Number of Participants Alive at 3 Years
NCT00248534 (4) [back to overview]	Percentage of Participants With Objective Response
NCT00248534 (4) [back to overview]	1 Year Overall Survival Rate
NCT00257933 (1) [back to overview]	Time Measured From the Administration of the Loading Dose of Prednisolone (2mg/kg up to Max 60mg) in the Emergency Department (ED) Until the Home Dose of Albuterol is Administered
NCT00278564 (1) [back to overview]	Survival
NCT00290589 (3) [back to overview]	Numerical Rating Scale (0-10), an Interval Pain Scale, on Which 0 Indicates no Pain and 10 Indicates the Worst Pain Imaginable
NCT00290589 (3) [back to overview]	Functional Disability Scales
NCT00290589 (3) [back to overview]	Number of Patients Using Analgesics
NCT00309907 (6) [back to overview]	Estimate Percentage Pulmonary Response in Patients With IPS Treated With Etanercept + Corticosteroid Therapy
NCT00309907 (6) [back to overview]	Plasma Cytokine IL6 Level
NCT00309907 (6) [back to overview]	C-reactive Protein Levels
NCT00309907 (6) [back to overview]	Toxicity of Etanercept Plus Corticosteroid Therapy Using the Common Terminology Criteria Version 4.0
NCT00309907 (6) [back to overview]	Survival Rate
NCT00309907 (6) [back to overview]	Response of IPS (Idiopathic Pneumonia Syndrome) to Etanercept Plus Corticosteroid Therapy by Day 28.
NCT00332696 (11) [back to overview]	Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 1
NCT00332696 (11) [back to overview]	Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 14
NCT00332696 (11) [back to overview]	Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 7
NCT00332696 (11) [back to overview]	Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 1
NCT00332696 (11) [back to overview]	Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 2
NCT00332696 (11) [back to overview]	Number of Participants With Treatment Success From Day 5 to Day 7
NCT00332696 (11) [back to overview]	Participant's Quality of Life Using the Edmonton Scale
NCT00332696 (11) [back to overview]	Number of Vomiting Episodes Per Day at Day1, Day 2 and Day 14
NCT00332696 (11) [back to overview]	Number of Participants With Treatment Success From Day 10 to Day 13
NCT00332696 (11) [back to overview]	Number of Participants With Relief From Obstruction at Day 7 and Day 14
NCT00332696 (11) [back to overview]	Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 3
NCT00345046 (1) [back to overview]	Percent Change in Flare at Resolution
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Were Disease-free and Alive at 12 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Were Disease-free and Alive at 6 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) With Acute Graft-versus-host Disease (GVHD) Grade II-IV
NCT00354172 (15) [back to overview]	Number of Participants (Patients) With Acute Graft-versus-Host Disease at Grade III-IV
NCT00354172 (15) [back to overview]	Number of Participants (Patients) With Chronic Graft-Versus-Host Disease
NCT00354172 (15) [back to overview]	Number of Participants (Patients) With Successful Natural Killer Cell Expansion
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Experienced Relapse by 24 Months
NCT00354172 (15) [back to overview]	Number of Patients Who Were Disease-free and Alive at 24 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Attained Neutrophil Engraftment
NCT00354172 (15) [back to overview]	Chimerism After Double Umbilical Cord Blood Transplant (UCBT)
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Attained Platelet Engraftment
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Died by 12 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Died by 24 Months
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Died Due to Transplant.
NCT00354172 (15) [back to overview]	Number of Participants (Patients) Who Experienced Relapse by 12 Months
NCT00393367 (12) [back to overview]	Number of Subjects Moving From the Severe Asthma to Mild Asthma Category
NCT00393367 (12) [back to overview]	Change in Mean Heart Rate
NCT00393367 (12) [back to overview]	Median Change in Asthma Score 2 Hours After Intervention
NCT00393367 (12) [back to overview]	Mean Change in Asthma Score at 2 Hours
NCT00393367 (12) [back to overview]	Serious Adverse Events
NCT00393367 (12) [back to overview]	Number of Subjects Moving From the Severe Asthma to Moderate Asthma Category
NCT00393367 (12) [back to overview]	Number of Participants With Adverse Events (Non-serious).
NCT00393367 (12) [back to overview]	Relapse / Readmission Numbers.
NCT00393367 (12) [back to overview]	Oxygen Saturation.
NCT00393367 (12) [back to overview]	Number of Subjects Remaining in the Severe Asthma Category
NCT00393367 (12) [back to overview]	Mean Change in Respiratory Rate.
NCT00393367 (12) [back to overview]	Number of Patients Hospitalized
NCT00423098 (10) [back to overview]	Number of Patients With Treatment Failure
NCT00423098 (10) [back to overview]	Duration of Exposure to Study Medication
NCT00423098 (10) [back to overview]	Change From Baseline in Overall Disease Activity With British Isles Lupus Assessment Group (BILAG)
NCT00423098 (10) [back to overview]	Change From Baseline in Overall Disease Activity With Systematic Lupus Erythematosus Disease Activity Index (SLEDAI)
NCT00423098 (10) [back to overview]	Cumulative Dose of Prednisone Equivalent Corticosteroids (CS)
NCT00423098 (10) [back to overview]	Number of Patients With Adverse Events and Infections
NCT00423098 (10) [back to overview]	Number of Patients With Complete Remission
NCT00423098 (10) [back to overview]	Number of Patients With Complete Remission
NCT00423098 (10) [back to overview]	Number of Patients With Moderate to Severe Flares
NCT00423098 (10) [back to overview]	Number of Patients With Partial Remission
NCT00424489 (1) [back to overview]	Survival
NCT00443430 (3) [back to overview]	Clinical Remission on Medication
NCT00443430 (3) [back to overview]	Proportion of Participants Who Attain Inactive Disease by 6 Months
NCT00443430 (3) [back to overview]	Safety Profiles, Including the Number of Treatment-emergent, Serious, or Unexpected Adverse Events and Other Important Medical Events
NCT00481832 (10) [back to overview]	Relapse Rate
NCT00481832 (10) [back to overview]	Overall Survival (OS)
NCT00481832 (10) [back to overview]	Overall Mortality Rate
NCT00481832 (10) [back to overview]	Median Time to Platelet Engraftment
NCT00481832 (10) [back to overview]	Median Time to Neutrophile Engraftment
NCT00481832 (10) [back to overview]	Incidence of Chronic Graft Versus Host Disease (GvHD)
NCT00481832 (10) [back to overview]	Event-free Survival (EFS)
NCT00481832 (10) [back to overview]	Incidence of Acute Graft Versus Host Disease (GvHD)
NCT00481832 (10) [back to overview]	Achieving Full Donor Chimerism
NCT00481832 (10) [back to overview]	Incidence of Chemotherapy-associated Pneumonitis
NCT00492973 (5) [back to overview]	Amount of Pain Medication Taken Per Day
NCT00492973 (5) [back to overview]	Length of Hospital Stay
NCT00492973 (5) [back to overview]	Complications, Such as Infections, Hospital Readmissions, Manipulations Under Anesthesia, Etc.
NCT00492973 (5) [back to overview]	Knee Society Scores
NCT00492973 (5) [back to overview]	Knee Range of Motion
NCT00493064 (1) [back to overview]	Number of Participants With An Improvement in Vision, as Measured by an Increase of 15 Letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) Vision Chart.
NCT00521989 (1) [back to overview]	Change From Baseline to Day 98 Using the WOMAC Pain Question #1
NCT00551707 (2) [back to overview]	Percent Change From Baseline to Day 98 in C-reactive Protein (CRP) Values - As Treated Population
NCT00551707 (2) [back to overview]	Absolute C-reactive Protein (CRP) Values at Day 98 - As Treated Population
NCT00553202 (2) [back to overview]	Cumulative Incidence of NK Cell Reconstitution
NCT00553202 (2) [back to overview]	Overall Survival (OS)
NCT00555464 (2) [back to overview]	Response of Hemangioma (IH) to Treatment
NCT00555464 (2) [back to overview]	Toxicity to Medications
NCT00557193 (10) [back to overview]	Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)
NCT00557193 (10) [back to overview]	Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)
NCT00557193 (10) [back to overview]	Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm
NCT00557193 (10) [back to overview]	Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) for Patients on Arm A
NCT00568633 (8) [back to overview]	Transplant-related Mortality
NCT00568633 (8) [back to overview]	Early Graft Loss
NCT00568633 (8) [back to overview]	Disease-free Survival (DFS)
NCT00568633 (8) [back to overview]	Overall Survival (OS)
NCT00568633 (8) [back to overview]	Relapse Rate
NCT00568633 (8) [back to overview]	Patients Completing the Intended Therapy in Both Arms
NCT00568633 (8) [back to overview]	Complete Donor Hematopoietic Cell Chimerism
NCT00568633 (8) [back to overview]	Non-relapse Mortality
NCT00577993 (2) [back to overview]	Number of Participants With Progression Free Survival (10 Years) by Treatment
NCT00577993 (2) [back to overview]	Number of Participants With Overall Survival (10 Years) by Treatment
NCT00595335 (8) [back to overview]	Graves' Ophthalmopathy Quality of Life Score Using the Short Form-12 (SF-12) Health Survey
NCT00595335 (8) [back to overview]	Failure Rate
NCT00595335 (8) [back to overview]	Change in Proptosis
NCT00595335 (8) [back to overview]	Change in Lid Fissure
NCT00595335 (8) [back to overview]	Failure Rate at One Year
NCT00595335 (8) [back to overview]	Change in Clinical Activity Score (CAS)
NCT00595335 (8) [back to overview]	Change in Extraocular Motility
NCT00595335 (8) [back to overview]	Change in Disease Severity
NCT00609609 (3) [back to overview]	Non-relapse Mortality (NRM) at 6 Months
NCT00609609 (3) [back to overview]	Day 56 Treatment Success
NCT00609609 (3) [back to overview]	Percentage of Participants Alive, In Remission & Without GVHD Progression Day 28 & Day 56
NCT00624416 (3) [back to overview]	The Average Percent Volume Reduction in the Lipoma.
NCT00624416 (3) [back to overview]	The Number of Subjects Elected to Have the Lipoma Removed.
NCT00624416 (3) [back to overview]	The Number of Lipoma Increased in Volume.
NCT00634933 (12) [back to overview]	Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
NCT00634933 (12) [back to overview]	Number of Tender Joints
NCT00634933 (12) [back to overview]	Percentage of Participants With an American College of Rheumatology 50% (ACR 50) Response at Week 24
NCT00634933 (12) [back to overview]	Number of Swollen Joints
NCT00634933 (12) [back to overview]	Health Assessment Questionnaire Disability Index (HAQ-DI)
NCT00634933 (12) [back to overview]	Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
NCT00634933 (12) [back to overview]	Disease Activity Score Based on 28-joints Count (DAS28)
NCT00634933 (12) [back to overview]	Physician Global Assessment (PGA) of Disease Activity
NCT00634933 (12) [back to overview]	Visual Analogue Scale for Pain (VAS-pain)
NCT00634933 (12) [back to overview]	Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
NCT00634933 (12) [back to overview]	Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
NCT00634933 (12) [back to overview]	Patient Global Assessment (PtGA) of Disease Activity
NCT00671658 (1) [back to overview]	Number of Participants With a Response
NCT00682357 (4) [back to overview]	Change in Serum Osteocalcin
NCT00682357 (4) [back to overview]	Change in Serum Cortisol
NCT00682357 (4) [back to overview]	Change in Testosterone
NCT00682357 (4) [back to overview]	Change in Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b)
NCT00689078 (10) [back to overview]	Ocular Redness at Day 28
NCT00689078 (10) [back to overview]	Ocular Redness at Day 7
NCT00689078 (10) [back to overview]	Ocular Redness at Day 6
NCT00689078 (10) [back to overview]	Ocular Itching at Day 28
NCT00689078 (10) [back to overview]	Ocular Redness at Day 27
NCT00689078 (10) [back to overview]	Ocular Redness at Baseline (Day 0)
NCT00689078 (10) [back to overview]	Ocular Itching at Day 7
NCT00689078 (10) [back to overview]	Ocular Itching at Day 6
NCT00689078 (10) [back to overview]	Ocular Itching at Day 27
NCT00689078 (10) [back to overview]	Ocular Itching at Baseline (Day 0)
NCT00699803 (1) [back to overview]	Mean Aqueous Humor Prednisolone Acetate Concentration
NCT00720109 (5) [back to overview]	Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)
NCT00720109 (5) [back to overview]	Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation
NCT00720109 (5) [back to overview]	Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events
NCT00720109 (5) [back to overview]	Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy
NCT00720109 (5) [back to overview]	Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy
NCT00732498 (4) [back to overview]	Overall Response Rate
NCT00732498 (4) [back to overview]	Complete Response Rate
NCT00732498 (4) [back to overview]	Median Time to Progression
NCT00732498 (4) [back to overview]	Progression-free Survival at 1 Year
NCT00733096 (4) [back to overview]	Numerical Rating Leg Pain Score
NCT00733096 (4) [back to overview]	Global Perceived Effect
NCT00733096 (4) [back to overview]	Medication Reduction
NCT00733096 (4) [back to overview]	Oswestry Disability Score
NCT00782717 (2) [back to overview]	Percent of Patients With a Decrease of More Than 5 Letters in Best-corrected Visual Acuity (BCVA).
NCT00782717 (2) [back to overview]	Percent of Patients Who Developed Macular Edema (ME) Within 90 Days Following Cataract Surgery
NCT00787722 (6) [back to overview]	Quality of Life (QOL) Short Form - 36 (SF-36)
NCT00787722 (6) [back to overview]	Disability Score: Expanded Disability Status Scale (EDSS)
NCT00787722 (6) [back to overview]	Survival
NCT00787722 (6) [back to overview]	Post HSCT Immune -Modulating Medication and Relapse
NCT00787722 (6) [back to overview]	NMO-IgG Aquaporin- 4 Autoantibody Titer
NCT00787722 (6) [back to overview]	Number of Patients Who Require No Device Assistance for Ambulation
NCT00792948 (3) [back to overview]	Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation
NCT00792948 (3) [back to overview]	Overall Survival (OS)
NCT00792948 (3) [back to overview]	Continuous Complete Remission (CCR) Rate
NCT00802529 (3) [back to overview]	Vertigo Attacks
NCT00802529 (3) [back to overview]	Change in Hearing
NCT00802529 (3) [back to overview]	Change in Speech Discrimination
NCT00806598 (1) [back to overview]	Overall Response
NCT00807586 (3) [back to overview]	Number of Participants With Clinically Significant Atrial Arrhythmias at 6 Weeks
NCT00807586 (3) [back to overview]	Repeat Intervention
NCT00807586 (3) [back to overview]	Cardiac Pain Assessment
NCT00854061 (1) [back to overview]	Means Aqueous Humor Prednisolone Acetate Concentration
NCT00908583 (4) [back to overview]	Number of Patients Whose Cytotoxic Panel Reactive Antibody (PRA) is Decreased by 50%
NCT00908583 (4) [back to overview]	Number of Living Donor Transplant Candidates That Are Transplanted
NCT00908583 (4) [back to overview]	Acute Rejection Rate
NCT00908583 (4) [back to overview]	Overall Safety of Bortezomib
NCT00915473 (4) [back to overview]	Mean Number of Days With Acute Medication Use
NCT00915473 (4) [back to overview]	Number of Subjects With at Least 50% Reduction in the Frequency of Days With Moderate or Severe Migraine in the 4 Week Post Injection Compared to the 4 Week Pre-injection Baseline Period
NCT00915473 (4) [back to overview]	Mean Frequency of Days With a Migraine
NCT00915473 (4) [back to overview]	Mean Number of Hours With Moderate or Severe Migraine
NCT00929695 (12) [back to overview]	Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment
NCT00929695 (12) [back to overview]	Non-relapse Mortality
NCT00929695 (12) [back to overview]	Overall Survival
NCT00929695 (12) [back to overview]	Prednisone-associated Toxicity as Assessed by Hyperglycemia
NCT00929695 (12) [back to overview]	Prednisone-associated Toxicity as Assessed by Hypertension
NCT00929695 (12) [back to overview]	Prednisone-associated Toxicity as Assessed by Invasive Infections (Bacterial, Fungal and Viral)
NCT00929695 (12) [back to overview]	Prednisone-associated Toxicity as Assessed by Myopathy
NCT00929695 (12) [back to overview]	Prednisone-associated Toxicity as Assessed by Quality of Life
NCT00929695 (12) [back to overview]	Progression to Grade III-IV Acute GVHD
NCT00929695 (12) [back to overview]	Recurrent or Progressive Malignancy
NCT00929695 (12) [back to overview]	Secondary Therapy for Acute GVHD Beyond Prednisone
NCT00929695 (12) [back to overview]	Chronic Extensive GVHD
NCT00929981 (7) [back to overview]	Treatment Status (Success/Failure) of Contact Dermatitis (CD) at the Second Follow-up Visit
NCT00929981 (7) [back to overview]	Treatment Status (Success/Failure) of CD at the First Follow-up Visit
NCT00929981 (7) [back to overview]	Change From Baseline in Participant-rated Pruritus Score at First, Second, Third and Final Follow-up Visits
NCT00929981 (7) [back to overview]	Treatment Status (Success/Failure) of CD at the Final Follow-up Visit
NCT00929981 (7) [back to overview]	Change From Baseline in Participant-rated Clinical Severity Score of Lesions at First, Second, Third and Final Follow-up Visits
NCT00929981 (7) [back to overview]	Change From Baseline in Investigator-rated Total Signs and Symptoms of CD Score at First, Second, Third and Final Follow-up Visits
NCT00929981 (7) [back to overview]	Treatment Status (Success/Failure) of CD at the Third Follow-up Visit
NCT00934843 (5) [back to overview]	Total Intake/Output of Fluid
NCT00934843 (5) [back to overview]	Urine Output
NCT00934843 (5) [back to overview]	Number of Participants Who Died Between 36 Hours and 30 Days Following Cardiac Surgery
NCT00934843 (5) [back to overview]	Inotropic Score
NCT00934843 (5) [back to overview]	Primary Endpoint: Number of Participants With Low Cardiac Output Syndrome (LCOS) or Death at 36 Hours From Admission to the Intensive Care Unit (ICU) After Surgery.
NCT00947765 (8) [back to overview]	Pain(at 6 Months): Nirschl Staging
NCT00947765 (8) [back to overview]	Pain (at 1 Week): Visual Analogue Scale(0 to 10)
NCT00947765 (8) [back to overview]	Pain(at 1 Week): Nirschl Staging (0 to 7)
NCT00947765 (8) [back to overview]	Pain(at 12 Weeks): Nirschl Staging
NCT00947765 (8) [back to overview]	Pain(at 12 Weeks): Visual Analogue Scale
NCT00947765 (8) [back to overview]	Pain(at 4 Weeks): Nirschl Staging
NCT00947765 (8) [back to overview]	Pain(at 4 Weeks): Visual Analogue Scale
NCT00947765 (8) [back to overview]	Pain(at 6 Months): Visual Analogue Scale
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 2
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured Before Treatment on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Serum Estradiol Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Serum Estradiol Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 4
NCT00957801 (40) [back to overview]	C-Reactive Protein (CRP) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Prostate Specific Antigen (PSA) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Prostate Specific Antigen (PSA) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Low-Density Lipoproteins (LDL) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	C-Reactive Protein (CRP) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Insulin Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Insulin Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Insulin Like Growth Factor 1 (IGF-1) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Cortisol Measured on Treatment Day 1 (Baseline Study) AFTER Exercise Protocol
NCT00957801 (40) [back to overview]	Very Low-Density Lipoproteins (VLDL) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Triglycerides Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Triglycerides Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Total Cholesterol Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Total Cholesterol Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Insulin Like Growth Factor 1 (IGF-1) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	High-Density Lipoproteins (HDL) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	High-Density Lipoproteins (HDL) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Hematocrit Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Sex Hormone Binding Globulin (SHBG) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Low-Density Lipoproteins (LDL) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Hematocrit Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Global Fatigue Score as Measured by Brief Fatigue Inventory (BFI) in the Pre-treatment Week
NCT00957801 (40) [back to overview]	Global Fatigue Score as Measured by Brief Fatigue Inventory (BFI) During the Treatment Week
NCT00957801 (40) [back to overview]	Dehydroepiandrosterone Sulfate (DHEA-S) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Dehydroepiandrosterone Sulfate (DHEA-S) Measured on Treatment Day 1 (Baseline Study)
NCT00957801 (40) [back to overview]	Very Low-Density Lipoproteins (VLDL) Measured on Treatment Day 8 (Post Study)
NCT00957801 (40) [back to overview]	Cortisol Measured on Treatment Day 8 (Post Study) BEFORE Exercise Protocol
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 7
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 6
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 5
NCT00957801 (40) [back to overview]	Serum Total Testosterone Measured on Treatment Day 3
NCT00957801 (40) [back to overview]	Cortisol Measured on Treatment Day 8 (Post Study) AFTER Exercise Protocol
NCT00957801 (40) [back to overview]	Cortisol Measured on Treatment Day 1 (Baseline Study) BEFORE Exercise Protocol
NCT00957801 (40) [back to overview]	Sex Hormone Binding Globulin (SHBG) Measured on Treatment Day 8 (Post Study)
NCT00968253 (3) [back to overview]	Participant Responses by Daily Dose Level Assignment (RAD001 5 mg, 10 mg and MTD 5 mg)
NCT00968253 (3) [back to overview]	Overall Response Rate (OR) Where OR = CR + CRp + CRi
NCT00968253 (3) [back to overview]	Maximum Tolerated Dose [MTD] Determination by Number of Participants With Dose Limiting Toxicity (DLT)
NCT00987831 (2) [back to overview]	Time to Flare Comparing Patients With (at Baseline) British Isles Lupus Assessment Group Index (BILAG) >/= 17 (Severe Disease) to Those With BILAG < 17 (Moderate Disease Activity).
NCT00987831 (2) [back to overview]	Time to Flare Comparing Patients With Moderate vs Severe Disease Activity at Baseline
NCT01000610 (4) [back to overview]	Change in Bone Density (in Participants Untreated With Bisphosphonates)
NCT01000610 (4) [back to overview]	Number of Participants Reporting Adverse Events (AEs)
NCT01000610 (4) [back to overview]	Percentage Change in Disease Activity Score 28 (DAS28) From Baseline to Week 24
NCT01000610 (4) [back to overview]	Percentage of Participants Whose DAS28 Improved by >1.2 at Week 24
NCT01085097 (2) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01085097 (2) [back to overview]	Percent Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 24
NCT01093586 (14) [back to overview]	Recurrence or Relapse
NCT01093586 (14) [back to overview]	Overall Survival
NCT01093586 (14) [back to overview]	Overall Survival
NCT01093586 (14) [back to overview]	Recurrence or Relapse
NCT01093586 (14) [back to overview]	Overall Survival
NCT01093586 (14) [back to overview]	Toxicity Related to UCB Transplantation and Cytoreduction as Assessed by CTC v3.0
NCT01093586 (14) [back to overview]	Transplant Related Mortality
NCT01093586 (14) [back to overview]	Transplant Related Mortality
NCT01093586 (14) [back to overview]	Disease Free
NCT01093586 (14) [back to overview]	Disease Free
NCT01093586 (14) [back to overview]	Incidence of Acute Graft-versus-host Disease (GVHD)
NCT01093586 (14) [back to overview]	Occurrence of Serious Infections
NCT01093586 (14) [back to overview]	Incidence of Chronic GVHD
NCT01093586 (14) [back to overview]	Hematologic Engraftment
NCT01105650 (4) [back to overview]	Time to Disease Progression
NCT01105650 (4) [back to overview]	Response Rate
NCT01105650 (4) [back to overview]	Overall Survival
NCT01105650 (4) [back to overview]	Number of Participants With Progressive Disease at One Year
NCT01114503 (8) [back to overview]	Number of Participants With Vital Signs Abnormalities Meeting the Criteria for PCC
NCT01114503 (8) [back to overview]	Number of Participants With Thyroid Function Assessment, Hormone and Glucose Assay Abnormalities Meeting the Criteria for PCC
NCT01114503 (8) [back to overview]	Number of Participants With Laboratory Urinalysis Abnormalities Meeting the Criteria for PCC
NCT01114503 (8) [back to overview]	Number of Participants With Laboratory Hematology Abnormalities Meeting the Criteria for PCC
NCT01114503 (8) [back to overview]	Number of Participants With Laboratory Clinical Chemistry Abnormalities Meeting the Criteria for Potential Clinical Concern (PCC)
NCT01114503 (8) [back to overview]	Number of Participants With Electrocardiogram (ECG) Abnormalities Meeting the Criteria for PCC
NCT01114503 (8) [back to overview]	Number of Participants With an Epstein Barr Virus (EBV) Viral Load Abnormalities Meeting the Criteria for PCC
NCT01114503 (8) [back to overview]	Number of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Hypopyon
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Corneal Clarity
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Conjunctival Injection
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Anterior Chamber Cell Grade
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Lacrimation
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Photophobia
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Wound Integrity
NCT01124045 (13) [back to overview]	Global Assessment Score of Postoperative Inflammation by Visit
NCT01124045 (13) [back to overview]	Percentage of Patients With an Anterior Cell Grade of 0 (no Cells) at Day 15 ± 2 Days
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Anterior Chamber Flare Grade
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Chemosis
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Ciliary/Limbal Injection
NCT01124045 (13) [back to overview]	Global Assessment of Inflammation - Individual Component Scoring by Visit: Vitritis
NCT01144143 (5) [back to overview]	Change in Levels of Serum IL-6
NCT01144143 (5) [back to overview]	Change in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score Target Knee
NCT01144143 (5) [back to overview]	Change in Joint Effusions From Day 0 to Day 56 Target Knee
NCT01144143 (5) [back to overview]	Change in Serum CRP Day 0 to Day 56
NCT01144143 (5) [back to overview]	Change in Serum SAA Levels Day 0 to Day 56
NCT01201798 (10) [back to overview]	Proportion of Subjects With Anterior Chamber Cell Count ≤5 and Flare Grade of 0
NCT01201798 (10) [back to overview]	Change From Baseline (Day 0) in Slit-Lamp Total Sign Score at All Visits
NCT01201798 (10) [back to overview]	Change From Baseline (Day 0) in Anterior Chamber Flare Grade at All Time Points
NCT01201798 (10) [back to overview]	Proportion of Subjects With Anterior Chamber Cell Count of 0
NCT01201798 (10) [back to overview]	Change From Baseline (Day 0) in Anterior Chamber Cell Grade at Day 14
NCT01201798 (10) [back to overview]	Proportion of Subjects Who Discontinued Due to Lack of Efficacy
NCT01201798 (10) [back to overview]	Change From Baseline (Day 0) in Visual Analog Scale (VAS) Total Symptom Score at All Time Points
NCT01201798 (10) [back to overview]	Proportion of Subjects With Anterior Chamber Cell Grade of 0
NCT01201798 (10) [back to overview]	Proportion of Subjects With Anterior Chamber Cell Grade ≤1
NCT01201798 (10) [back to overview]	Change From Baseline (Day 0) in Anterior Chamber Cell Grade at All Time Points Other Than Day 14
NCT01211665 (3) [back to overview]	Severity of AEs and SAEs
NCT01211665 (3) [back to overview]	Number of Participants Who Survived at 6 Months Following Completion of Plasma Exchange (PLEX)
NCT01211665 (3) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01219933 (33) [back to overview]	DAS28-ESR During the Noninterventional Phase
NCT01219933 (33) [back to overview]	HAQ-DI During the Interventional Phase
NCT01219933 (33) [back to overview]	Health Assessment Questionnaire Disability Index (HAQ-DI) During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Median GC Dose Taken During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Number of Erosions During the NonInterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants Positive for Anti-cyclic Citrullinated Peptide (Anti-CCP) Antibody During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants Positive for Rheumatoid Factor (RF) During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants With Erosions During the NonInterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants With LDA or Remission During the Interventional Phase Assessed Using CDAI
NCT01219933 (33) [back to overview]	Percentage of Participants With LDA or Remission During the Interventional Phase Assessed Using DAS28-CRP
NCT01219933 (33) [back to overview]	SF-36 Subscale Scores During the Interventional Phase
NCT01219933 (33) [back to overview]	Short-Form 36 (SF-36) Mental Component Score (MCS) and Physical Component Score (PCS) During the Interventional Phase
NCT01219933 (33) [back to overview]	SJC and TJC During the Interventional Phase
NCT01219933 (33) [back to overview]	Type of GC Taken at the End of the Noninterventional Phase
NCT01219933 (33) [back to overview]	VAS for Pain (VAS-Pain) During the Interventional Phase
NCT01219933 (33) [back to overview]	VAS-Physician's Global Assessment of Disease Activity (GDA) During the Interventional Phase
NCT01219933 (33) [back to overview]	Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score During the Interventional Phase
NCT01219933 (33) [back to overview]	Median Dose of Tocilizumab During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Median Time Interval Between V1 and V2
NCT01219933 (33) [back to overview]	Number of Participants With Changes in Tocilizumab Dose During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Number of Participants With GC Switches During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants Able to Acheive LDA Assessed Using DAS28 While Receiving Oral GC on Background Tocilizumab Treatment During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants Able to Discontinue GCs During the Interventional Phase by V9
NCT01219933 (33) [back to overview]	Percentage of Participants Able to Reduce Oral GCs by ≥50 Percent (%) During the Interventional Phase by V9
NCT01219933 (33) [back to overview]	Percentage of Participants Able to Start the GC Reduction Phase at V3
NCT01219933 (33) [back to overview]	Percentage of Participants Acheiving Remission Assessed Using DAS28 While Receiving Oral GC on Background TocilizumabTreatment During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Percentage of Participants in the Interventional Phase Who Achieved LDA and Discontinued Oral GC Within 20 Weeks
NCT01219933 (33) [back to overview]	Percentage of Participants With Changes in RA Treatment During the Noninterventional Phase
NCT01219933 (33) [back to overview]	Time-Averaged GC Dose Changes During the Interventional Phase
NCT01219933 (33) [back to overview]	CDAI Score During the Interventional Phase
NCT01219933 (33) [back to overview]	Clinical Disease Activity Index (CDAI) During the Noninterventional Phase
NCT01219933 (33) [back to overview]	DAS28-CRP During the Interventional Phase
NCT01219933 (33) [back to overview]	DAS28-CRP During the Noninterventional Phase
NCT01238536 (4) [back to overview]	Pain Numeric Rating Scale
NCT01238536 (4) [back to overview]	Leg Pain NRS
NCT01238536 (4) [back to overview]	Roland Morris
NCT01238536 (4) [back to overview]	Roland Morris Disability Questionnaire (RDQ)
NCT01267201 (4) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT01267201 (4) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
NCT01267201 (4) [back to overview]	Plasma Decay Half-life (t1/2)
NCT01267201 (4) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT01272635 (5) [back to overview]	Urgent Care Visits, ED Visits and Hospitalizations
NCT01272635 (5) [back to overview]	Progression to Clinically Significant Lower Respiratory Tract Symptoms
NCT01272635 (5) [back to overview]	OCELOT: Pediatric Respiratory Assessment Measure
NCT01272635 (5) [back to overview]	Drug Related Side Effects
NCT01272635 (5) [back to overview]	Asthma Related Symptoms Among RTI Progressing to Severe LRTI
NCT01283009 (1) [back to overview]	60-day Mortality
NCT01319981 (3) [back to overview]	Complete Response Duration
NCT01319981 (3) [back to overview]	Number of Patients With Complete Remission at One Year
NCT01319981 (3) [back to overview]	Overall Survival
NCT01369745 (1) [back to overview]	Change From Baseline in DAS28-CRP at 12 Weeks
NCT01381874 (7) [back to overview]	Progression-Free Survival (PFS)
NCT01381874 (7) [back to overview]	Overall Survival (OS)
NCT01381874 (7) [back to overview]	Duration of Response
NCT01381874 (7) [back to overview]	Clinical Benefit Rate
NCT01381874 (7) [back to overview]	Overall Response Rate (ORR)
NCT01381874 (7) [back to overview]	Change From Baseline in Serum Endocrine Biomarkers (Estradiol and Estrone) at End of Treatment
NCT01381874 (7) [back to overview]	Change From Baseline in Serum Endocrine Biomarkers (Progesterone and Testosterone) at End of Treatment
NCT01448213 (2) [back to overview]	Number of Eyes With Intraocular Pressure (IOP) Elevation
NCT01448213 (2) [back to overview]	Number of Eyes With Immunologic Graft Rejection Episodes
NCT01465334 (11) [back to overview]	Number of Participants With Overall CR
NCT01465334 (11) [back to overview]	Transplant Rate
NCT01465334 (11) [back to overview]	Overall Objective Response Rate (ORR)
NCT01465334 (11) [back to overview]	3-year Overall Survival (OS) Probability
NCT01465334 (11) [back to overview]	3-Year Progression-Free Survival (PFS) Probability
NCT01465334 (11) [back to overview]	Induction Overall Response Rate (ORR)
NCT01465334 (11) [back to overview]	Number of Participants Achieving Induction Complete Response (CR)
NCT01465334 (11) [back to overview]	Overall MRD Negative Rate
NCT01465334 (11) [back to overview]	Number of Participants Completing Only 2 Cycles of Part A Treatment
NCT01465334 (11) [back to overview]	Number of Participants Completing Part A Treatment
NCT01465334 (11) [back to overview]	Number of Participants With Treatment-Related Grades 1-3 Hyperglycemia During Part A Induction
NCT01475643 (2) [back to overview]	Anterior Chamber Cells & Flare
NCT01475643 (2) [back to overview]	Anterior Chamber Inflammation
NCT01496976 (4) [back to overview]	Rate of Progression/Relapse Free Survival (PFS)
NCT01496976 (4) [back to overview]	Number of Participants With Partial Response (PR)
NCT01496976 (4) [back to overview]	Number of Participants With Overall Survival (OS)
NCT01496976 (4) [back to overview]	Number of Participants With Complete Response (CR)
NCT01497496 (1) [back to overview]	Objective Response Rate (ORR)
NCT01534195 (4) [back to overview]	Conjunctival Redness Change From Baseline to Day 11
NCT01534195 (4) [back to overview]	Ocular Itching Change From Baseline to Day 11
NCT01534195 (4) [back to overview]	Episcleral Redness Change From Baseline to Day 6
NCT01534195 (4) [back to overview]	Ciliary Redness Change From Baseline to Day 6
NCT01559675 (1) [back to overview]	Orthostatic Hypotension
NCT01579513 (5) [back to overview]	Duration of Mechanical Ventilation Post Cardiac Surgery.
NCT01579513 (5) [back to overview]	Intensive Care Unit Stay
NCT01579513 (5) [back to overview]	Number of Participants With a Clinically Derived Composite Morbidity-mortality Outcome
NCT01579513 (5) [back to overview]	Neurodevelopmental Outcome
NCT01579513 (5) [back to overview]	Hospital Stay
NCT01652495 (3) [back to overview]	Reduction of Pain Severity Expressed as Percentage Change in VAS Score
NCT01652495 (3) [back to overview]	Percentage of Patients With Suppression of Hypothalamus-pituitary-adrenal Axis
NCT01652495 (3) [back to overview]	Functional Improvement Measured According to Percentage Change in Constant Score
NCT01724021 (14) [back to overview]	Percentage of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies Over Time
NCT01724021 (14) [back to overview]	Cancer Therapy Satisfaction Questionnaire (CTSQ) Score
NCT01724021 (14) [back to overview]	Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV])
NCT01724021 (14) [back to overview]	Progression-free Survival (PFS)
NCT01724021 (14) [back to overview]	Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6
NCT01724021 (14) [back to overview]	Overall Survival (OS)
NCT01724021 (14) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (AEs)
NCT01724021 (14) [back to overview]	Event-free Survival (EFS)
NCT01724021 (14) [back to overview]	Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8
NCT01724021 (14) [back to overview]	Disease-free Survival (DFS)
NCT01724021 (14) [back to overview]	Complete Response (CR) Rate
NCT01724021 (14) [back to overview]	Summary of Observed Serum Rituximab Concentration
NCT01724021 (14) [back to overview]	Rituximab Administration Satisfaction Questionnaire (RASQ) Score
NCT01724021 (14) [back to overview]	Percentage of Participants With Anti-Rituximab Antibodies Over Time
NCT01730872 (3) [back to overview]	Inflammation Change From Baseline to Day 6
NCT01730872 (3) [back to overview]	Ocular Redness Change From Baseline to Day 6
NCT01730872 (3) [back to overview]	Ocular Itching Change From Baseline to Day 6
NCT01783847 (2) [back to overview]	Number of Participants With Relative Afferent Papillary Defect (RAPD) Grade +4
NCT01783847 (2) [back to overview]	Number of Participants With Change/Improvement Visual Acuity From the Beseline
NCT01809132 (4) [back to overview]	MELD Score at 28 Days
NCT01809132 (4) [back to overview]	MELD Score at 90 Days
NCT01809132 (4) [back to overview]	MELD Score at 180 Days
NCT01809132 (4) [back to overview]	180 Days Mortality
NCT01853072 (6) [back to overview]	Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90
NCT01853072 (6) [back to overview]	Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0)
NCT01853072 (6) [back to overview]	Percentage of Participants With a > 5-letter Loss in BCVA From Day 7 to Any Visit [Time Frame: Day 7 up to Any Visit]
NCT01853072 (6) [back to overview]	Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 60
NCT01853072 (6) [back to overview]	Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 90
NCT01853072 (6) [back to overview]	Percentage of Participants With With a > 10-letter Loss in BCVA From Day 7 to Any Visit
NCT01853696 (2) [back to overview]	Immunologic Graft Rejection Episode
NCT01853696 (2) [back to overview]	Intraocular Pressure
NCT01872611 (6) [back to overview]	Percentage of Participants With a > 5-letter Loss in BCVA From Day 7 to Any Visit
NCT01872611 (6) [back to overview]	Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0)
NCT01872611 (6) [back to overview]	Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 90
NCT01872611 (6) [back to overview]	Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 60
NCT01872611 (6) [back to overview]	Percentage of Participants With With a > 10-letter Loss in BCVA From Day 7 to Any Visit
NCT01872611 (6) [back to overview]	Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90
NCT01875237 (8) [back to overview]	To Assess the Proportion of Patients Developing Grade I-IV Acute GvHD
NCT01875237 (8) [back to overview]	To Assess the Proportions of GvHD Response Post-administration of AP1903.
NCT01875237 (8) [back to overview]	To Assess the Incidence of GvHD Treatment Failure Post-administration of AP1903.
NCT01875237 (8) [back to overview]	To Evaluate the Safety of Donor Lymphocyte Infusion Followed by Dimerizer Drug, AP1903 by Number of Participants With Adverse Events.
NCT01875237 (8) [back to overview]	To Assess the Incidence of Epstein-Barr Virus -PTLD or EBV Reactivation Requiring Therapy Post DLI.
NCT01875237 (8) [back to overview]	To Assess the Incidence of Acute GvHD Flare After CR/PR Requiring Additional Agent for Systemic Therapy Before Day 56 Post-administration of AP1903.
NCT01875237 (8) [back to overview]	To Assess Post Donor Lymphocyte Infusion (DLI) Chimerism
NCT01875237 (8) [back to overview]	Number of Participants Assessed Post Donor Lymphocyte Infusion (DLI): Disease-free Survival & Non-relapse Mortality, Chimerism and GVHD.
NCT01977781 (7) [back to overview]	Ocular Burning Sensation, Ocular Discharge, Ocular Redness, Ocular Itching, Foreign Body Sensation
NCT01977781 (7) [back to overview]	Visual Acuity
NCT01977781 (7) [back to overview]	Tear Film Break-Up Time
NCT01977781 (7) [back to overview]	Schirmer Tear Test (mm)
NCT01977781 (7) [back to overview]	Ocular Surface Disease Index (OSDI) Questionnaire
NCT01977781 (7) [back to overview]	Intraocular Pressure
NCT01977781 (7) [back to overview]	Corneal Epitheliopathy (Corneal Fluorescein Staining Using the NEI Grading Scheme)
NCT02006706 (2) [back to overview]	Health Assessment Questionnaire-Disability Index (HAQ-DI)
NCT02006706 (2) [back to overview]	Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24
NCT02038452 (44) [back to overview]	QALYS at 6 Months (Cross-walk Tariff)
NCT02038452 (44) [back to overview]	QALYS at 24 Months (Cross-walk Tariff)
NCT02038452 (44) [back to overview]	QALYS at 12 Months (Cross-walk Tariff)
NCT02038452 (44) [back to overview]	NHS Cost Differences at 6 Months (CC)
NCT02038452 (44) [back to overview]	NHS Cost Differences at 6 Months
NCT02038452 (44) [back to overview]	NHS Cost Differences at 24 Months
NCT02038452 (44) [back to overview]	NHS Cost Differences at 12 Months
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity Over 24 Months: 6 Weeks
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity Over 24 Months: 6 Months
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity Over 24 Months: 24 Months
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity Over 24 Months: 12 Months
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity 6 Weeks (PP)
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity 6 Weeks (CC)
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity 6 Weeks
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity 6 Months (PP)
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity 6 Months (CC)
NCT02038452 (44) [back to overview]	BCTQ Functional Limitations Subscale 6 Months
NCT02038452 (44) [back to overview]	BCTQ Functional Limitations Subscale 6 Months (CC)
NCT02038452 (44) [back to overview]	BCTQ Functional Limitations Subscale 6 Months (PP)
NCT02038452 (44) [back to overview]	BCTQ Functional Limitations Subscale 6 Weeks
NCT02038452 (44) [back to overview]	BCTQ Functional Limitations Subscale 6 Weeks (CC)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Months
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Months (CC)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Months (PP)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (Complete Case Analysis (CC))
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (Per-Protocol Analysis (PP))
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (SG, Did Not Receive the Intervention of Their Preference)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (SG, Did Not State a Preference of Intervention)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (SG, Preferred Injection)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (SG, Preferred Splint)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations 6 Weeks (Subgroup Analysis (SG), Intervention of Their Preference)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations Over 24 Months: 12 Months
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations Over 24 Months: 6 Months
NCT02038452 (44) [back to overview]	Hand-wrist Pain Intensity 6 Months
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity Subscale 6 Weeks (PP)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity Subscale 6 Weeks (CC)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity Subscale 6 Weeks
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity Subscale 6 Months (PP)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity Subscale 6 Months (CC)
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity Subscale 6 Months
NCT02038452 (44) [back to overview]	BCTQ Symptom Severity and Functional Limitations Over 24 Months: 6 Weeks
NCT02038452 (44) [back to overview]	BCTQ Functional Limitations Subscale 6 Weeks (PP)
NCT02038452 (44) [back to overview]	Symptom Severity and Limitations in Hand Function as Assessed by the BCTQ 6 Weeks
NCT02038452 (44) [back to overview]	Secondary: BCTQ Symptom Severity and Functional Limitations Over 24 Months: 24 Months
NCT02166463 (3) [back to overview]	Percentages of Patients Experiencing Grade 3+ Peripheral Neuropathy Assessed by Modified Balis Scale
NCT02166463 (3) [back to overview]	Event Free Survival (EFS), Where Events Include Disease Progression or Relapse, Second Malignancy, or Death
NCT02166463 (3) [back to overview]	Percentages of Patients With Early Response Defined as no Slow Responding Lesions (SRL) and no Progressive Disease (PD) at Any Disease Sites Determined by Positron Emission Tomography (PET) Per Deauville Criteria Through Central Review
NCT02167217 (1) [back to overview]	Bayley III Gross Motor Scaled Score (Change From Baseline to 12 Month)
NCT02176031 (6) [back to overview]	GVHD-free Survival Rate
NCT02176031 (6) [back to overview]	Rate of GVHD Flares
NCT02176031 (6) [back to overview]	GI aGVHD Response Rate
NCT02176031 (6) [back to overview]	Graft-verus-host Disease (GVHD) Response Rate
NCT02176031 (6) [back to overview]	Percentage Steroid Dose Was Reduced at Day 28, 56, and 100 in Comparison to Steroid Dose at First Administration of Natalizumab.
NCT02176031 (6) [back to overview]	Overall Survival (OS) Rate
NCT02199041 (9) [back to overview]	Number of Participants With Transplant-related Mortality (TRM)
NCT02199041 (9) [back to overview]	Number of Participants With Secondary Graft Failure
NCT02199041 (9) [back to overview]	Number of Participants With Overall Survival (OS)
NCT02199041 (9) [back to overview]	Number of Participants With Neutrophil Engraftment
NCT02199041 (9) [back to overview]	Number of Participants With Event-free Survival (EFS)
NCT02199041 (9) [back to overview]	Number of Participants With Transplant-related Morbidity
NCT02199041 (9) [back to overview]	Number of Participants With Malignant Relapse
NCT02199041 (9) [back to overview]	Number of Participants by Severity With Chronic Graft Versus Host Disease (GVHD) in the First 100 Days After HCT
NCT02199041 (9) [back to overview]	Number of Participants by Severity With Acute Graft Versus Host Disease (GVHD) in the First 100 Days After HCT
NCT02242630 (2) [back to overview]	Change in Subject Reported Shoulder Pain as Measured by the Visual Analogue Scale
NCT02242630 (2) [back to overview]	Change in Shoulder Function, as Measured by the QuickDASH ®
NCT02256969 (4) [back to overview]	Tear Break Up Time (TBUT)
NCT02256969 (4) [back to overview]	Ocular Surface Disease Index (OSDI)
NCT02256969 (4) [back to overview]	Symptom Assessment in Dry Eye (SANDE)
NCT02256969 (4) [back to overview]	Corneal Fluorescein Staining (CFS)
NCT02260934 (15) [back to overview]	Percentage of Participants With Grade 4 Hypogammaglobulinemia by Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With B Cell Reconstitution at Week 24, Week 48 and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With At Least One Grade 3 or Higher Infectious Adverse Event By Week 24, Week 48 and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With an Overall Response at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With an Negative Anti-dsDNA Result at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With a Complete Response at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants Hypocomplementemic for Complement Component C4 at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants Hypocomplementemic for Complement Component C3 at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Frequency of Specific Adverse Events of Interest By Participant, By Week 96
NCT02260934 (15) [back to overview]	Count of Participants: Frequency of Non-renal Flares by Week 96
NCT02260934 (15) [back to overview]	Frequency of Specific Adverse Events of Interest By Event by Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With Treatment Failure by Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Count of Participants: Frequency of Non-renal Flares by Week 24
NCT02260934 (15) [back to overview]	Count of Participants: Frequency of Non-renal Flares by Week 48
NCT02260934 (15) [back to overview]	Percentage of Participants With a Sustained Complete Response
NCT02296346 (1) [back to overview]	Multiple Sclerosis Functional Composite (MSFC) Z-score and Expanded Disability Status Scale (EDSS)
NCT02406209 (1) [back to overview]	Anterior Chamber Cell Grade at Week 8
NCT02464657 (4) [back to overview]	Relapse Free Survival
NCT02464657 (4) [back to overview]	Event-Free Survival (EFS)
NCT02464657 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Nivolumab
NCT02464657 (4) [back to overview]	Overall Survival
NCT02515045 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Intraocular Pressure (IOP)
NCT02515045 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Macular Thickness
NCT02515045 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Pachymetry (Corneal Thickness)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Fear Swallow)
NCT02539394 (19) [back to overview]	Patients' Pain Scores on the Visual Analog Scale - Left Arm Pain
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Eating Duration)
NCT02539394 (19) [back to overview]	Patients' Pain Scores on the Visual Analog Scale - Neck Pain
NCT02539394 (19) [back to overview]	Patients' Pain Scores on the Visual Analog Scale - Right Arm Pain
NCT02539394 (19) [back to overview]	Patients' Bazaz Dysphagia Score - Liquid
NCT02539394 (19) [back to overview]	Patients' Bazaz Dysphagia Score - Solid
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Food Selection)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Mental)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Sleep)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Burden)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Social)
NCT02539394 (19) [back to overview]	Patient Reported Swallowing Difficulty Over 1 Year
NCT02539394 (19) [back to overview]	Patients' Neck Disability
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Eating Desire)
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Communication)
NCT02539394 (19) [back to overview]	Adverse Event
NCT02539394 (19) [back to overview]	Fusion Rate
NCT02539394 (19) [back to overview]	Degree of Dysphagia Patients Experience (Fatigue)
NCT02569437 (5) [back to overview]	Subjective Symptom Composite Scoring
NCT02569437 (5) [back to overview]	Visual Analog Scale
NCT02569437 (5) [back to overview]	Endoscopic Nasal Polyp Score
NCT02569437 (5) [back to overview]	Middle Meatus Culture
NCT02569437 (5) [back to overview]	Sino-nasal Outcome Test (SNOT 22)
NCT02576249 (3) [back to overview]	Pain Scale Score
NCT02576249 (3) [back to overview]	Tegner Activity Level Scale
NCT02576249 (3) [back to overview]	The Knee Osteoarthritis Outcome Score (KOOS) Pain Subscale
NCT02652390 (6) [back to overview]	Palmar Pain Score
NCT02652390 (6) [back to overview]	Number of Patients Who Have Had Carpal Tunnel Release Surgery on the Study Hand
NCT02652390 (6) [back to overview]	Bodily Pain Score
NCT02652390 (6) [back to overview]	11-item Disabilities of the Arm, Shoulder and Hand (DASH) Score
NCT02652390 (6) [back to overview]	Symptom Severity Score
NCT02652390 (6) [back to overview]	Satisfaction Score
NCT02790788 (22) [back to overview]	Core Body Temperature in Degrees Celcius.
NCT02790788 (22) [back to overview]	Early Postresuscitation Central Venous Oxygen Saturation (%) Measured in Blood Samples Obtained Through a Central Venous Catheter Port.
NCT02790788 (22) [back to overview]	Organ Failure-free Days.
NCT02790788 (22) [back to overview]	Survival to Hospital Discharge With Favorable Functional Outcome.
NCT02790788 (22) [back to overview]	Cerebral Blood Flow Index by Near Infrared Spectroscopy With Indocyanine Green.
NCT02790788 (22) [back to overview]	Early Postresuscitation Inflammatory Response as Assessed by Serum Cytokine Levels (pg/mL).
NCT02790788 (22) [back to overview]	Early Postresuscitation Cardiac Output (L/Min) Measured by Either Pulse Index Continuous Cardiac Output (PiCCO) or a Continuous Cardiac Output (CCO) Thermodilution Pulmonary Artery Catheter.
NCT02790788 (22) [back to overview]	Early Postresuscitation Central Venous Oxygen Saturation (%) Measured in Blood Samples Obtained Through a Central Venous Catheter Port.
NCT02790788 (22) [back to overview]	Left and Right Ventricular Diastolic Area (cm^2) by Echocardiography.
NCT02790788 (22) [back to overview]	Left and Right Ventricular Ejection Fraction (%) by Echocardiography.
NCT02790788 (22) [back to overview]	Steroid-associated Complications.
NCT02790788 (22) [back to overview]	Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring.
NCT02790788 (22) [back to overview]	Eccentricity Index by Echocardiography.
NCT02790788 (22) [back to overview]	Early Postresuscitation Cardiac Output (L/Min) Measured by Either Pulse Index Continuous Cardiac Output (PiCCO) or a Continuous Cardiac Output (CCO) Thermodilution Pulmonary Artery Catheter.
NCT02790788 (22) [back to overview]	Early Postresuscitation Central Venous Oxygen Saturation (%) Measured in Blood Samples Obtained Through a Central Venous Catheter Port.
NCT02790788 (22) [back to overview]	Early Postresuscitation Central Venous Oxygen Saturation (%) Measured in Blood Samples Obtained Through a Central Venous Catheter Port (as Feasible).
NCT02790788 (22) [back to overview]	Early Postresuscitation Cardiac Output (L/Min) Measured by Either Pulse Index Continuous Cardiac Output (PiCCO) or a Continuous Cardiac Output (CCO) Thermodilution Pulmonary Artery Catheter.
NCT02790788 (22) [back to overview]	Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring (as Feasible).
NCT02790788 (22) [back to overview]	Early Postresuscitation Cardiac Output (L/Min) Measured by Either Pulse Index Continuous Cardiac Output (PiCCO) or a Continuous Cardiac Output (CCO) Thermodilution Pulmonary Artery Catheter.
NCT02790788 (22) [back to overview]	Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring.
NCT02790788 (22) [back to overview]	Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring.
NCT02790788 (22) [back to overview]	Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring (as Feasible).
NCT02798523 (1) [back to overview]	Number of Participants Sampled for RNA-seq Differential Expression Analysis (Biological Replicates)
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to Second Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of First Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of Second Course of Azacitidine
NCT02828358 (5) [back to overview]	Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to First Course of Azacitidine
NCT02847494 (3) [back to overview]	Number of Participants With Sustained Headache Freedom
NCT02847494 (3) [back to overview]	Headache Days as Self-reported by Participants
NCT02847494 (3) [back to overview]	Medication Preference as Assessed by Self-report
NCT02953678 (10) [back to overview]	Nonrelapse Mortality (NRM)
NCT02953678 (10) [back to overview]	Relapse-related Mortality Rate
NCT02953678 (10) [back to overview]	Relapse Rate
NCT02953678 (10) [back to overview]	Percentage of Participants With Three-month DOR
NCT02953678 (10) [back to overview]	Percentage of Participants With Six-month Duration of Response (DOR)
NCT02953678 (10) [back to overview]	Overall Survival (OS)
NCT02953678 (10) [back to overview]	Failure-free Survival (FFS)
NCT02953678 (10) [back to overview]	Overall Response Rate (ORR) at Day 28
NCT02953678 (10) [back to overview]	Overall Response Rate (ORR)
NCT02953678 (10) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAES), Serious TEAEs, And Grade 3 or Higher TEAEs
NCT02956122 (22) [back to overview]	Graft-versus-host Disease (GvHD)-Related Mortality - Percentage of Participants With an Event
NCT02956122 (22) [back to overview]	Incidence of Chronic Graft-versus-host Disease (GvHD)
NCT02956122 (22) [back to overview]	Infection-related Mortality - Percentage of Participants With an Event
NCT02956122 (22) [back to overview]	Number of Participants With Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs and Temporally-associated AEs
NCT02956122 (22) [back to overview]	Overall Survival (OS) - Percentage of Participants With an Event
NCT02956122 (22) [back to overview]	Transplant-related Mortality
NCT02956122 (22) [back to overview]	Acute Graft-versus-host Disease (GvHD) Grading at Days 28, 56 and 180
NCT02956122 (22) [back to overview]	Failure-free Survival - Percentage of Participants With an Event
NCT02956122 (22) [back to overview]	All-cause Mortality - Percentage of Participants With an Event
NCT02956122 (22) [back to overview]	Graft-versus-host Disease (GvHD)-Free Survival - Percentage of Participants With an Event
NCT02956122 (22) [back to overview]	Systemic Clearance at Steady State (CLss) of GLASSIA
NCT02956122 (22) [back to overview]	Percentage of Participants Achieving Overall Response at Day 56
NCT02956122 (22) [back to overview]	Percentage of Participants Achieving Overall Response (OR) At Day 28
NCT02956122 (22) [back to overview]	"Area Under the Plasma Concentration Curve From Time Zero to Time t AUC(0-t) of GLASSIA"
NCT02956122 (22) [back to overview]	Apparent Terminal Half-life (t1/2) of GLASSIA
NCT02956122 (22) [back to overview]	Apparent Volume of Distribution at Steady State (Vss) of GLASSIA
NCT02956122 (22) [back to overview]	Number of Participants With Recurrence of Primary Malignancies
NCT02956122 (22) [back to overview]	Number of Participants With Clinically Significant Changes in Vital Signs
NCT02956122 (22) [back to overview]	Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
NCT02956122 (22) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of GLASSIA
NCT02956122 (22) [back to overview]	Area Under the Plasma Concentration Curve (AUC0-inf) From Time Zero to Infinity
NCT02956122 (22) [back to overview]	Percentage of Participants Achieving Gastrointestinal (GI) Response at Day 28
NCT02962284 (6) [back to overview]	Number of Subjects With Adverse Events
NCT02962284 (6) [back to overview]	Percentage of Subjects With Prostate Specific Antigen - 50 Response
NCT02962284 (6) [back to overview]	Proportion of Subjects With Disease Progression
NCT02962284 (6) [back to overview]	Prostate Specific Antigen Levels
NCT02962284 (6) [back to overview]	Testosterone Complete Suppression
NCT02962284 (6) [back to overview]	Testosterone Levels
NCT03123614 (4) [back to overview]	Uncorrected Visual Acuity
NCT03123614 (4) [back to overview]	Number of Eyes With Corneal Haze
NCT03123614 (4) [back to overview]	Change in Intraocular Pressure (IOP) From Baseline Through Month 3
NCT03123614 (4) [back to overview]	Best Corrected Visual Acuity at 3 Months
NCT03139604 (20) [back to overview]	Proportion of Subjects Who Discontinue Immunosuppressive Medications
NCT03139604 (20) [back to overview]	Cmax of Itacitinib When Administered in Combination With Corticosteroids
NCT03139604 (20) [back to overview]	AUC of Itacitinib When Administered in Combination With Corticosteroids
NCT03139604 (20) [back to overview]	CL/F of Itacitinib When Administered in Combination With Corticosteroids
NCT03139604 (20) [back to overview]	Cmin of Itacitinib When Administered in Combination With Corticosteroids
NCT03139604 (20) [back to overview]	Duration of Response
NCT03139604 (20) [back to overview]	Failure-free Survival
NCT03139604 (20) [back to overview]	Incidence Rate of aGVHD Flares
NCT03139604 (20) [back to overview]	Incidence Rate of Secondary Graft Failure
NCT03139604 (20) [back to overview]	Malignancy Relapse-related Mortality Rate
NCT03139604 (20) [back to overview]	Number of Treatment-emergent Adverse Events With INCB39110
NCT03139604 (20) [back to overview]	Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response Index
NCT03139604 (20) [back to overview]	Overall Survival (OS)
NCT03139604 (20) [back to overview]	Relapse Rate of Malignant and Nonmalignant Hematologic Disease
NCT03139604 (20) [back to overview]	Time to Response
NCT03139604 (20) [back to overview]	Tmax of Itacitinib When Administered in Combination With Corticosteroids
NCT03139604 (20) [back to overview]	Incidence Rate of cGVHD
NCT03139604 (20) [back to overview]	Nonrelapse Mortality
NCT03139604 (20) [back to overview]	Objective Response Rate
NCT03139604 (20) [back to overview]	Proportion of Subjects Who Discontinue Corticosteroids
NCT03229538 (7) [back to overview]	Number of Participants With Mortality, Including In-hospital Mortality or Mortality After Hospital Discharge But Within 30 Days of the Last Dose of Study Drug
NCT03229538 (7) [back to overview]	Number of Participants With Death or Major Complication as Defined by an Outcome in One of the 7 Highest Global Ranking Categories
NCT03229538 (7) [back to overview]	Number of Participants With Any Other Post-operative Complications From the Start of Study Drug Administration Until Hospital Discharge.
NCT03229538 (7) [back to overview]	Number of Participants With a Post-operative Length of Stay Greater Than 90 Days
NCT03229538 (7) [back to overview]	Number of Participants With Prolonged Mechanical Ventilation (Greater Than 7 Days)
NCT03229538 (7) [back to overview]	Number of Participants With Post-operative Low Cardiac Output Syndrome
NCT03229538 (7) [back to overview]	Number of Participants With Occurrence of Any One or More of the Following STS-CHSD-defined Major Post-operative Infectious Complications: Postprocedural Infective Endocarditis, Pneumonia, Sepsis, Deep Wound Infection, Mediastinitis.
NCT03232749 (3) [back to overview]	Visual Analog Scale Scores at Each Time Point.
NCT03232749 (3) [back to overview]	ASES Scores at Each Time Point
NCT03232749 (3) [back to overview]	SST (Simple Shoulder Test) Scores at Each Time Point
NCT03320434 (4) [back to overview]	Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 15
NCT03320434 (4) [back to overview]	Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 1
NCT03320434 (4) [back to overview]	Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 15
NCT03320434 (4) [back to overview]	Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 1
NCT03387046 (16) [back to overview]	Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24
NCT03387046 (16) [back to overview]	Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24
NCT03387046 (16) [back to overview]	9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8
NCT03387046 (16) [back to overview]	Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24
NCT03387046 (16) [back to overview]	Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24
NCT03387046 (16) [back to overview]	Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)
NCT03387046 (16) [back to overview]	Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24
NCT03387046 (16) [back to overview]	Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03387046 (16) [back to overview]	Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)
NCT03387046 (16) [back to overview]	Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
NCT03403517 (5) [back to overview]	Total Complication Rate
NCT03403517 (5) [back to overview]	Mortality
NCT03403517 (5) [back to overview]	Hospital Stay
NCT03403517 (5) [back to overview]	Complications, Post-anesthesia Care Unit (PACU)
NCT03403517 (5) [back to overview]	PACU Stay
NCT03578276 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Pachymetry (Corneal Thickness)
NCT03578276 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Macular Thickness
NCT03578276 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Intraocular Pressure (IOP)
NCT03593902 (2) [back to overview]	Survival of Treatment
NCT03593902 (2) [back to overview]	Change in Skin Score by mRSS
NCT03704584 (3) [back to overview]	Visual Analog Pain Scale (VAS-pain) Daily Until Post-injection Day 7
NCT03704584 (3) [back to overview]	10 Point Likert Scale of Pain Scores Before the Injection and After the Injection and During Follow up in the Corticosteroid Plus Lidocaine Group as Compared to the Corticosteroid Alone Group
NCT03704584 (3) [back to overview]	Number of Patients With Subsequent Reinjection and Surgical Operation
NCT03797872 (1) [back to overview]	Number of Participants Who Are Eligible, Consent, and Complete the 48 Weeks Study
NCT03818737 (6) [back to overview]	Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Total Score
NCT03818737 (6) [back to overview]	Change in Visual Analog Pain Scale (VAS-pain) Score
NCT03818737 (6) [back to overview]	Change in EuroQuality of Life (EQ-5D-3L) Index Score
NCT03818737 (6) [back to overview]	Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Pain Subscale Score
NCT03818737 (6) [back to overview]	Overall MRI Grade of Osteoarthritis
NCT03818737 (6) [back to overview]	Patient-Reported Outcomes Measurement Information System (PROMIS-29) Score
NCT03852537 (14) [back to overview]	Oxygen-free Days
NCT03852537 (14) [back to overview]	Cardiovascular Dysfunction
NCT03852537 (14) [back to overview]	Timely Initiation of Corticosteroids and Implementation of Biomarker-titrated Corticosteroid Dosing
NCT03852537 (14) [back to overview]	Organ Failure
NCT03852537 (14) [back to overview]	ICU Admission
NCT03852537 (14) [back to overview]	Mortality
NCT03852537 (14) [back to overview]	Myocardial Injury
NCT03852537 (14) [back to overview]	Need for High Flow Nasal Cannula Oxygen
NCT03852537 (14) [back to overview]	Need for Invasive Mechanical Ventilation
NCT03852537 (14) [back to overview]	Need for Noninvasive Mechanical Ventilation
NCT03852537 (14) [back to overview]	New Onset Cardiac Arrhythmias
NCT03852537 (14) [back to overview]	Occurrence of Delirium
NCT03852537 (14) [back to overview]	Occurrence of Hyperglycemia
NCT03852537 (14) [back to overview]	Occurrence of Secondary Infection
NCT04046549 (7) [back to overview]	Percentage of Participants With Antibody-Mediated Rejection
NCT04046549 (7) [back to overview]	Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR)
NCT04046549 (7) [back to overview]	Percentage of Participants With Treated Acute Rejections
NCT04046549 (7) [back to overview]	Percentage of Participants With Biopsy Proven Acute Rejection (BPAR)
NCT04046549 (7) [back to overview]	Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Week 24
NCT04046549 (7) [back to overview]	Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR), Graft Loss, Death or Loss to Follow-up (LTFU)
NCT04046549 (7) [back to overview]	Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Weeks 12 and 48
NCT04184999 (1) [back to overview]	Evaluation of Intraoperative Use of Dexycu on Tear Film Osmolarity at 3 Weeks Postoperatively
NCT04233164 (1) [back to overview]	Number of SLE Patients That Were Sampled for RNA-seq Differential Expression Analysis (Biological Replicates)
NCT04323592 (6) [back to overview]	Admission to Intensive Care Unit (ICU)
NCT04323592 (6) [back to overview]	Change in C-reactive Protein (CRP)
NCT04323592 (6) [back to overview]	Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28
NCT04323592 (6) [back to overview]	Endotracheal Intubation (Invasive Mechanical Ventilation)
NCT04323592 (6) [back to overview]	Number of Days Free From Mechanical Ventilation
NCT04323592 (6) [back to overview]	In-hospital Death Within 28 Days
NCT04380857 (5) [back to overview]	Loss of Lines in Uncorrected Visual Acuity
NCT04380857 (5) [back to overview]	Mean Change in Pain
NCT04380857 (5) [back to overview]	Patient Preference Between Groups
NCT04380857 (5) [back to overview]	Number of Lines Lost From Best Corrected Visual Acuity
NCT04380857 (5) [back to overview]	Post op Pain Management Per Eye
NCT04900220 (2) [back to overview]	Incidence of Pain
NCT04900220 (2) [back to overview]	Intensity of Pain
NCT05113901 (18) [back to overview]	Number of Participants With Complications Following Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee 6 Weeks After Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee 6 Weeks After Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee 6 Weeks After Treatment
NCT05113901 (18) [back to overview]	Adverse Events or Outcomes Outside of Manipulations Under Anesthesia
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee After Surgery and Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Post Treatment Pain Scores (6 Weeks)
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee 6 Wks After Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Post Treatment Pain Scores
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Pre Treatment Pain Scores Using Knee Society Scores
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Post Treatment Pain Scores
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee Prior to Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee Prior to Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee After Surgery and Treatment
NCT05113901 (18) [back to overview]	Range of Motion in Degrees at Pre and Post Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures:(Immediate) Post Treatment Pain Scores
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee Before Treatment
NCT05113901 (18) [back to overview]	Patient Reported Outcome Measures: Overall Assessment of Knee Before Treatment
NCT05438277 (1) [back to overview]	Incidence of a Flare Reaction

Response Rate

Response includes both complete and partial responses. Per protocol, complete Response is defined as the complete disappearance of all clinical evidence of disease by physical examination, by imaging studies, by bone marrow biopsy (where indicated), by CNS evaluation (where indicated) and by biopsy where there is a residual abnormality on an imaging study. Bone marrow must contain <5% blasts. CSF WBC must be <5/μL with no blasts or lymphomatous cells present. Partial response is defined as: at least a 50% reduction in the size of all measurable tumor areas. Each site is to be defined by the product of the maximum length, width and depth (3 dimensions). No lesion may progress. No new lesion may appear. Bone marrow must contain <5% blasts. CSF WBC must be <5/μL with no blasts or lymphomatous cells present.. (NCT00057811)
Timeframe: Up to 5 years

Intervention	percentage of participants analyzed (Number)
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)	88
Group C (Chemotherapy, Monoclonal Antibody Therapy)	83

Intervention	participants (Number)
	Incidence of grade ≥ 3 stomatitis	No incidence of grade ≥ 3 stomatitis
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)	4	41
Group C (Chemotherapy, Monoclonal Antibody Therapy)	6	34

Intervention	participants (Number)
	Toxic death	No toxic death
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)	0	45
Group C (Chemotherapy, Monoclonal Antibody Therapy)	2	38

Intervention	Participants (Number)
	Albumin, serum-low (hypoalbuminemia)	Allergic reaction/hypersensitivity	Anorexia	Ataxia (incoordination)	Auditory/Ear-Other (Specify)	Blood/Bone Marrow-Other (Specify)	Colitis, infectious (e.g., Clostridium difficile)	Creatinine	Diarrhea	Dysphagia (difficulty swallowing)	Dyspnea (shortness of breath)	Fatigue (asthenia, lethargy, malaise)	Febrile neutropenia	Gastrointestinal-Other (Specify)	Glucose, serum-high (hyperglycemia)	Glucose, serum-low (hypoglycemia)	Hemoglobin	Hemorrhage, CNS	Hypotension	Incontinence, anal	Inf (clin/microbio) w/Gr 3-4 neuts - Blood	Inf (clin/microbio) w/Gr 3-4 neuts - Colon	Inf w/normal ANC or Gr 1-2 neutrophils - Bladder	Inf w/normal ANC or Gr 1-2 neutrophils - Lung	Leukocytes (total WBC)	Lymphopenia	Magnesium, serum-low (hypomagnesemia)	Nausea	Neurology-Other (Specify)	Neuropathy: motor	Neuropathy: sensory	Neutrophils/granulocytes (ANC/AGC)	Pain - Abdomen NOS	Platelets	Potassium, serum-low (hypokalemia)	Renal failure	Sodium, serum-low (hyponatremia)	Thrombotic microangiopathy	Tinnitus	Tumor lysis syndrome	Uric acid, serum-high (hyperuricemia)
PEGS	1	1	2	1	1	1	2	2	2	1	1	2	4	1	4	1	9	1	2	1	1	1	1	1	8	7	2	1	1	1	2	16	1	8	1	2	2	1	1	1	1

Intervention	participants (Number)
	Complete Response	Unconfirmed Complete Response	Partial Response	No Response
PEGS	6	2	5	20

Intervention	Percentage of participants by disease (Number)
Prophylactic Rituximab (CLL Patients)	73
Prophylactic Rituximab (MCL Patients)	69

Intervention	Participants (Number)
	Mortality within 100 days, all causes	Nonrelapse mortality within 1 year	Relapse + mortality within 1 year
Prophylactic Rituximab	0	1	2

Intervention	pg/ml (Mean)
	Baseline	Day 7	Day 28
Etanercept and Corticosteroid Therapy	205.2	28.8	23.1

Intervention	mg/dL (Mean)
	Baseline	Day 7 Non Responders	Day 7 Responders	Day 14 Non Responders	Day 14 Responders	Day 21 Non Responders	Day 21 Responders	Day 28 Non Responders	Day 28 Responders
Etanercept and Corticosteroid Therapy	28.1	5.4	1.8	4.9	1	10.7	1.6	19.6	5.3

Intervention	participants (Number)
	With Response	Without Response
Etanercept and Corticosteroid Therapy	20	8

Intervention	Participants (Number)
	Recurrence at Month 1	No Recurrence at Month 1
Octreotide	1	13
Placebo	2	13

Intervention	Participants (Number)
	Recurrence at Month 2	No Recurrence at Month 2
Octreotide	2	6
Placebo	2	5

Intervention	Participants (Number)
	TREATMENT SUCCESS	Vomiting episodes <2 (per day) since Day 5	Vomiting episodes ≥2 (per day) since Day 5	No Nasogastric Tube since Day 5	Nasogastric Tube used since Day 5	No Anticholinergic agents	Anticholinergic agents taken	Premature discontinuation/missing data
Octreotide	22	28	1	22	7	26	3	3
Placebo	20	25	2	24	3	25	2	5

Intervention	Scores on a scale (Mean)
	Day 1 (n=30,29)	Day 7 (n=24,26)	Day 14 (n=20,14)	Month 1 (n=11,13)	Month 2 (n=7,4)	Month 3 (n=2,2)
Octreotide	4.12	4.23	4.30	4.18	3.46	0.05
Placebo	4.12	3.37	3.85	4.49	3.23	1.60

Intervention	Vomiting episodes (Mean)
	Day 1	Day 7 (n=31,31)	Day 14 (n=28,27)
Octreotide	1.2	0.3	0.3
Placebo	0.6	0.4	0.5

Intervention	Participants (Number)
	TREATMENT SUCCESS	Vomiting episodes <2 (per day)	Vomiting episodes ≥2 (per day)	No Nasogastric Tube since Day 10	Nasogastric Tube used since Day 10	No Anticholinergic agents	Anticholinergic agents taken	Premature discontinuation/missing data, failure
Octreotide	12	19	2	14	7	18	3	11
Placebo	9	13	2	13	2	11	4	17

Intervention	Participants (Number)
	Relief from Obstruction: Day 7	No Relief from Obstruction: Day 7	Relief from Obstruction: Day 14	No Relief from Obstruction: Day 14
Octreotide	9	20	11	10
Placebo	15	12	10	5

Intervention	Participants (Number)
	Recurrence at Month 3	No Recurrence at Month 3
Octreotide	0	3
Placebo	0	2

Intervention	Percent change in flare (Mean)
Pred Forte 1%	64.8
Econo Pred Plus 1%	68.3
Predisolone Acetate 1%	65.7

Intervention	Participants (Number)
Budesonide Inhalation Suspension (BIS)	8
Placebo (Normal Saline)	10

Intervention	Units on a scale (Mean)
Budesonide Inhalation Suspension (BIS)	-2.9
Placebo (Normal Saline)	-3.0

methylprednisolone acetate

Description

Cross-References

Synonyms (112)

Research Excerpts

Effects

Actions

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (8)

Protein Targets (18)

Potency Measurements

Inhibition Measurements

Biological Processes (23)

Molecular Functions (6)

Ceullar Components (7)

Bioassays (21)

Research

Studies (704)

Market Indicators

Research Demand Index: 59.69

Study Types

Clinical Trials (714)

Trial Overview

Trial Outcomes

Response Rate

Grade ≥ 3 Stomatitis

Minimal Residual Disease

Toxic Death

Event-free Survival

Hearing Improvement

2-year Overall Survival Rate

2-year Progression-free Survival Rate

Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug

Response Rate

Duration of ICU Stays

Duration of Hospital Stay in Days

Development of Serum Creatinine Greater Than or Equal to 3.0 mg/dL After Study Entry

Number of Participants With SAEs

The Proportion of Subjects Who Develop Death, PaO2/FiO2 Ratio Less Than or Equal to 55, Cardiac Index Less Than or Equal to 2.2, Pulseless Electrical Activity, Ventricular Tachycardia or Fibrillation

Number of Participants Who Developed Refractory Shock Despite Fluid Resuscitation After Study Entry

Duration of Shock and/or Pressor/Inotropic Support

Length of Time on a Ventilator

Number of Participants Intubated and Placed on a Ventilator After Study Entry.

Number of Participants on Extracorporeal Membrane Oxygenation (ECMO)

Engraftment of Haploidentical CD34+ Selected Blood Stem Cells in Older Patients or Those With Medical Co-morbidities Following Total Lymphoid Irradiation and Antithymocyte Globulin Transplant Conditioning

Acute Graft-versus-Host Disease (GVHD) Grade 2-4 Risk From Time of Transplant Until Day 90 Post-transplant

Incidence of Relapse

Chronic Graft-vs-Host Disease (cGvHD)

Overall Survival

Mortality

6-month Progression-free Survival

Number of Participants Alive at 3 Years

Percentage of Participants With Objective Response

1 Year Overall Survival Rate

Time Measured From the Administration of the Loading Dose of Prednisolone (2mg/kg up to Max 60mg) in the Emergency Department (ED) Until the Home Dose of Albuterol is Administered

Survival

Numerical Rating Scale (0-10), an Interval Pain Scale, on Which 0 Indicates no Pain and 10 Indicates the Worst Pain Imaginable

Functional Disability Scales

Number of Patients Using Analgesics

Estimate Percentage Pulmonary Response in Patients With IPS Treated With Etanercept + Corticosteroid Therapy

Plasma Cytokine IL6 Level

C-reactive Protein Levels

Toxicity of Etanercept Plus Corticosteroid Therapy Using the Common Terminology Criteria Version 4.0

Survival Rate

Response of IPS (Idiopathic Pneumonia Syndrome) to Etanercept Plus Corticosteroid Therapy by Day 28.

Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 1

Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 14

Number of Participants Reporting Scores 0 to 3 on the Nausea Intensity World Heath Organization (WHO) Scale at Day 7

Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 1

Number of Participants With Recurrence of an Episode of Bowel Obstruction at Month 2

Number of Participants With Treatment Success From Day 5 to Day 7

Participant's Quality of Life Using the Edmonton Scale

Number of Vomiting Episodes Per Day at Day1, Day 2 and Day 14

Number of Participants With Treatment Success From Day 10 to Day 13

Number of Participants With Relief From Obstruction at Day 7 and Day 14

Intervention	participants (Number)
	Return within 5 days with hosptial admission	Increased level of care
Budesonide Inhalation Suspension (BIS)	2	1
Placebo (Saline)	2	0

Intervention	Participants (Number)
	Rhinorrhea	Headache	Diarrhea	Sore throat	Cough	Hyperglycemia
Budesonide Inhalation Suspension (BIS)	6	5	3	4	2	2
Placebo (Normal Saline)	11	9	7	3	3	0

Intervention	participants (Number)
	At 12 weeks - Yes	At 12 weeks - No	At 24 weeks - Yes	At 24 weeks - No
Low Dose	25	14	22	17
Standard Dose	23	19	21	21

Intervention	Units on a scale (Mean)
	Change from baseline Week 4: (N= 40, 37)	Change from baseline Week 12: (N= 41, 35)	Change from baseline Week 24: (N= 40, 34)
Low Dose	-5.5	-8.7	-9.4
Standard Dose	-4.8	-8.6	-8.6

Intervention	Units on a scale (Mean)
	Change from Baseline to Week 4: (N= 39, 37)	Change from Baseline to Week 12: (N= 41, 35)	Change from Baseline to Week 24: (N= 39, 34)
Low Dose	-7.7	-10.3	-9.8
Standard Dose	-7.4	-9.7	-10.3

Intervention	participants (Number)
	At least one adverse event	Any severe adverse event	Any drug related adverse event	Any serious adverse event	Any infection	Any severe infection	Any drug related infection	Any serious infection
Low Dose	30	3	16	4	17	1	6	1
Standard Dose	35	7	18	8	25	3	10	4

Intervention	participants (Number)
	At week 12 - Yes	At week 12 - No	At week 24 - Yes	At week 24 - No
Low Dose	0	39	0	39
Standard Dose	0	42	1	41

Intervention	participants (Number)
Methotrexate Arm	10
Methotrexate-Prednisolone-Etanercept Arm	17

Intervention	millimeters (Mean)
CRx-102 (2.7/90 mg)	-32.4
CRx-102 (2.7/180 mg)	-33.2
CRx-102 (2.7/360 mg)	-37.3
Prednisolone	-40.4
Placebo	-34.6

Intervention	percentage of change from baseline (Median)
CRx-102 (2.7/180)	-29.90
CRx-102 (2.7/360)	-40.84
Prednisolone	15.92
Dipyridamole	-33.67
Placebo	-27.64